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The reliability of data obtained from the existing United States Pharmacopeia (USP) method, 
USP <231> for elemental impurities (EI) have been questioned in the literature(1). New 
regulations regarding EI in pharmaceutical products were recently implemented on the 1st 
January 2018. The new regulations are USP <232>/<233> and the International Council for 
Harmonisation equivalent guidelines (ICH Q3D). The new regulations include the use of 
instrumentation such as inductively coupled plasma optical emission spectroscopy (ICP-OES) 
and inductively coupled plasma mass spectrometry (ICP-MS).  
The aim of this work was to develop, optimise and validate analytical methods for the 
determination of Class 1 and Class 2A elements, arsenic (As), cadmium (Cd), mercury (Hg), 
lead (Pb), cobalt (Co), nickel (Ni) and vanadium (V) simultaneously in pharmaceutical 
products in compliance with the new guidelines. The developed ICP-OES and ICP-MS 
methods were validated using the only available solid standard reference material (SRM) 
NIST 3280 Multivitamin/Multielement tablets. It was found that relying solely on spiked 
addition technique as suggested by USP<233> is inefficient as it may not reflect clearly the 
method’s accuracy particularly when the sample preparation involves the use of microwave 
(MW)-assisted acid digestion step, which is very common for pharmaceutical samples. 
Sample preparation was performed using a developed MW-assisted acid digestion method 
with reverse aqua regia. It was found that reaching a temperature of 210°C for sample’s 
digestion is necessary to get EI recoveries of greater than 95% and pre-digestion grinding was 
found to be beneficial to minimise variation in data and get relative standard deviation (RSD) 
of less than 5%. The validation results showed good linearity (R2>0.995) over a wide range 
with low limits of detection (LoDs) and limits of quantification (LoQs). The calculated LoQs in 
ng/mL are As (5.86, 1.149), Cd (0.87, 0.037), Hg (2.23, 1.701) Pd (4.73, 0.041), Co (1.58, 0.299), 
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Ni (1.74, 0.159) and V (7.64, 0.485) for ICP-OES and ICP-MS incorporated with collision 
reaction cell (CCT) respectively.  
Twenty-four commercially available pharmaceutical products including analgesic tablets, 
cough remedies, flu powders and antacids were analysed. Four products contained Cd in 
concentrations exceeding the permitted daily exposure limit (PDE) of 5µg/day when the 
maximum dose is taken, and nine products exceeded the 5µg/day PDE of Pb. This is especially 
concerning for the paediatric products because children are more susceptible to EI adverse 
effects as for example, they can absorb up to 40-70% of ingested Pb. 
 The antacids were found to contain As and although the levels quantified were below the 
PDE (15µg/day), a speciation method using an ion-pair reversed phase high performance 
liquid chromatography (HPLC)-ICP-MS was optimised and validated according to ICH Q2B 
guidelines as no information regarding what species are present in such products is available 
in the literature. Four arsenic species were selected, arsenite (AsIII), arsenate (AsV), 
monomethyl arsonate (MMA) and dimethyl arsenate (DMA). Calibrations with R2>0.995 for 
all four species in the range of 1 to 50 ng/L and % recoveries>95% with RSD<5% were 
obtained. Arsenic was extracted from the samples using MW assissted extraction with 0.3M 
phosphoric acid at 55°C for 10 miutes, 75°C for 10 minutes and 95°C for 1 hour. The species 
were stable after being exposed to the extraction procedure (spiked recoveries >95%). This 
method was able to extract 95% or more of arsenic for all products. The ion-pair reversed 
phase chromatography was performed using a mobile phase: 10mmol/L 
tetrabutylammonium, 20mmol/L potassium dihydrogen orthophosphate and 2% methanol 
at pH 6 with a C18 column. The speciation analysis results for all the antacids showed that 
approximately 50% of the extracted As was present as the most toxic AsIII form. 
The work demonstrates some of the potential issues with the new regulations and the 
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1. Introduction  
The toxicity of various elements has been well-documented for many years. Early 
recorded cases including the poisoning of the Chinese emperor, Qin-Shi-Huang from 
his attempt to become immortal by taking pills containing mercury (Hg), which 
resulted in his death(2). Another common example is arsenic (As) which is historically 
known for its toxicity. It was used for centuries as a poison and during the Middle 
Ages, the acutely toxic tasteless powder; arseneous oxide was used for homicides 
particularly by impatient heirs(3). During the First World War, an organoarsenic 
compound with high toxicity known as Lewisite was used as a chemical weapon(4, 
5). Lead (Pb) is another famous element for its toxicity, especially on the blood, renal 
tubules and motor neurons. Children who lived in old houses where leaded paints 
were used developed symptoms of lead poisoning including weight loss, irritability, 
abdominal pain, renal failure as well as behaviour and learning difficulties(6, 7).  
Recently, elemental impurities (EI) in pharmaceutical products and excipients have 
been gaining more interest, especially with the new guidelines being implemented 
on the 1st January 2018. These guidelines are the United States Pharmacopeia (USP) 
<232>/<233>(8, 9) and the International Conference on Harmonisation (ICH) Q3D 
guidelines(10). The purpose of the guidelines is to help produce more reliable EI data, 
to minimise the unwanted effects of EI and to reduce the potential toxicity of such 
elements(11).  
1.1 Elemental impurities in pharmaceutical products and excipients 
Elemental impurities in pharmaceutical products may arise from many different 
sources(12). They may be intentionally added during synthesis, such as catalysts, or 
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from the reagents used such as raw materials, solvents and formulation agents(12). 
They also may just be present as contaminants introduced during the manufacturing 
process from the transferring pipelines or reaction vessels for example, or by leaching 
from the packaging materials(12). Figure 1.1 illustrates the different sources that 
contribute to elemental impurities in pharmaceutical products.  
 
Figure 1.1 Source of elemental impurities in the final pharmaceutical product. 
(Adopted from ICH Q3D guidelines(10)). 
*Fulfilling the water quality requirements as stated in the various pharmacopoeias reduces 
elemental impurities introduced from water. 
**Maintaining Good Manufacturing Practice (GMP) processes in the selection and qualification 
of equipment reduces the risk of introducing elemental impurities to the product. 
 
These impurities are of great concern, since they do not have a therapeutic benefit 
and some contaminants have inherent toxicity(13). In addition, these elements may 
have adverse effects on the active pharmaceutical ingredient(s)-(APIs) stability and 
shelf-life by catalysing the degradation of drug substances(13). 
This necessitates the monitoring of impurities throughout the manufacturing process 
from raw materials to the final pharmaceutical product and the control of elemental 
impurities levels within acceptable limits(14). 
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1.1.1 Active pharmaceutical ingredient (API) 
APIs are an important contributor to the total EI in a final pharmaceutical product. 
Their impurity profile depends on their synthetic route as EI can be from the solvents, 
organic and/or inorganic reagents, water or catalysts used during their synthesis in 
addition to the metals that can be introduced from the manufacturing equipment 
and the primary containers(15, 16). Although there are only a few papers published 
in the literature showing EI profile in APIs, from those a study where four APIs, 
(dicyclomin hydrochloride, ethambutol, pyrazinamide and furazolidone) were 
analysed using inductively coupled plasma mass spectrometry (ICP-MS) found that 
all four APIs contain iron (Fe)(17). In addition, dicyclomin hydrochloride contains 
titanium, manganese and zinc. Ethambutol and pyrazinamide contain chromium (Cr) 
and copper (Cu), while furazolidone contains lead (Pb), Cr, manganese (Mn), copper 
(Cu) and zinc (Zn)(17). The method used was validated using a standard reference 
water ; NIST 1643b, rather than a solid pharmaceutical reference material, which is 
more representative of the solid APIs(17). 
In another study, atenolol, captopril, levodopa, primaquine diphosphate, propranolol 
hydrochloride and sulfamethoxazole were analysed by ICP-MS validated using the 
spike addition technique recommended by the regulations. A single reaction 
chamber digestion was used and As, cadmium (Cd),mercury (Hg), Pb,  nickel (Ni), 
vanadium (V), Cr and molybdenum (Mo) were quantified in levels less than 5.44 
µg/g(18).  Additionally, calcium folinate, enalapril maleate and levodopa were 
analysed using ICP-MS and found to contain different concentrations of Pd, V, Cu, Zn, 
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Mo and tin (Sn) in concentrations ranging from 0.13 to 8.2 µg/g(19).  Again, in this 
study the spike addition technique was used to validate the method.  
Since the analysed medications in both studies are not taken in concentrations higher 
than 300 mg daily, the EI levels are not posing a great risk, especially considering the 
more toxic metals like Cd and Pb were found in concentrations not exceeding 
0.2µg/g(18, 19).  
Many APIs are synthesised with the aid of metal catalysts to accelerate the rate of 
the chemical reaction, such as platinum group catalysts, so they are a source of trace 
metal contamination(20). However if Good Manufacturing Practices (GMPs) are 
maintained, catalysts are usually considered a low risk of contamination as they are 
usually efficiently removed after completion of the API synthesis(21). Catalysts may 
be classified as either homogeneous or heterogeneous depending on whether their 
molecules are dispersed in the same reactant phase or not. Recovering the catalyst 
after completion of the chemical reaction is necessary to keep the commercial 
applications affordable. Most catalysts are more expensive than the products(22). 
Heterogeneous catalysts like platinum-bismuth-carbon or palladium-carbon can be 
filtered and removed easily from the reaction mixture(21).  
There are some published studies where analysts looked for catalysts in 
pharmaceuticals, for example palladium (Pd) was found in a concentration of 0.077 
µg/g in enalapril maleate and platinum (Pt) was found in a concentration of 2.36 µg/g 
in calcium folinate(19). Techniques other than ICP-MS were also used to measure 
metal catalysts in APIs such as total reflection X-ray fluorescence (TXRF)  
spectrometry that was used to determine rhodium (Rh), Pd, iridium (Ir) and Pt in an 
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antifungal medication and a pyridinyl bisphosphonate(23). The precision of the TXRF 
method ranged between 9% to 20% probably due to the deposition of the dissolved 
API sample on the reflector as noted by the researchers(23).  Pd, Pt and Rh were also 
determined using high resolution continuum source graphite furnace atomic 
absorption spectrometry and direct solid sample analysis(24). Pd was found in 
concentrations ranging from 4.9-24.1 µg/g and it was mentioned that having a solid 
matrix-matched standard for calibration was challenging(24). 
Other factors that contribute to elemental impurities found in the API include the 
processing aids, inorganic reagents, solvents and manufacturing equipment used 
during their synthesis. For example, processing aids like silica and charcoal as well as 
inorganic reagents like magnesium stearate, sodium chloride and potassium sulphate 
are commonly used in the manufacturing of APIs. In general, using pure compounds 
as required by regulators minimise the risk of metal contamination(15). In the case 
of solvents, if they are used in compliance with the corresponding guidelines such as 
ICH Q3C; guideline for residual solvents, the risk of introducing metals to the API is 
insignificant(25). For manufacturing equipment, they are usually made of compatible 
materials that ensure minimal leaching of metals such as stainless steel, hastelloy 
steel and glass that are resistant to corrosions. Steels are known to contain chromium, 
nickel, copper, cobalt, vanadium and molybdenum that may leach under harsh 
reaction conditions like high or low pH and high temperature(15).  
1.1.2 Excipients 
One of the major sources of EI in pharmaceutical products are the excipients that 
play an important role in delivering the API to the patient(26, 27). They are added as 
bulking agents to make small doses physically large enough to be handled easily, 
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binders to help hold a tablet together, coating to protect the formulation from 
moisture or light, colouring and flavouring agents to enhance patient compliance, as 
well as lubricants to facilitate the dosage form handling in the manufacturing 
facility(26, 27). These excipients usually constitute a considerable amount of the final 
pharmaceutical product consumed by patients(28).   
Factors that contribute to the final EI profile of the excipients are similar to those 
contributing to the APIs elemental impurities. In addition, the source of excipients 
used in the formulation of pharmaceuticals plays an important role in the overall of 
EI in the final product, because the metal content in excipients is often inherent, so 
reducing, removing or controlling the metals content in them is not easy(28). 
Excipients used in pharmaceuticals industry have different origins as illustrated in 
Figure 1.2. 
 
Figure 1.2 Different sources of excipients used in the pharmaceutical formulations 
(Adopted from Teasdale et al, 2015(15)) 
 
Mined excipients, such as talc are more challenging when assessing the risk of EI 
contributed from their use, because of the natural variations resulting from the 
geographical and geological location of the mine(15). For example, a kaolin mine near 
Kaznejov, Czech Republic was found from periodic testing to contain 12 to 55 µg/g of 
Pb, while Trimouns talc mine in Midi-Pyrenees, France is tested once a year and 
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found to contain less than 10 µg/g of Pb. Some of these excipients are mineral based 
and obtained by the conversion of mined ores like titanium dioxide that is widely 
used in sunscreens to protect from ultraviolet light and is also used in capsule 
shells(29). 
Excipients obtained from plant or animal origin, such as cellulose derivatives, alginate, 
carrageenan, lactose, gelatine, etc. also have variable levels of metals depending on 
their uptake by the living organism(28). Factors contributing to that are for example 
the soil composition and its metal content that can be absorbed by the plant in the 
case of plant derived excipients(30). For marine plants, a factor that contributes to 
their metal content is what oceans they were harvested from(30).   
The control of trace metals levels in synthetic excipients, such as silicones and 
povidone is easier when GMPs similar to those of the APIs are adhered to(27).  
Many excipients contain metal impurities at the 1 to 10 µg/g level and most of them 
have not been routinely tested, so the variability in metals concentration is often 
unknown(29). In addition, because the pharmaceutical business for many excipient 
companies is minor, they may not be willing to comply with the new regulations or 
may not be able to.  This may require buying expensive instrumentation and provide 
highly skilled operators to minimise the EI content, which may not be feasible for the 
manufacturers or may result in increasing the pricing to cover for these additional 
costs(28, 29). 
As a result, pharmaceutical companies may find it necessary to perform the EI 
analysis on the excipients to determine their contribution to the final pharmaceutical 
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product EI level. The EI in the final product should not exceed the permitted daily 
exposure (PDE) limits stated in the new guidelines. 
Li et al(31) used ICP-MS to analyse 190 samples prepared using microwave-assisted 
digestion from 31 different excipients. The highest concentration of arsenic was 
found in ferric oxide yellow (0.80 µg/g). For cadmium the highest concentration was 
0.84 µg/g in magnesium hydroxide granular, while for lead, about 2.15 µg/g were 
determined in titanium dioxide.  Metals with lower toxicity were also quantified and 
the highest concentrations were 123.5 µg/g of cobalt in talc, 154.4 µg/g of nickel in 
ferrous oxide (black) and 436 µg/g of vanadium in ferric oxide (red). Other metals 
mentioned in the new guidelines were also analysed and found in concentrations 
ranging between 0.01 to 59.4 µg/g(31).  
The data obtained above clearly indicates that some pharmaceutical products 
containing these excipients may require changes in excipient sourcing and/or 
reformulation in order to meet the new PDE requirements. 
1.1.3 Utilities and environmental factors 
1. Water  
The water used in the manufacturing of APIs and the final pharmaceutical product 
must meet the pharmacopeial requirements, that is to meet the World Health 
Organisation (WHO) requirements for drinking water, which is then further purified 
to produce purified water (PW) and water-for injection (WFI)(32). The water quality 
is monitored routinely as part of standard GMP. As a result the potential of water or 
water purification systems introducing elemental impurities to the pharmaceutical 
product is highly unlikely even in large-volume parenterals that contain high volumes 




As part of appropriate GMPs, high-efficiency particulate air (HEPA) filters, which are 
a type of mechanical air filters that force the air through a fine mesh of about 0.3 
micrometres (µm) in diameter, are used in pharmaceutical manufacturing facilities. 
The fine mesh is capable of trapping fine particle like dust mites and even tobacco 
smoke. As a result, the risk of air introducing EI to the pharmaceutical products is 
negligible(33).  
1.1.4 Manufacturing equipment  
The manufacturing of solid products require many processes like blending, particle 
size reduction, granulation, tableting, coating, etc. which require various types of 
equipment. In the case of liquid dosage forms, solid components are dissolved or 
suspended using metallic equipment(15).  As described in Section 1.1.1, this 
equipment is made of materials like for example stainless steel, that are known to 
contain Ni and other metals(15). Harsh conditions like the use of corrosive liquids 
and high or low pH may cause the transfer of metals present within the equipment 
to the pharmaceutical product(34). However again, maintaining standard GMP 
reduces the risk of metal contamination from the equipment, but more 
considerations are required when assessing the risk of metals known to be present 
in the alloys used in the equipment, as they are usually more likely to be transferred 
to the product under drastic conditions. 
An example of metal transfer from manufacturing equipment to a product is the 
transfer of iron during high-pressure homogenisation, a process in which the 
crystalline drug particles are forced with high-pressure to pass through a narrow 
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homogenisation gap to produce nanosuspensions. The nanosuspensions were 
analysed by atomic absorption spectroscopy (AAS) and it was found that the erosion 
of metal is below 1 µg/g(35). AAS sensitivity is inferior to ICP techniques(36), and in 
the mentioned study the limit of detection (LoD) and limit of quantification (LoQ) 
were not provided(35). 
1.1.5 Container closure system (CCS)  
Packaging provides a barrier that protect from biological and physical contamination 
in addition to facilitating the consumer access to the product by improving its 
handling(37). 
There are guidelines for the CCS to be used for pharmaceutical products. An example 
is the Food and Drug Administration (FDA) Guidance for Industry, Container Closure 
Systems for Packaging Human Drugs and Biologics(38). Solid-to solid contact is 
considered low risk when it comes to leachable or extractable metals form CCS.  For 
semi-solid and liquid dosage forms, the risk is higher. 




Figure 1.3 Illustration of risk factors associated with CCS (Adapted from Teasdale 
et al, 2015(15)) 
 
Polymers have been used in CCS for decades and a large number of catalysts used 
during their synthesis are organometallic or inorganic compounds(39). Common 
examples include the use of antimony-based catalysts in the production of 
polyethylene terephthalate (PET) and chromium-based catalysts for the 
polymerisation of polyolefins. Jenke et al(39) published a review about the elemental 
impurities that can be introduced from CCS to the pharmaceutical products by 
looking to common packaging materials metal content.   
Fliszar et al(40) profiled the metal ions leached from pharmaceutical packaging 
material using ICP-OES. They tested three types of glass, type 1 clear, type 1 amber 
and type 1 with silicon dioxide inert coating and found the levels of Pb, Cd and Mg 
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not exceeding 0.2 µg/g. On the other hand, the level of aluminium (Al) was affected 
by the presence or absence of ethylenediaminetetraacetic acid (EDTA) as an 
extracting agent in the tested solution, as 4.7 µg/g were measured with EDTA and 
500 ng/g without it. This is because Al has been shown to precipitate in the presence 
of phosphate solutions. In the same study three plastic CCS were also profiled, those 
include low-density polyethylene (LDPE), high-density polyetheylene (HDPE), and 
PET bottles. HDPE and PET had metal concentrations not exceeding 0.15 µg/g, while 
LDPE was found to contain 1.5 µg/g of Al, 0.43 µg/g of Zn, 0.28 µg/g of Mg and 
0.26µg/g of calcium(Ca)(40). 
It was reported that tungsten microparticles that may be introduced into some pre-
filled syringes used with monoclonal antibodies were found to induce protein 
precipitation and coagulation especially when these protein products are formulated 
at pH below 6(41). 
1.2 Elemental impurities guidelines 
1.2.1 USP <231> Heavy metals test limitations 
The traditional method for determining heavy metals was introduced over hundred 
years ago in the United States Pharmacopeia’s National Formulary (NF) and 
described as “Heavy Metal Test, USP <231>”(42). Similar tests were provided in the 
European Pharmacopoeia (Ph. Eur.) and the Japanese Pharmacopoeia (JP).  
The method is a wet chemical screening classic colourimetric test and involves the 
precipitation of insoluble metal sulphides after ignition and combustion of the 
samples in a high temperature furnace. This is required as a preliminary step to 
consume the carbon followed by pH adjustment and the addition of freshly prepared 
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hydrogen sulphide or thioacetamide solution. The results are obtained from visually 
comparing the obtained colour with a standard solution of Pb. The method assumes 
that all potential elements behave similarly to the Pb standard(1, 14). 
Industry criticism of this method began around fifteen years ago, because it has many 
limitations, Firstly, high temperatures between two-hundred and six-hundred 
degrees Celsius (°C) leads to sample loss and can also remove volatile elements such 
as arsenic (As), cadmium (Cd), mercury (Hg) and lead (Pb) and gave falsely low 
results(43, 44). In fact, some studies have shown that the use of a furnace may lead 
to up to fifty percent loss of volatile elements like mercury (Hg) and selenium (Se)(45). 
The loss is also matrix dependent and recoveries can vary significantly among 
different analysts because the procedures are labour intensive and time 
consuming(46). 
Secondly, the method lacks sensitivity and specificity, there is no information about 
the identities of the metals that caused the positive result and the method does not 
provide any information about the identity of inorganic impurities in the samples. It 
also assumes that the test is not affected significantly by the sample matrix(1).  
However, since many metals sulphides may form colloids, and those behave 
differently to solutions, the traditional method requires that the visual comparison is 
done in a relatively short time after the formation of the precipitate but before the 
sample starts to become unstable. Thirdly, the colours of the different metal 
sulphides range from white to yellow, orange, brown, and black, which makes the 
visual comparison with the dark brown–coloured lead sulphide difficult and the 
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interpretation of a result differs between analysts as they differ in how they perform 
the visual comparison, especially when the analysts are inexperienced(17). 
Another disadvantage of the test is that it consumes about two grams (g) of sample 
in order to achieve appropriate detection (the tests limit is around 10 µg/mL) and 
such  large quantities are usually difficult to obtain at the early stages of drug 
development, or when the amount of the drug substances to be tested are limited(1). 
Fourthly, the procedure involves the use of potentially hazardous solvents like 
thioacetamide and the fact that the limits specified by the test are based on the 
ability to observe the precipitate, rather than on the analysis of toxicological data is 
an important drawback to the traditional method(12, 47). 
Finally, the test does not necessarily detect all potential forms and/or valences of 
elements of concern and it is not applicable to drug substances that are inorganic in 
nature(48).   
In 2008, a panel of experts in a workshop organised by the Institute of Medicine (IOM) 
agreed to the fact that that USP <231> was inadequate and needed replacement, but 
finding a suitable analytical method that can be combined with toxicological risk 
assessment studies was challenging(49). 
Attempts have been made to improve these pharmacopeial methods in order to 
alleviate some of the limitations and shortcomings by introducing instrumental 
analytical procedures that provide greater selectivity, sensitivity, better precision 
and yield higher recoveries for a wide range of metals of interest(12, 50).  
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Based on that, techniques such as inductively coupled plasma optical emission 
spectroscopy (ICP-OES) and inductively coupled plasma mass spectrometry (ICP-MS) 
were introduced in the new USP chapters <232>/<233> and (ICH) Q3D guidelines.  
1.2.2 USP <232> elemental impurities-limits, USP <233> elemental 
impurities-procedures, and ICH Q3D guidelines  
The limits of elemental impurities in pharmaceutical products are expressed as 
permitted daily exposure limits (PDEs) in µg (of element)/day. The PDEs are set for 
each element based on their toxicity evaluation that is related to the extent of 
exposure and it takes into consideration different route of administrations, oral, 
parenteral and inhalational as well as the daily dose of the medication. 
The limits in ICH Q3D are also expressed as maximum limits when the drug product 
intake are 10 g/day in addition to the PDEs based on the actual medication daily 
intake, which can provide higher limits if the maximum daily intake is less than 10 g.   
The elements in ICH Q3D are categorised to three different classes those are: 
Class 1: arsenic (As), cadmium (Cd), mercury (Hg) and lead (Pb). Inherently toxic 
elements that require risk assessment for all routes of administration.  
Class 2: This class is further subdivided to sub-class 2A, which include elements with 
high likelihood of occurrence; those are cobalt (Co), nickel (Ni) and vanadium (V), so 
they require risk assessment for all routes of administration. On the contrary, sub-
class 2B includes silver (Ag), gold (Au), iridium (Ir), osmium (Os), palladium (Pd), 
platinum (Pt), rhodium (Rh), ruthenium (Ru), selenium (Se) and thallium (Tl) that 
require risk assessment only if they were intentionally added. 
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Class 3: barium (Ba), chromium (Cr), copper (Cu), lithium (Li), molybdenum (Mo), 
antimony (Sb), and tin (Sn), these elements are considered to have low toxicity and 
require rick assessment for oral route only if they were intentionally added, however 
may require assessment for parenteral and inhalational routes. 
The PDEs for all the classified elements are represented in Table 1.1. 
Table 1.1 PDEs (µg/day) for Elemental Impurities(10) 
Element Class Oral Parenteral Inhalation 
Cd 1 5 2 2 
Pb 1 5 5 5 
As 1 15 15 2 
Hg 1 30 3 1 
Co 2A 50 5 3 
V 2A 100 10 1 
Ni 2A 200 20 5 
Tl 2B 8 8 8 
Au 2B 100 100 1 
Pd 2B 100 10 1 
Ir 2B 100 10 1 
Os 2B 100 10 1 
Rh 2B 100 10 1 
Ru 2B 100 10 1 
Se 2B 150 80 130 
Ag 2B 150 10 7 
Pt 2B 100 10 1 
Li 3 550 250 25 
Sb 3 1200 90 20 
Ba 3 1400 700 300 
Mo 3 3000 1500 10 
Cu 3 3000 300 30 
Sn 3 6000 600 60 
Cr 3 11000 1100 3 
 
PDEs have not been established for elements that have low inherent toxicity, such as 
aluminium (Al), boron (B), calcium (Ca), iron (Fe), potassium (K), magnesium (Mg), 
manganese (Mn), sodium (Na), tungsten (W) and zinc (Zn). 
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There two options to calculate the level of EI and compare the results with the 
guidelines. The first is to analyse the final finished product. The second is to analyse 
the individual ingredients from which the product is manufactured, and by knowing 
the mass of each ingredient, calculate the contribution of the EIs from each 
component and hence the total exposure. 
The guidelines require evaluation of the elemental impurities in the pharmaceutical 
products by performing a risk assessment procedure to predict the EI introduced 
from all possible sources and comparing that to the established PDEs. Table 1.2 
shows the elements to be considered in risk assessment. 
Table 1.2  Elements to be considered in risk assessment(10) 
Element Class 
If intentionally 
added (all routes) 
If not intentionally added 
Oral Parenteral Inhalation 
Cd  1 yes yes yes yes 
Pb  1 yes yes yes yes 
As  1 yes yes yes yes 
Hg  1 yes yes yes yes 
Co  2A yes yes yes yes 
V  2A yes yes yes yes 
Ni  2A yes yes yes yes 
Tl  2B yes no no no 
Au  2B yes no no no 
Pd  2B yes no no no 
Ir  2B yes no no no 
Os  2B yes no no no 
Rh  2B yes no no no 
Ru  2B yes no no no 
Se  2B yes no no no 
Ag  2B yes no no no 
Pt  2B yes no no no 
Li  3 yes no yes yes 
Sb  3 yes no yes yes 
Ba  3 yes no no yes 
Mo  3 yes no no yes 
Cu  3 yes no yes yes 
Sn  3 yes no no yes 
Cr  3 yes no no yes 
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If the total EI level is consistently less than 30% of the PDE, then there is no need for 
additional controls. However, if that is not the case, then establishment of controls 
is required to ensure that the EI level does not exceed the PDE in the pharmaceutical 
product.  
The USP <232> chapter specifies the elements and the limits. The revised <232> 
chapter that was published in the Pharmacopeial Forum (PF) 42(2) [Mar-Apr 
2016](51) has identical PDEs as the ICH Q3D(10). The alignment of the guidelines 
helped resolving the confusion caused by the different limits and requirements that 
the USP and ICH guidelines used to have(8). On the other hand, chapter <233> deals 
with the analytical procedure including sample preparation and instrumental 
methods for analysing the elements. It describes two ICP techniques, ICP-OES and 
ICP-MS as well as the validation requirements(9). 
1.3 Human toxicity of Class 1 and Class 2A elements  
1.3.1 Toxicity of Class 1 elements 
1.3.1.1 Arsenic toxicity 
Many As poisoning incidents have been reported over the years. For example, in 1943, 
As-tainted sausage poisoned around 150 people and caused the death of two 
consumers in St. Andrews, Scotland. In 1955, As-contaminated infant formula 
poisoned 12,000 Japanese infants and resulted in the death of 130 infants(52). 
Moreover, in 1972, 11 cases of poisoning occurred in western Minnesota after well 
water and soil As levels were elevated due to contamination from grasshopper bait 
placed on the ground in the 1930s(52). 
19 
 
Arsenic is predominantly absorbed from the small intestine.  Minimal absorption 
occurs via inhalation and skin contact. The major pathway for elimination of As 
compounds from the body is urinary excretion(53).  
The toxic effects result from the ability of arsenic to activate up to two hundred 
enzymes particularly those required for the synthesis and repair of deoxyribonucleic 
acid (DNA) and those required for cellular energy pathways(54). 
Exposure to high doses of As may result in a life threatening acute poisoning 
characterised initially by abdominal pain, nausea, vomiting, severe diarrhoea, diffuse 
skin rash, cardiac abnormalities, acute psychosis and seizures(54). In addition, 
peripheral neuropathy and encephalopathy may occur and were reported with acute 
As poisoning. On the other hand, chronic As poisoning results in multisystem 
diseases(5, 54). Residual amounts of As stay in highly keratinised tissues like hair and 
nails. Finally, the carcinogenicity of arsenic is also proven and it can affect several 
organs such as skin, liver, bladder, kidneys, prostate and lungs(55, 56). 
1.3.1.2 Cadmium toxicity 
Cadmium is highly absorbed from the lungs, while only about 5% of it is absorbed 
from the GI tract(57). Once absorbed, it is rapidly cleared from the blood and 
accumulated in various tissues particularly those rich in metallothionin like the liver 
and kidneys(57). Metallothionin is a low molecular weight metal binding protein and 
when Cd binds to it its residence time in the body is prolonged due to it is very slow 
clearance and that enhances the probability of neoplastic transformation induced by 
Cd(57). The internalised Cd- metallothionin is degraded in endosomes and lysosomes 
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releasing free Cd into the cytosol generating reactive oxygen species that activate 
cell death pathways(58). 
Both the IARC and the US National Toxicology Program concluded that there is 
enough evidence of Cd human carcinogenicity as it is linked to cancers of the 
respiratory system, liver, kidneys, prostate, hematopoietic system and stomach(57, 
59). 
Acute Cd poisoning caused by oral ingestion of large doses of the metal is 
characterised by severe salivation, nausea, vomiting, abdominal pain, bloody 
diarrhoea, painful spasm of the anal sphincter, vertigo and loss of consciousness(58). 
If the acute poisoning is caused as a result of inhaling Cd, the symptoms include in 
addition to vomiting, metallic taste, dry throat or cough, headache with flu-like 
symptoms, muscle weakness, chest pain, asthma-like bronchospasm, pneumonitis 
and even fatal acute pulmonary oedema(58, 60, 61). Damage to the liver and kidneys 
can also occur in case of cute Cd poisoning(61). Chronic exposure to cadmium affects 
the kidneys, lungs and the skeleton causing chronic bronchitis, emphysema, 
pulmonary fibrosis and renal dysfunction characterized by tubular proteinuria(58). 
The nephrotoxicity is also partially responsible for the skeletal manifestations like 
bone defects due to osteomalacia, osteoporosis and spontaneous fractures(60). 
Chronic Cd exposure also increases blood pressure and causes myocardic 
dysfunctions(58, 59). 
1.3.1.3 Mercury toxicity 
Mercury toxicity is long known and it is reported as an inducer for public health 
disasters in Minamata Bay, Japan when methylmercury chloride effluent from a 
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factory that used Hg as a catalyst in the production of vinyl chloride and acetaldehyde 
was released into Minamata Bay(62, 63).  In Iraq, bread made from methylmercury-
treated grain was consumed by people in two different occasions, 1959-1960 and 
1971-1972 poisoning many and causing foetal deformities when pregnant women 
consumed that bread during those periods(62, 63).  
Inhalation of Hg vapour is very hazardous because it is almost completely absorbed 
and about 75% of it is retained(62). The systems that are affected the most are the 
nervous, pulmonary, genitourinary (GU), GI and haemopoietic systems. Hg induces 
mitochondrial dysfunction and oxidative stress(64). 
Elemental mercury is poorly absorbed in the GI tract and is readily eliminated in 
faeces(62). Inorganic salts of mercury are corrosive to gastric mucosa and 
accumulate in the proximal convoluted tubules of the kidneys(62). Organic mercury 
compounds are more toxic and the poisoning symptoms can be delayed for weeks 
with methyl and ethyl mercury being the most toxic because of their complete 
absorption from the GI tract and slow excretion(62, 63).  
In addition to the elimination of mercury in faeces, it is also eliminated in urine and 
significant amounts are shed in sweat, tears, saliva and milk in case of breast-feeding 
women(63). It also crosses the placental and is teratogenic(62). Prenatal exposure 
have been associated with neurodevelopmental delays and cognitive deficits and 
larger doses induce a form of cerebral palsy(63).   
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Acute Hg poisoning by inhalation causes symptoms that include cough, chest 
tightness, dyspnea, fever, chills, general weakness and GI upset. In addition to 
peripheral neuropathy and even renal failure(62). 
Chronic exposure to organic Hg affects the central nervous system (CNS) because 
compounds like methylmercury can cross the blood brain barrier (BBB)(62) causing 
irritability, insomnia, headache, hearing loss,  constricted visual fields, decreased 
cognitive function, tremors, seizures, ataxia, slurred speech, hallucinations, paralysis, 
coma, and eventually death(63). Chronic mercury poisoning also causes pneumonitis, 
necrotizing bronchiolitis, pulmonary oedema, nephrotic syndrome, hypertension, 
myocardial infarction, arrhythmia, reduction in heart rate variability, generalized 
atherosclerosis and overall increase in total cardiovascular mortality(64). 
Skin contact results in gray or blue-black pigmentation, cutaneous burns, contact 
dermatitis, and exfoliation. Chronic exposure also result in mercurialentis, which is 
gray or brown discoloration of the lens of the eye(62). 
1.3.1.4 Lead toxicity 
In 1678, Vernatti probably made the earliest record of Pb poisoning among white-
lead workers in England(65). In 1892, Pb poisoning of children exposed to white 
leaded paint was reported in Brisbane, Australia(66). 
In 1900s, Hamilton, who was a pathologist that pioneered industrial control of 
occupational Pb exposure, recognized occupational Pb exposure by inhalation of dust 
and fumes. Additionally, in 1904, Gibson concluded that lead paint in houses was 
responsible for poisoning children(67). Children exposed to lead showed signs of 
learning difficulties, school failure and behavioral disorders(66). 
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Human exposure to Pb could occur via inhalation and ingestion. Lead’s absorption is 
affected by many factors with pregnant women and children being more vulnerable 
as they may absorb 40% to 70% of ingested Pb. Pb is excreted with urine and faeces. 
The unexcreted portion is distributed and exchanged among haematologic, renal, 
neurologic and mineralised tissues like teeth and bones. 
Lead’s toxicity results from its ability to bind strongly to sulfhydryl groups on proteins 
leading to distortion of structural proteins and enzymes. In addition to its ability to 
interfere with the development of the endogenous opiate system. It can also mimic 
or compete with calcium hindering its physiological functions. Due to that, lead 
poisoning affects many systems in the human, but the one most affected is the 
CNS(66, 68, 69).  
Acute Pb poisoning causes limb and joint pains, haemolysis, renal tubular damage 
with glycosuria and aminoaciduria, acute hepatorenal failure, convulsions, coma and 
eventually death. Surviving severe lead poisoning in children left them with permeant 
neurological disorders including deafness and mental retardation(65, 70). 
Chronic Pb poisoning affect the central and peripheral nervous systems, 
haemopoietic system, GU system, musculoskeletal system and GI tract(65-67). CNS 
Pb toxicity symptoms include headaches, irritability, agitation, ataxia, drowsiness 
confusion and convulsions. Peripheral neuropathy is associated with wrist or foot 
drop(65, 66). Haemopoietic toxicity symptoms are characterised by anaemia, 
hemolysis and hypertension(66, 67). Regarding the GU system, Pb poisoning reduces 
glomerular filtration rate, causes interstitial nephritis and nonspecific proximal 
tubular dysfunction(66, 67).  Because Pb is deposited in mineralised tissues, bones 
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formation is altered(65). Additionally, GI symptoms like nausea, vomiting, abdominal 
pain, metallic taste, anorexia, constipation or diarrhoea appear with Pb  
poisoning(67). Because of lead’s ability to cross the placenta, it was associated with 
preterm delivery and low birth weights. It is also secreted with breast milk increasing 
infants’ exposure to the toxic metal(69). Finally, inorganic lead is classified as a Group 
2A carcinogen by IARC, which means it is likely to cause human cancer(71). 
1.3.2 Toxicity of Class 2A elements 
1.3.2.1 Cobalt toxicity 
Cobalt is an essential element required for human and animals metabolism. It is 
necessary for the formation of cobalamin, also known as vitamin B12, which catalyses 
the production of genetic material.  Co also plays a role in the formation of red blood 
cells(72). Traditionally, Co was used in medicine as a treatment for anaemia, however, 
in the 1940s it was found that it blocks iodine uptake by the thyroid gland and thus 
reduces its activity and causing goiter(73, 74).   
Cobalt poisoning has been  reported over a number of years. In the 1960s, some 
breweries in Quebec City; Canada, Omaha; Nebraska and in Minneapolis; Minnesota 
used 1–1.5 mg cobalt chloride/L beer to reduce the foaming of soap residues from 
electric dishwashers causing what was known as beer drinker's cardiomyopathy. 
However, co-factors like inadequate protein and vitamin intake as well as Zn 
depletion contributed to the development of the cardiomyopathy in those who 
consumed that beer(75). 
In the 1970s high-speed grinding disks coated with abrasive microdiamonds 
embedded in binding cobalt powder were introduced to the diamond industry in 
Belgium. This was accompanied by progressive increase in respiratory disease among 
25 
 
workers due to inhaling the metal’s dust and it was referred to as hard-metal 
pneumoconiosis. Acute exposure causes cough, wheezing and malaise, while chronic 
exposure led to pulmonary fibrosis(76). Several other cases of Co poisoning in 
patients who had undergone metal-on-metal hip replacement or other procedures 
involving similar prostheses were reported as well(77-79).  
Cobalt is absorbed from both the GI and respiratory tracts. Following absorption, it 
is distributed to the liver, kidneys, pancreas, and heart, with the relative content in 
skeleton and skeletal muscle increasing with time. Co is mainly eliminated with 
urine(73, 80). 
Cobalt poisoning symptoms are nausea, vomiting, chronic thyroiditis, goiter, 
myxoedema, blindness, deafness and peripheral neuropathy(81). In addition to 
cognitive decline characterised by memory loss and poor concentration, 
disorientation as well as muscle weakness, numbness and tremor(74, 80, 82). In case 
of acute inhalational exposure, hypersensitivity pneumonitis usually occurs that 
evolves to chronic fibrosis after long-term exposure.  Skin contact with Co is reported 
to cause allergic contact dermatitis(74, 80, 82).  
1.3.2.2 Nickel toxicity 
In 1890, Mond and co-workers(83) discovered one of the most toxic chemicals 
encountered industrially; nickel carbonyl. Nickel carbonyl is a highly volatilised 
compound produced as an intermediate in the separation of nickel from its ores, the 
fabrication of nickel and nickel alloy components, the manufacturing of high purity 
nickel powders and catalysts(83). Inhalation of nickel carbonyl produces initial and 
delayed symptoms. The initial symptoms include cough, tightness in the chest, 
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nausea, vomiting and frontal headache, while chronic exposure for several years can 
induce carcinoma of the respiratory tract(84, 85). 
Nickel is normally present in human tissues. It helps maintaining proper functioning 
of the body, increasing hormonal activity and is involved in lipid metabolism. It is 
absorbed via the skin, respiratory and GI tracts(86). Toxicity of Ni results from its 
interference with the metabolism of essential elements like Fe, Mn, Ca, Zn, Cu and/or 
Mg(85). 
Skin contact causes dermatitis and produces erythema, eczema and lichenification 
of the skin. Dermatitis and eczema can be aggravated when Ni is ingested. Other 
symptoms resulting from exposure to high concentrations of Ni are asthma, 
conjunctivitis, high blood pressure, dizziness, difficulty sleeping, neurological deficit 
and developmental deficits in children. In addition, it increases the risk of lung cancer 
and cardiovascular diseases(87). Finally, when Ni is introduced into the body, it 
generates reactive oxygen species and free radicals that may also damage the 
kidneys and the liver(88). 
1.3.2.3 Vanadium toxicity 
Vanadium compounds like sodium metavanadate were traditionally used to treat 
tuberculosis, syphilis, diabetes and anaemia(89).  
Vanadium has oxidising abilities and can inhibit oxidative phosphorylation in the 
body(89). It is absorbed from the lungs and accumulates there with age. Limited 
amounts are absorbed via GI tract following ingestion and skin absorption is minor in 
humans. It is mainly excreted in the urine and a fraction is eliminated in the 
faeces(90). Exposure to toxic amounts of V causes headache, dizziness, skin rash, 
digestive problems like nausea, vomiting, stomach pain, diarrhoea, inflammation to 
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the GI tract, and loss of appetite. Respiratory symptoms include rhinitis, wheezing, 
cough, sore throat, nasal haemorrhage, irritation to nose, throat and the upper 
respiratory tract mucosa, chest pain, bronchitis and pneumonia(89, 90).   
1.4 Validation Issues 
The validation of any optimised analytical procedure is important to make sure that 
the method is accurate and precise.  
In USP <233>(9), the recommended validation procedure is to spike the samples at 
concentrations ranging from 50% to 150% of the indicated limit value for each target 
element. The method is considered accurate if the spike recovery was between 70% 
to 150% for the mean of three replicate preparations at each concentration. For 
precision, six spiked samples are required to be analysed and the acceptance criteria 
for the repeatability is a relative standard deviation (RSD) not more than 20% for 
each target element and for intermediate precision, RSD of not more than 25% for 
each target element is acceptable(9). 
Many methods published in the literate regarding the determination of EI in 
pharmaceuticals were validated as described in USP <233> (13, 17, 47, 123-129). 
However, using a standard reference material (SRM) ensures the highest level of 
accuracy and precision in routine analytical measurements(91). 
SRM is a well characterised material that is sufficiently homogenous, stable and is 
certified for one or more chemical and physical properties. It is used to validate 
analytical measurements by ensuring the accuracy and precision of an analytical 
method as well as its long-term adequacy(92). 
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For EI in pharmaceutical products only one solid SRM is available and that is from the 
National Institute of Research and Technology, NIST 3280 multivitamin/multielement 
tablets. Each tablet weighs approximately 1.5 g and consists of vitamins, carotenoids, 
and minerals. It is usually used to validate analytical methods developed for the 
analysis of vitamins and carotenoids. However, it also has certified levels of elements. 
The elements included in the NIST 3280 tablets are B, Ca, Cl, Cu, I, Fe, Mg, K, Zn, As, 
Cr, Pb, Mo, Ni, Se, Cd, Co, Na, Ti, V, Sb, Sn, silicon (Si), phosphorus (P) lanthanum (La) 
and strontium (Sr). It is produced by blending vitamin and mineral pre-mixes with the 
remaining excipients. Fat-soluble vitamins and carotenoids were added as gelatine 
beadlets and then the tablets were coated with yellow aluminium lake, triethyl 
citrate, polysorbate 80, hypromellose, and titanium dioxide(93). 
However, this reference material has Class 1 elements in levels unrepresentative of 
the guidelines. Arsenic for example is present in a concentration of 0.132 ± 0.044 
µg/g(93) in comparison with the guidelines limit of 6 µg/g in the finished drug product 
with daily intake of 2.5 g(10). In addition, it does not include Hg. 
1.5 Principles of instruments used in this work 
The following sections discuss the principles of the instruments used in this work for 
the determination of Class 1 and Class 2A elements in pharmaceutical products. 
1.5.1 Microwave assisted extraction of elements form pharmaceuticals for 
ICP-OES and ICP-MS determination 
One of the challenges facing pharmaceutical industry now regarding the 
implementation of the new EI guidelines is preparing the different samples for 
analysis using appropriate procedures. Most analytical procedures require samples 
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to be prepared as solutions. This include ICP-OES and ICP-MS, the two techniques 
suggested as an alternative to USP <231> in addition to other techniques useful for 
this purpose such as AAS(94). The use of microwave (MW) assisted wet digestion to 
prepare samples was first described in 1975 by Abu-Samra et al(95)  to prepare 
biological samples for  metals analysis using flame atomic absorption and since that 
time it has become widely used in many fields.  
In the USP <233> chapter, the proposed sample preparation method for materials 
that are not directly soluble in organic or aqueous solvents is closed vessel digestion 
using concentrated acid(s)(96). The closed vessel digestion is chosen in order to 
minimise the loss of volatile impurities like Hg which was shown to be completely 
lost when the samples are digested using techniques that require ignition and 
combustion at high temperatures(8, 97). It also minimises contamination from the 
surrounding laboratory environment. Using closed vessel digestion method allows 
the use of temperatures higher than the boiling point of the acids involved in the 
digestion due to the elevated pressure of the system. The pressure builds up in the 
vessel from the gases obtained as a result of heating the liquid mixture. Vapour will 
also be produced from the heated acids themselves, but it lacks the ability of 
absorbing MW energy, so will have a lower temperature than the liquid mixture. 
Eventually the vapour will condense on the cool vessel wall(98). 
MW assisted digestion provides a suitable way for digesting samples in pressurised 
closed vessels with minimum loss of elements when appropriate acids are used.  
 The method gives efficient digestion in a reasonable amount of time and was found 
to be superior to the dry ashing method in recovering elements like Pb and Hg when 
analysing EI in medicinal plants(99, 100). In one of the mentioned studies, up to 0.5 
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g of Peumus boldus, Paulinia cupana, Passiflora incamata L., and  Maytenus ilicifolia 
were digested in closed vessels using nitric acid (HNO3) and gave recoveries ranging 
between 96 and 103% for Class 1 elements; As, Cd, Hg and Pb(99). 
In general for MW assisted digestion, HNO3 is used as oxidizing agent alone or 
combined with other acids such as hydrochloric acid (HCl), sulfuric acid (H2SO4) or 
even hydrofluoric acid (HF) to get complete digestion of silica containing 
matrices(101). Sometimes it also used in combination with hydrogen peroxide (H2O2) 
and many others including alkaline reagents(102, 103). HNO3 is used widely due to 
its suitability to most instrumental techniques.  
Accordingly, the use of MW assisted acid digestion followed by analysis using ICP-
OES or ICP-MS became very popular to fulfil the new pharmacopeial requirement. In 
a study to determine elemental impurities in pharmaceutical excipients, the samples 
were prepared using closed-vessel MW assisted digestion with a “vent-and-reseal” 
design to control the pressure and avoid over-pressurising the system which may 
lead to sample loss(31). 
Even though MW assisted acid digestion was successfully applied to many samples, 
it has some limitations with certain type of applications due to the nature of the 
samples used. It was reported that the used of MW assisted digestion using HNO3 for 
tricyclic APIs including carbamazepine, imipramine hydrochloride and amitriptyline 
hydrochloride was not effective as a yellow-orange solid residue was formed and it 
was identified as stable nitro compounds using proton nuclear magnetic resonance 
(1H NMR)(97). To overcome the problem MW induced combustion (MIC) that 
integrates the combustion and acid digestion into an oxygen-pressurised thick-wall 
closed-vessel was used. It was very efficient and  gave recoveries for As, Cd, Hg and 
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Pb of 94-103%(97). Combustion techniques convert carbon and hydrogen to their 
corresponding oxidation products allowing organic matrices to be completely 
decomposed and thus minimise analysis interferences(100).  
1.5.1.1 Microwave Fundamentals  
The interaction between the sample during digestion and the MW electromagnetic 
radiation is similar to that between energy and matter in general. MW have 
frequencies ranging from 300 up to 300,000 megahertz (MHz) and wavelengths (λ) 
ranging from one meter (m) to one millimetre (mm)(104). They are between infrared 
radiation and radio frequencies in the electromagnetic radiation spectrum(104). 
Frequencies between 915 and 22,125 MHz can be used for scientific, medical and 
industrial purposes according to the US Federal Communications Commission 
(FCC)(105).  
Figure 1.4 illustrates the position of MW in regards to the electromagnetic radiation 
spectrum.  
 
Figure 1.4  Electromagnetic radiation spectrum(106) 
 
Material may transmit, absorb and/or reflect MW depending on their nature, such 
as structure and composition. Transparent materials allow MW to pass through them 
easily. Absorptive and conductive materials will increase in temperature when they 
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are exposed to MW because of energy transfer. Unlike conventional heating, MW 
heating does not result from direct heat transfer, but it is due to the energy 
conversion from electromagnetic energy to thermal energy(107). MW heating is 
usually referred to as dielectric heating because of the electric field resulting from 
the electromagnetic radiation(108). 
For liquids, energy transfer occurs via two mechanisms when they are subjected to 
MW. Those are dipolar rotation and ionic conduction, and this depends on the 
dipoles and ions present in them which affect the type of interaction occurring. Both 
interactions increase the molecular movement throughout the volume of the 
material and thus produce volumetric heating(107, 109). In homogeneous liquids, 
the MW energy will redistribute between molecules giving uniform heating, while for 
heterogeneous systems the heating may become selective. This non-uniformity 
heating results from the different components ability to interact with MW 
energy(110). 
1.5.1.2 Dipole Rotation 
This process occurs when polar molecules, e.g. water,  are subjected to the oscillated 
electric field from the MW and align with it, followed by returning to the disordered 
state and vice versa in a relatively very short time, see Figure 1.5 This result in a very 




Figure 1.5 Schematic representation of the water molecules alternating alignment 
under the oscillating electric field induced by MW. A) Water molecules without 
the influence of MW. B) Water molecules under the influence of MW. (Adapted 
from Flores EM,2014(112)) 
 
1.5.1.3 Ionic conduction  
This occurs when the liquid’s charges flow as a result of the interaction with the 
oscillating MW electric field, causing the ions to be in motion and thus suffers from 
resistance to its movement from the other species present. This process generates 
heat around the ions and as the temperature increases the ion flow will increase as 
well and the cycle continues(109, 111, 113). Anions and cations must be present in 
the solution to contribute to the heating process and so, their concentration and 
mobility are directly related to the heating resulting from MW.  
Solutions heating degrees with MW can vary due to many factors including ion 
mobility, which depends on the ions size, charge, conductivity and temperature(109, 





Figure 1.6 Schematic representation of the ionic conduction under the oscillating 
MW electric field. (Adapted from Flores EM,2014(112)) 
 
1.5.1.4 Dielectric Heating 
The dielectric properties of materials play an important role in their interaction with 
MW. It represents the different materials abilities to convert electromagnetic energy 
into heat(111, 114).  
The materials capacity of absorbing MW is directly related to the MW penetration 
degree into the material. Reflective materials are not penetrated by MW, while 
transparent materials will be easily penetrated. For absorptive materials, 
electromagnetic energy will convert to heat according to their dissipation factors, or 
loss tangent (tan δ) which depends on the relation between the dielectric loss factor 
(εʺ) and the dielectric constant, also known as relative permittivity (εʹ) of the 
material(19, 115), as presented in Equation 1.1: 
 𝒕𝒂𝒏 𝜹 = 𝜺ʺ 𝜺ʹ⁄  ... Equation 1.1 
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εʺ expresses the ability of a material to convert the absorbed electromagnetic energy 
to heat by dissipating it, while εʹ  measures the ability of a material to polarise under 
the influence of external electric field(19, 115).  
Polar liquids that have permanent dipole moments within their molecules have 
comparatively higher εʹ than nonpolar liquids that become polarised when an 
external electric field is applied to them(113). 
Regarding the microwave equipment components, the walls are made of reflective 
materials and the accessories inside are made of transparent materials(116). 
1.5.1.5 Monomode and multimode microwave equipment 
Microwave digestion systems can be categorised according to the delivery method 
of the MW energy to monomode and multimode systems. These are constructed 
differently to meet research applications(117). Magnetrons are commonly used as 
the radiation source in microwaves(118).  
Monomode microwaves have small cavities that allow the MW to be directly focused 
on the liquid mixture, resulting in a well defined MW field with high density that 
enhance heating rates, yet only one sample can be digested each run(119). As 
heating and digestion proceed, the internal pressure of the vessel usually increases 
due to the vaporisation of part the digested material. To prevent damage to the 
vessel because of the excessive pressure developed during digestion, the cap is 
displaced from a sealing position into a non-sealing position when internal pressure 
exceeds a predetermined value(120). 
 Because the vessels used with monomode microwaves are smaller, the likelihood of 
high pressure build up is more probable. The high pressure activates the cap-
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releasing mechanism causing sometimes significant losses of elements like Hg or 
those that form volatile compounds like As, Sb and Sn(98).  
On the other hand, multimode microwaves have large cavities that distribute the 
MW in a chaotic manner, causing non-uniform distribution of heat. However, they 
can take more than one sample in the same run, but the time required for heating 
and cooling the system is much longer with the bigger cavity(110, 117). 
Homogenizing the MW field for multimode microwaves can be obtained by using two 
magnetrons facing each other, to help irradiating the samples from all 
directions(118). Figure 1.7 represents graphical illustration of monomode and 
multimode microwaves. 
 
Figure 1.7 Graphical illustration of monomode and multimode microwaves. 
(Adapted from Nüchter et al, 2003(118)) 
 
Recently microwaves that have direct multimode cavities to provide efficient heating 
like monomode microwaves and at the same time can take more than one sample in 
the same run as multimode microwaves have become available to provide the 
advantages of both types(121). 
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1.6 Inductively coupled plasma (ICP) for elemental impurities analysis 
in pharmaceuticals 
ICP based instruments have been used in the pharmaceutical applications discussed 
in the previous sections(13, 17, 47, 122-128).  
Plasma is a state of matter that consist of positively and negatively charged particles 
with approximately equal charge density in addition to neutral atoms, molecules and 
radicals, so its overall charge is roughly zero(129). It is formed by heating a gas 
enough to cause the atoms to collide and ionise as the random kinetic energy of the 
molecules exceeds the ionisation energy. That is why sometimes it is simply referred 
to as an ionised gas and it is considered the fourth state of matter(130). Plasma was 
given its name which means ‘moldable substance’ in Greek by Irving Langmuir in the 
1920s who pioneered this type of work(131). 
The plasma has distinctive characteristics because it is electrically conductive, so its 
behavior can be dominated by electric and magnetic fields(132). 
Argon (Ar) is usually the gas used to produce plasma for ICP-OES and ICP-MS. Once 
generated, the plasma is then used to dissociate the sample as well as exciting and 
ionising atoms for atomic and ionic emission. In addition, Ar-ICP is able to efficiently 
generate singly charged ions from the elements in the sample making the metals 
detection with OES and MS very suitable(133, 134). 
ICP development started In 1940s by Babat, who published a paper about the 
characteristics of ‘electrodless discharges’ produced at atmospheric pressure during 
World War II(19, 135). The next step in the evolution of ICP was in 1960s when Reed 
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described the formation, stabilisation and thermal isolation Ar-ICP(136).  In 1970s, 
Velmer Fassel in the United States of America (USA) made breakthrough 
developments of the ICP, which is now used today(136). He(g) demonstrated its use 
as ion source for mass spectrometry(137). In the same period, Greenfield in the 
United Kingdom (UK) also recognised the use of ICP as a spectroscopic source(135, 
138, 139).  
For modern ICP, a pure gas, usually argon is directed through a torch. Other gases 
that are used including helium (He) and nitrogen, the gas purity is important as 
contaminants might quench the torch(130-132). Conventional torches consist of 
three accurately aligned concentric tubes made of silica, quartz or any other suitable 
material for argon flow and sample aerosol injection(134-136, 140). The spacing 
between the outer and middle tubes is narrow to allow high velocity emerging of gas 
introduced in between. The outside chamber design makes the gas spiral tangentially 
around it as it proceeds upward. See Figure 1.8. 
 
Figure 1.8 Graphical illustration of ICP torch 
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The outermost, longest tube at the top end of the torch is surrounded by a water or 
gas cooled induction coil, usually made of copper and known as the load coil that is 
connected to a radio frequency (RF) generator. When RF power (700 -1500 watts (W)) 
is applied to the load coil, a rapidly oscillating current that moves back and forth 
within the coil at a rate corresponding to generator’s frequency (27-40 MHz) 
generates magnetic and electric fields(134-136). As the gas is swirled in a controlled 
flow rate through the two annular spaces between the tubes in the torch, a spark is 
applied to it from a Tesla coil initiating the gas ionisation by stripping some electrons 
from the gas atoms. The resulting electrons then interact with the magnetic field and 
are accelerated by it(135, 136). This process is called inductive coupling(134). The 
electrons produced with high energy will then ionise more gas atoms by collision 
excitation and this chain reaction continues forming the ICP discharge that consists 
of the gas atoms, ions and electrons and is sustained by the continuous supply of RF 
energy that is transferred to it through inductive coupling between the coil and the 
ionised gas within the torch(137, 141, 142). 
The ICP discharge has a very intense white colour, sometimes called the argon 
continuum, when Ar(g) is used. The ICP temperature ranges from 6000 to 10000 °K, 
so one of the controlled high gas flow rate (10-20 Liter/minute (L/min)) between the 
outer and middle tubes functions is to protect the wall and the tip of the torch from 
the intense heat by cooling it, so it is referred to as the coolant flow. This gas is also 
called the plasma flow or the "outer" gas flow and is normally about 7-15 L/min(134-
136). It is worth mentioning that different plasma regions differ in their temperature. 
In addition, the plasma can be divided to zones where different processes occur, 
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Koirtyohann et al. suggested names for each zone(134, 140, 143). Figure 1.9 
represents the ICP torch, plasma regions temperature and the different plasma zones.   
 
Figure 1.9 Plasma regions and temperatures (°K ± 10%) and the different plasma 
zones 
 
ICP's resemble a toroidal or annular shape in the energy input region. The base of the 
discharge is doughnut-shaped as the sample aerosol injected from the nebuliser via 
the inner gas flow forms a hole through the center of the discharge.  
The sample aerosol introduction into the plasma is made easier by the auxiliary flow, 
a.k.a intermediate flow that runs directly under the plasma toroid and keeps the 
plasma discharge off the intermediate and injector tubes in the torch. It is usually 
about 1-3 L/min and when organic samples are analysed, the auxiliary flow helps 
reducing carbon formation on the tip of the injector tube(134, 136). 
The doughnut itself is where the induction energy transfers from the coil to the 
plasma, so it is called the induction zone(134-136, 138). As mentioned before, the 
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aerosol, which is a very fine mist of droplets produced from the liquid samples is 
carried into the center of the plasma by the inner gas flow; the nebuliser, and is 
produced as a result of the high plasma temperature desolvating the samples by 
removing the solvents in which its dissolved leaving small salt particles(134-136, 138). 
Then, these particles are vaporised into individual molecules of gas, which then 
dissociate into atoms in a process known as atomization, these processes occur in 
the preheating zone. Finally, the ICP excites and ionises the formed atoms in the 
initial radiation zone and the normal analytical zone(134-136). The exact mechanisms 
of excitation and ionisation are not very clear, but it is believed to be as a result of 
the analytes atoms collisions with the high-energy electrons(134, 140).  See Figure 
1.10  
 
Figure 1.10 Different processes that occur when an aerosol droplet is injected into 
the ICP discharge (Adopted from Boss CB and Fredeen KJ, 1999(134)) 
The Figure originally presented here cannot be 
made freely available via LJMU E-Theses 
Collection because of copyright. The Figure was 
sourced at Boss CB, Fredeen KJ. Concepts, 
instrumentation and techniques in inductively 
coupled plasma optical emission spectrometry. 
Chapter 2: General Characteristics of ICP-OES. 
Norwalk: Perkin Elmer; 1999. 
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1.6.1 ICP advantages  
Compared to flames, furnaces and electrothermal methods, ICP provides many 
advantages due to its superiority in vaporing, atomizing, exciting and ionising 
multielements in different samples reproducibly. This is due to the higher 
temperature provided by ICP in comparison to the mentioned techniques, where the 
temperature maximally reaches 3300 °K. The elevated ICP temperature also reduces 
chemical interferences as the analyte particles reside for about two milliseconds in 
the high temperature and that is considerably longer time compared to flames and 
furnaces that helps reducing matric interferences(134, 136). Furthermore, the 
sample’s aerosol is directed into the center of the ICP discharge, which prevent it 
from interfering with the energy transfer from the load coil to the discharge unlike 
non-ICP discharges and this leads to minimised matrix effects and higher stability. 
Finally, ICP is capable of analysing large number of samples in a relatively short period 
with very good detection limits over a wide range for most elements(135, 140). 
1.6.2 ICP-Sample Introduction 
The samples are introduced to the ICP using nebulisers that generally use gas flow to 
deliver the aerosol after converting liquids into a fine mist in a spray chamber and 
thence the torch. The samples introduced to ICP can be liquids in nature or solids 
dissolved in suitable solvents. The nebulisation process is critical to deliver the 
sample in a suitable form; that is small droplets, so that the plasma can then 
desolvate, vaporise, atomise, ionise, and excite(134, 135). 
Two forces are successfully able to break up the liquid sample into aerosols to be 
delivered for ICP; those are ultrasonic mechanical forces and pneumatic forces. The 
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latter is the most commonly used for commercial ICP nebulisers(125, 144). The 
different types of nebulisers used with ICP instruments are concentric, micro-
concentric, cross-flow, Babington and ultrasonic nebulisers(136, 145-148).  
The produced sample aerosol is then transported to the torch in order to be injected 
into the plasma. A spray chamber is placed between the nebuliser and the torch, to 
ensure that only small droplets reach the plasma(148, 149). The main function of the 
spray chamber is to eliminate large droplets (>10 µm in diameter) produced by the 
nebuliser. Another function is to smooth out pulses during nebulisation that result 
from pumping the sample solution(134). 
In addition, some ICP-MS spray chambers are externally cooled to 2–5°C  
to minimize the amount of solvent going into the plasma, enhance the sample’s 
thermal stability, reduce oxide species and allow the aspiration of organic solvents 
more easily(145). 
The drainage characteristics have an impact on the performance of ICP instrument 
and it is important to be continuous and smooth(148). In addition to the drainage 
system carrying away excess sample from the spray chamber to a waste container, it 
provides the backpressure required to force the nebuliser gas carrying the sample 
aerosol to flow through the torch and into the plasma discharge(134, 148, 150). The 






1.6.3 Inductively coupled plasma optical emission spectroscopy (ICP-OES) 
Figure 1.11 illustrates the layout and major components of ICP-OES instrument 
 
Figure 1.11 Basic components of ICP-OES instrument (Adopted from Boss CB and 
Fredeen KJ, 1999(134)) 
 
ICP-OES is one of the most common methods for elemental analysis. It can analyse 
various types of dissolved samples with good detection limits and low interference 
for most elements. After the sample is introduced as an aerosol and became excited 
and ionised by the plasma, the emitted radiation in the ultraviolet (UV)/visible range 
from the excited elements decaying back to lower energy states is sampled for 
measurement using optical spectrometer(134, 135, 151). Each excited element has a 
typical emission spectrum and emits specific λ. Furthermore, the element 
concentration in the sample is proportional to the radiation intensity(151). 
Understanding the nature of atomic and ionic spectra is useful to better understand 
these processes.  
1.6.3.1 Nature of atomic and ionic spectra 
In 1913, Ernest Rutherford and Niels Bohr introduced the Rutherford–Bohr model of 
atoms. The model describes the atom as a positively charged nucleus surrounded by 
negatively charged electrons that travel in circular, discrete orbitals around the 
The Figure originally presented here cannot be made freely available via LJMU E-
Theses Collection because of copyright. The Figure was sourced at Boss CB, 
Fredeen KJ. Concepts, instrumentation and techniques in inductively coupled 
plasma optical emission spectrometry. Chapter 3: ICP-OES Instrumentation. 
Norwalk: Perkin Elmer; 1999. 
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nucleus. These orbitals have distinct energy levels that increase as it gets far from the 
nucleus. Each atom has a certain number of orbitals(152-154).  
Normally, electrons are in their ground state that is the lowest energy state available. 
The atoms energy can be increased by collision with other atoms, ions, electrons or 
molecules, or by absorbing electromagnetic radiation. When this happens, many 
possible phenomena can take place, but mostly the absorbed energy will excite the 
atom, or will increase its kinetic energy(152, 154).  
When the atom is in the excited state, an electron from the ground state orbital 
promotes to an orbital with higher energy level. This state is less stable, so the atom 
will lose energy by collision with other particles or emission of a photon i.e. 
electromagnetic radiation to decay back to a more stable, less energy state, thus the 
excited electron returns to its original orbital. The energy required for electron 
transitions between orbitals must be equal to the energy difference between two 
levels regardless whether it was radiational or thermal, i.e. collisions(152, 154). 
Sometimes, when absorbed energy is high, electrons may completely dissociate from 
the atom in a process called ionisation, because it leads to the formation of ions with 
a net positive charge. For many atoms, more than one electron can be completely 
removed when applying suitable energies known as ionisation potentials that differ 
for each element. Ions also have ground and excited states and behave similarly to 
atoms regarding excitation and decay processes(134, 155). 
For radiative transitions, a photon’s energy can be derived through Planck’s equation: 
 ∆𝑬 = 𝒉𝒇 = 𝒉𝒄/𝝀  … Equation 1.2  
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Where the energy (ΔE) equals Planck’s constant (h) times its frequency (f) and thus 
is proportional to its f, or inversely to its wavelength (λ), since c is the speed of light 
and equals f λ. 
Each element has characteristic energy levels and consequently unique absorption 
and emission wavelengths(134, 154). Figure 1.12 represents the excitation of atom 
followed by its decay to a more stable state. 
Figure 1.12 Rutherford-Bohr model of an atom showing its excitation to a higher 
energy state followed by its decay to a lower energy state by releasing the gained 
energy (Adapted from Boss CB and Fredeen KJ, 1999(134)) 
 
 The ICP in the instrument can populate a wide number of different energy levels for 
various elements simultaneously all the time, which gives flexibility to the technique 
by allowing the measurement of several emission λ for the same element and the 
emission obtained for various different elements concurrently. This characteristic 
provide advantages as explained, but is also disadvantageous, because the 
interferences increases with increasing the number of emission λ(134, 151). 
The torch can be operated in vertical position, so the analytical zone is viewed radially; 
i.e. side-on viewing, or it can be put horizontally, so the analytical zone is viewed 
axially; i.e. end-on viewing. In addition, a combination of both can be used called dual 
viewing. Radial ICPs are more robust and more resistant to matrix effects, but less 
The Figure originally presented here cannot be made freely available via LJMU E-
Theses Collection because of copyright. The Figure was sourced at Boss CB, 
Fredeen KJ. Concepts, instrumentation and techniques in inductively coupled 
plasma optical emission spectrometry. Chapter 1: An Overview of Elemental 
Analysis via Atomic Spectroscopy Techniques. Norwalk: Perkin Elmer; 1999. 
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sensitive. On the other hand, axial ICPs are more sensitive to analytes but also more 
prone to matrix effects. This is because of the  longer bath length which allows the 
production of higher analyte emission and thus improved the sensitivity that is 
reflected in five to ten fold improvement in detection limits(156, 157). Regardless of 
the ICP viewing configuration, a focusing optic like a concave mirror or convex lens is 
usually needed to collect the radiation and focus the plasma image onto the 
spectrometer or the wavelength dispersion device(134, 151).  
Wavelength dispersion devices discriminate emissions from an element as well as 
from other elements or molecules. Diffraction grating are the most common physical 
wavelength dispersion devices. Other devices like interferometers, filters and prisms 
are used, but are less common(134, 158). After the emission line is isolated by the 
spectrometer, a detector is used to measure the emission intensity. For ICP-OES, 
photomultiplier tube (PMT) used to be very common(134).  
More advanced detectors referred to as array detectors were developed and used in 
ICP-OES. These include photodiode array (PDA)(159, 160) and solid-state or 
semiconductor radiation detectors like the charge-injection device (CID) and the 
charge-coupled device (CCD)(161-163). CID and CCD provide greater flexibility and 
greater choice of analyte λ compared to PMT-ICP-OES in addition to the simultaneous 
measurements and faster analysis time. Both CID and CCD contain a two dimensional 
array of light sensitive elements called pixels that are capable of storing a number of 




Finally, the electrical current measured by the detector is converted into voltage 
signal, which in turn is converted into digital information via an analog-to-digital (A/D) 
converter. The digital information is then processed by a computer to be used by the 
analyst with the aid of a computer software(134). 
1.6.3.2 ICP-OES interferences  
When a spectral line produced by one element is very close to a line produced by 
another element, interference between them occurs and the measured intensity in 
this case is a combination of the intensities of the two emission lines that does not 
give a true indication of the abundance of either element(165). 
By analysing calibration standards of known concentrations, quantitative 
measurement of the sample becomes possible. However, interferences can cause 
the signals coming from the sample different than those from the calibration solution 
of the same concentration of the analytes and thus affects the method accuracy(166). 
The level of interference is dependent upon the composition of the sample, the gases 
used in the instrument, and the resolution of the spectrometer.  
The biggest problems in ICP-OES is spectral interferences, so selecting suitable lines 
for trace element analysis is a prerequisite(165).  
The matrix of the sample to be analysed also plays a role in increasing or decreasing 
interferences. Simple matrices like for example deionised water are easier to analyse 
with minimum interferences, while matrices containing elements that emit line-rich 
spectra like Na, K, Ca, Mg, Fe and Al are more problematic(166). 
1.6.3.2.1 Spectral interferences  




Figure 1.13 represents the spectral interferences discussed in this section. 
 
Figure 1.13 Spectral interferences: A) Background shift, B) wing overlap and C) 
direct spectral overlap 
 
Background Continuum: It is radiation distributed continuously over the wavelength 
range of the spectrometer and increases with decreasing wavelength, particularly 
below 200 nm(167). 
It originates from stray light within the spectrometer, the presence of molecular 
species, line-broadening or recombination which is the capture of electrons by ions. 
About 200 argon lines have been observed predominantly between 350 and 450nm 
when Ar(g) is for ICP-OES, making it inapplicable to be used for the analysis of halides 
and other non-metals(166). 
Additional worsening of this type of interference occurs when the samples are 
dissolved in organic solvents due to the intense carbon lines(167). 
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Line-Broadening and Wing Interference: Broadening of spectral lines can occur due 
to several different reasons. These can be due to Doppler effects, foreign gas, or 
resonance effects(167). 
Atoms motion is random and in many directions with slightly different speeds. This 
leads to single atoms emitting the light at slightly different wavelengths according to 
their individual movement away from or toward the detector. This phenomenon 
causes Doppler broadening and produces a Gaussian profile as the wing intensities 
diminish rapidly contributing with not more than 0.01 nm to the background. 
Foreign gas broadening is usually ignored, because it is even less than Doppler 
broadening. It results from collisions between unlike atoms. A similar phenomenon 
called Stark broadening is caused by collisions between excited atoms and ions 
and/or electrons(166, 167). 
The collisions between atoms and other particles changes atoms’ energy and thus 
the required excitation energy will also change slightly(166, 167).  
The presence of an element in a very high concentration in the sample also causes 
very intense emission and broadened spectral line resulting in sloping background 
shift. This occurs due to the collisions between similar atoms and is referred to as 
resonance broadening(134). 
Direct Spectral Overlap: It is the appearance of two lines to be directly overlapped 
when both are within the spectral bandpass of the spectrometer.  Usually in 
detectors, observing only one wavelength is impossible due to the finite widths of 
the exit slits, so the light reaching the detector is of small range of wavelengths and 
this limitation is responsible for direct spectral overlap(166, 167) 
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Techniques for correcting ICP-OES spectral interferences 
i. Line selection 
Selecting λ with highest emission for the analyte is useful to get the best sensitivity, 
however, if this spectral line suffers from severe interferences, alternative λ can be 
selected for the same analyte(166, 167).  
ii. Background correction 
This is used to compensate for continuum interferences. A one-point background 
correction method can be used when the background is static across the spectral 
wavelengths of interest and is performed by measuring a single point at the 
background and subtracting the intensity from the gross signal to derive the analyte 
concentration(134, 167). 
Practically the background is much more complicated and using the one-point 
correction leads to erroneous results, so mathematical procedures have been 
developed to automatically extract the analyte line from a structured background 
comprising continuum, line interferences and instrument drift such as interelement 
correction (IEC). Convolution techniques, Fourier deconvolution give two to three 
fold improvements in resolution, but multivariate statistical methods such as Kalman 
filtering, multiple linear regression (MLR), partial least squares (PLS) analysis and the 
generalized standard additions method (GSAM) give greater resolutions(167). 
1.6.3.2.2 Non-spectral matrix effects 
These effects are produced because of the physical or chemical properties of the 




Matrix-induced effects can depress or enhance the analyte signal intensity and they 
can also affect the resolution of the observed signals. They are highly dependent on 
the experimental conditions such as the applied power, the pump speed, the gas flow 
rate, etc.(170)  
For example, the matrix influences the nebulisation efficiency, which is proportional 
to the signal intensity. Nebulisation efficiency is the percent of sample aerosol that 
reaches the plasma. As mentioned before, only droplets that have a diameter of 
10µm or less can reach the plasma(168, 170).  
The aerosol droplet size is governed by the physical properties of the sample matrix 
such as viscosity, surface tension and density. The flow rate of the sample solution 
also plays a role and is influenced by the peristaltic pump speed and the tubing 
diameter, in addition to the sample gas flow rate(168, 170).  
The acid content of samples is the most common influencer of the matrix physical 
properties. High acid concentrations increase the viscosity, which in turn reduces the 
nebulisation efficiency(168, 170). 
Other differences such as the dissolved solid content and the presence of trace 
organics also contribute to the matrix-induced effects(169, 170).  
Matrix matching between samples and standards is difficult. This is due to the fact 
that one can never matrix match standards to samples exactly all the time and 
attempts to do so are time consuming. However, matrix interferences can be 
reduced by preparing samples and all standards in the same acid matrix and by using 
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an internal standard to compensate for physical interferences such as scandium (Sc) 
and yttrium (Y)(168). 
1.6.4 Inductively coupled plasma mass spectrometry (ICP-MS) 
Figure 1.14 illustrates the layout and major components of ICP-MS instrument 
 
Figure 1.14 Basic components of ICP-MS instrument (Adopted from Thomas R, 
2004 (145)) 
 
In this technique, the number of singly charged ions from the elemental species 
within a sample is measured instead of the emitted radiation. A mass spectrometer 
is used to separates the ions of various elements according to their mass-to-charge 
(m/z) ratio. ICP-MS has high sample throughput rates similar to ICP-OES, but with 
higher linear dynamic range and sensitivity(168, 171). This is because, in ICP-MS, 
the plasma torch is used to generate positively charged ions, not photons. These 
positive ions are detected in large quantities giving ICP-MS its low detection 
capability(145, 172). 
As mentioned before, the high temperature of ICP atomises the analyte, which is 
then ionised by a number of processes. These include thermal ionisation, which is 
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induced by the collision of atoms, ions and free electrons in the plasma(173) as 
illustrated in equations 1.3 and 1.4: 
A + e-→ A+ + 2e-  … Equation 1.3 
A + M → A+ + M + e-  …Equation 1.4 
Other processes are penning ionisation, which is caused by charge exchange between 
analyte atoms and plasma gas metastable species (Equation 1.5), in addition to 
charge transfer resulting from the transfer of energy from an ion to an analyte 
(Equation 1.6). 
X* + A → X + A+ + e- … Equation 1.5 
X+ + A → X + A+  … Equation 1.6 
Both penning ionisation and charge transfer are effective when the energy of the 
colliding species is similar to the ionisation energy of the analyte atom(173).  
The point at which the ions produced from the ICP are introduced to the mass 
spectrometer is generally referred to as the interface. It is the most critical region of 
ICP-MS, because the produced ions must be consistently transported efficiently and 
with the electrical integrity from the plasma, which is at atmospheric pressure of 760 
Torr, to the mass spectrometer analyser at approximately 10-6 Torr. This is achieved 
through the intermediate vacuum region created by the two interface cones(171, 
172). The interface region is maintained at a pressure of about 1 to 2 Torr using a 
mechanical roughing pump. The interface consists of two metallic cones, usually 
made of nickel, but could also be made of platinum to improve tolerance to corrosive 
acids(145, 166). They have very small orifices to allow the ions to pass through to the 
ion optics, where they are guided into the mass separation device(145, 171).  
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The first cone is called the sampler cone and it is the one closer to the plasma with 
an orifice of about 0.8 to 1.2 mm. The second cone is called the skimmer cone and it 
is located shortly after the sampler cone. It is more pointed and smaller with an 
orifice of about 0.4 to 0.8 mm(171). Figure 1.5 represents Thermo XSeries ICP-MS 
cones.  
 
Figure 1.15 Thermo XSeries ICP-MS cones 
 
Because of the small cones orifices, it is recommended to keep the dissolved solids 
below 0.2%. Otherwise, the matrix components will deposit rapidly around the cones 
orifices leading to a decrease in the sensitivity and signal stability if the instrument is 
used for extended time. Dissolved solid materials can also be deposited on the ion 
optics of the mass spectrometer(166). 
The load coil in ICP-MS is grounded to keep the interface region as close to zero 
potential as possible, by eliminating the secondary discharge or pinch effect resulting 
from the capacitive coupling between the load coil and the plasma that causes a 
potential difference of a few hundred volts (100– 200 volts). This secondary 
discharge increases interferences by increasing the number of the doubly charged 
species, spreading the kinetic energy of sampled ions widely making the optimisation 
of the  ion optics erratic and decrease orifices lifetime(145, 172).   
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The ions are separated according to their m/z using a mass separation devise that is 
kept at an operating vacuum of about 10-6 Torr with a second turbomolecular pump. 
The classical mass analysers are the quadrupole mass analysers that consist of four 
parallel cylindrical rods. The rods have the same diameter and length and serve as 
electrodes. They are made of metals like molybdenum or stainless steel and are 
sometimes coated with ceramic to resist corrosion. Opposite rods are connected 
electrically by placing a direct currant (DC) field and a time dependant radiofrequency 
alternating current (AC) to each pair of rods. Ions of a selected mass are then allowed 
to pass through the rods to the detector by selecting optimum AC/DC ratio on each 
pair of rods. Ions that are not of the correct m/z are pumped out of the system by 
colliding with the rods or exiting the path between them(174, 175). The ions 
emerging from the mass analysers are converted into electrical signals that have 
magnitudes proportional to analytes concentrations using a detector(176). Several 
detectors are available such as channel electron multiplier, discrete dynode electron 
multiplier and Faraday cup(177-180). The obtained signal is then processed using 
computers and sophisticated software(166). 
1.6.4.1 ICP-MS Interferences  
Most elements have more than one isotope, which is the same chemical element 
with the same number of protons, but with a different number of neutron, so they 
have different mass numbers. ICP-MS can be used to measure individual isotopes of 
an element or the ratio between two isotopes. As in ICP-OES, the interferences in 




1.6.4.1.1 Spectral interferences 
There are three main types of spectral interferences, isobaric, polyatomic and doubly 
charged ion interferences(181). 
Isobaric interferences: Isobaric interferences refer to different elements whose 
isotopes share the same mass(182). An example is Fe and Ni as both have isotopes 
at mass 58, so any measurement at m/z 58 will have contribution from both 
elements. Similar interferences occur at m/z 40 when Ca is measured, because 
argon’s most abundant isotope is at mass 40. 
Polyatomic interferences: Polyatomic interferences result from the combination of 
two or more isotopes from different elements that usually occur in the plasma(183). 
Various factors contribute to this type of interferences, these include the used 
plasma/nebuliser gas, other elements in the sample, matrix components and the 
used solvents. In addition, oxygen and nitrogen from the surroundings air can cause 
polyatomic interferences. Spectral overlaps caused by argon ions alone or in 
contribution with other species are very common(184). Examples include 40Ar16O+, 
which is formed when argon and oxygen are co-present and interferes with Fe major 
isotope at mass 56. 40Ar35Cl+ which is formed when HCl is used as part of the sample 
matrix interferes with the only arsenic isotope at mass 75. Another example is 
40Ar12C+ which is formed when organic solvents are used and it interferes with the 
most abundant isotope of Cr at mass 52. In addition, matrix and solvent species 
combine and form interferences of their own like 32S32O2+  that forms when sulfuric 
acid is used and interferes with the major isotope of Zn at mass 64(183). 
Doubly charged interferences: Doubly charged interferences occur when an ion is 
generated with a double positive charge producing an isotopic peak at half its 
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mass(185). An example is barium (Ba) that can form 138Ba2+, m/z 69, which interferes 
with gallium (Ga) most abundant isotope at mass 69. Alkaline and rare earth 
elements form doubly charged ions to a greater extent than other elements(186). 
These spectral interferences can create challenges to measuring certain elements 
like for example V, which has two isotopes at 50 and 51 atomic mass unit (amu). 51V 
is the most abundant isotope, but cannot be used with chloride matrices due to the 
great contribution from 16O35Cl+ at mass 51, leaving 50V that have an abundance of 
0.25% as the only practical isotope to use(187).  
Tables with the most common ICP-MS spectral interferences are available online and 
in literature(183). 
Techniques for correcting ICP-MS spectral interferences 
i. Mathematical correction equations 
The principle is similar to IEC in ICP-OES, where the intensity of interfering ions or 
species is measured at another mass free from interference and a correction is 
applied taking into consideration the ratio of the intensity of the interfering 
ion/species at the analyte mass to its intensity at the alternate mass. However, if 
analyte intensity is extremely low and the intensity of the interference is high, 
mathematical equations are not ideally suited for correcting interferences(145). 
ii. Cool/cold plasma use 
Using lower RF powers (650-800 W) produce plasma with lower temperature and this 
reduces interferences resulting from the ionisation of argon and it also minimises the 
formation of doubly charged species. Cool plasma was proved to benefit elements 
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with low ionisation potential like Na and Li, however, maintaining the plasma stability 
at such low temperature is difficult and the majority of other elements are hard to 
ionise at these temperatures, thus require hotter plasma(145). 
Attempts to minimise Ar-based interferences include using different gases such as 
nitrogen, or Ar-N2-H2 mixed gas, but careful optimisation is required, and other 
interferences appear such as ArNH+ and ArN+(181). 
iii. Collision/reaction cells (CRC) 
In this technique a collision or reaction gas such as helium, hydrogen or xenon, is 
introduced into a cell under vacuum positioned prior to the analyser. This gas will 
collide with both the interfering polyatomic species and the analytes. However, 
polyatomic species will lose kinetic energy more readily than the analytes, because 
they are usually larger in size. As a result, the interfering polyatomic species get 
expelled in the mass analyse without being detected. In other word, this technique 
depends on kinetic energy discrimination (KED) to minimise polyatomic 
interferences(181, 188). See Figure 1.16. 
 
Figure 1.16 Graphical illustration of the position of CRC in ICP-MS instrument 




Another approach is to use a dynamic reaction cell (DCR) in which a reaction gas such 
as oxygen, hydrogen, methane or ammonia are introduced in the  pressurised cell 
positioned prior to the analyser. The gas reacts with the interfering species and 
convert them to other species that have different masses and do not overlap with 
the analyte of interest to form interference-free species(181, 182, 189). 
An example is the reduction of 38Ar1H+ to the harmless H3+ ion to minimise the 
interference with 39K+. 
The limitation of DRC is that it cannot correct for doubly charged interfering 
species(181, 190). 
iv. High-resolution mass analysers or sector field (SF) analysers 
A disadvantage to quadrupole-base ICP-MS is the limited resolving power of 300 
m/m; (has a resolution of 0.7–1.0 atomic mass unit (amu)) of ions interfering with 
the analyte(191). Although collision cell technology (CCT) reduces polyatomic 
interferences, high resolution mass analysers ICP-MS have more powerful resolving 
capability than quadrupole-based instruments(179, 181). Their resolving power 
amounts to 10,000 m/m(191). 
This approach, particularly using double focusing magnetic sector mass analysers, 
has proved to be able to separate many of the problematic polyatomic and molecular 
interferences, without the need to use cool plasma conditions or collision/reaction 
cells(192). 
1.6.4.1.2 Matrix effects  
In addition to the matrix effects described for ICP-OES in Section 1.4.5.4, ICP-MS 
suffers from salt buildup on the orifice of the interface sampler cone and space 
discharge affects(193).  
61 
 
Space charge effects occur at the interface between the skimmer cone and the ion 
optics and result in suppressing the signal with high concentrations of a matrix 
element(194). This can be particularly severe when the matrix ions are of a heavier 
mass then the analyte ions due to the fact that heavier masses have higher kinetic 
energy than lighter masses. Space charge effect may lead to poor sensitivity and 
detection limits when trace levels of low-mass analytes are being measured in the 
presence of high-mass matrices that dominate the ion beam by pushing the lighter 
ions out of the way(195).  
The most common method to compensate for matrix effects is the use of suitable 
internal standard(s)(196). Furthermore, diluting samples with high level of dissolved 
solids reduces the clogging of the sampler cone(195).  
1.7 Metals speciation  
A chemical species is a specific form of an element defined regarding its electronic or 
oxidation state or isotopic composition and molecular structure. Speciation analysis 
can be defined as analytical analysis in which individual chemical species of an 
element are quantified in a sample. The use of hyphenated techniques which are 
developed by the coupling of a separation technique and an on-line spectrometric 
detection technology became very popular for this purpose to exploit the advantages 
of both(197). 
Several techniques have been used throughout the years for the speciation of metals, 
such as soft X-ray spectromicroscopy, electrophoretic separations with 
suitable detection devices(198-200). In addition to the combination of GC separation 
with an element-specific detectors, the combination of chromatography systems 
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with atomic fluorescence spectrometry (AFS) instrumentation(201), electrospray 
ionization mass spectrometry, chemical vapour generation (CVG)-AAS(202),  hydride 
generation (HG) coupled with infrared spectroscopy or spectrophotometry(203, 204) 
and most commonly the combination of chromatographic techniques with ICP-OES 
and ICP-MS(205, 206). 
One of the advantages of ICP-OES and ICP-MS is that they can be easily interfaced to 
gas chromatographic gas chromatographic (GC) or liquid chromatographic (LC) 
separation techniques as part of the sample introduction system, which would allow 
speciation of elements. Identification of individual chemical forms gives an in depth 
understanding of the toxicity of elements(207).  
According to ICH Q3D guidelines, the total concentration of elemental impurities in 
pharmaceuticals is what is needed to assess compliance with PDEs. However, 
providing speciation information could be used to justify higher levels for less toxic 
species(10). In the USP <232>, As and Hg speciation are required in certain cases. For 
As, speciation is needed when the As limit is exceeded using a total procedure. For 
Hg, only specific monographs for articles that have the potential to contain 
methylmercury requires speciation. Other than that if the total Hg is not exceeding 
the limit, speciation is not necessary(8).   
Speciation of trace metals in pharmaceutical products is a complex task and require 
proper extraction and separation techniques. This research area still need more 
development and one of the challenges is the lack of suitable pharmaceutical 
reference material for speciation of metals in pharmaceuticals(16, 201).  
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Very limited applications are available in the literature regarding the speciation of 
metals as impurities in pharmaceutical products. In one application, hydride 
generation-cryotrapping-gas chromatography-atomic absorption spectrometry (HG-
CTAAS) was applied for the analysis of arsenites and arsenates as well as  their mono-, 
di-, and trimethyl substituted species in the injectable medication, N-
methylglucamine antimonite, which is used for the treatment of visceral 
leishmaniasis(202). Five commercial samples were analysed and As was found in 
concentrations ranging from 0.9 to 2.3 mg/L with 7% to 10% of the content present 
as the trivalent form. This method was selected because of its cheaper cost, however, 
Moraes et al(202) acknowledged the superior sensitivity of ICP-MS as a detector for 
this purpose. 
Another study published by Narin et al(208), stated that a solid phase extraction (SPE) 
procedure for the speciation of chromium (CrIII and CrVI) in environmental and 
pharmaceutical samples was developed, however, the pharmaceutical sample used 
was Solgar chromium picolinate vegetable capsules, which are better described as 
nutritional supplements. In addition, only the total concentration of Cr was provided 
in the results section and compared with the manufacturer’s stated Cr 
concentration(208). 
Other than the mentioned studies the rest of speciation analysis of metals in the 
pharmaceutical field is for metal-based pharmaceuticals(48). An example is the 
speciation of SbIII and SbV in Sb-based medication(209-214). 
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1.7.1 Arsenic speciation using high performance liquid chromatography 
(HPLC)-ICP-MS 
1.7.1.1 Toxicity of arsenic species  
According to the WHO, chronic exposure to arsenic may cause many health issues 
including neurotoxicity, cardiovascular diseases, skin lesions and cancer(56, 215). 
Studies conducted for many years focused on analysing total arsenic levels rather 
than its species. Although ensuring low levels of total arsenic in commercial products 
will guarantee toxic forms to be low as well; however, it was demonstrated that the 
determination of total arsenic levels only is insufficient for risk assessment regarding 
the hazard it poses to humans, because different arsenic species differ in their 
bioavailability, biotransformation and toxicity. In general, inorganic arsenic 
compounds are more toxic than organic arsenics(4, 55, 216-221). 
Arsenite (AsIII) is more toxic than arsentae (AsV) which in turn is more toxic than 
monomethyl arsonic acid (MMA) while the least toxic is dimethylaresnic acid (DMA), 
also known as cacodylic acid. Trivalent arsenicals are more toxic than pentavalent 
forms and this includes organic compounds(222). On the contrary, arsenobetaine 
(AsB) and arsenocholine (AsC) are considered nontoxic due to their execration and 
elimination in urine(55, 217, 223-226). The structures of the mentioned arsenic 






Table 1.3  Arsenic species chemical formula and structure* 





















DMAIII Dimethylarsinous acid (CH3)2AsOH 
 
DMAv Dimethylarsinic acid (CH3)2AsOOH 
 
AsB Arsenobetaine (CH3)3As+CH2COO- 
 
AsC Arsenocholine (CH3)3As+CH2CH2OH 
 
*Structures are generated using ChemDraw 16.0.1 
** Abbreviation 
 
Arsenic was speciated in biological samples like blood, serum, plasma, urine, faeces, 
hair, nail, hepatocytes and bladder using various techniques(206, 227). 
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The IARC, which is part of the WHO, classifies inorganic arsenic compounds as 
“carcinogenic to humans” (Group 1), because there is evidence for their human 
carcinogenicity. Monomethlyarsonic acid and dimethylarsinic acid are classified as 
“possibly carcinogenic to humans” (Group 2B), based on experimental animals 
studies. The other organic compounds are not classifiable as to their carcinogenicity 
in humans(216, 228-231). 
With the increasing awareness of the fact that arsenic toxicity depends on its 
chemical form and oxidation state, speciation of arsenic for quantitative 
determination of individual species is gaining more importance (215, 217, 228, 230). 
In addition, the knowledge of different species stability under different conditions 
such as temperature, pH, redox potential and salinity is important and determines 
the type of procedures used for extracting arsenic species from solid samples as 
well as the suitable storage condition(215, 221, 232, 233). 
1.7.1.2 Sources of arsenic 
Arsenic is found in many environmental systems and is introduced naturally and 
from various human activities like agriculture and industry. It is well known as a 
contaminant for water systems as result of leaching from arsenic containing 
sediments and rocks; an example is the famous Bangladesh arsenic crisis that started 
in 1970s(224, 230, 234). The release of As from gold mine wastes in Northwest of 
Minas Gerais, Brazil was studied by collecting mine samples and windblown dust 
samples from that area. As was mainly found in the pentavalent form and all air 
particulate (filter) samples contained As-rich particles up to 313 mg As/kg. Both 
samples exhibited solid-phase As species and thus not easily available(235). 
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Seafood is another common source that exposes humans to arsenic, as marine 
organisms are capable of absorbing and bioaccumulating arsenic in high levels from 
sea water(236). Various arsenic species were found in fish, shellfish, crustaceans, 
algae and seaweeds due to biotransformation processes. This includes AsIII, AsV, MMA, 
DMA, AsB, AsC and trimethylarsine oxide (TMAO). Hizikia fusiformis, which is a type 
of brown algae widely used in Japanese diet, was found to contain high 
concentrations of inorganic arsenic(206). Arsenic was measured and speciated in 
three deep sea hydrothermal vent worms (Ridgeia piscesae, Paralvinella sulfincola 
and Paralvinella palmiformis) obtained from the Juan de Fuca Ridge in the Northwest 
pacific.  P. sulfincola and P. palmiformis were found to have significantly higher 
arsenic concentrations than R. piscesae. The arsenic species found in one worm 
species, R. piscesae were 36 µg/g ±14% inorganic arsenic, 2 µg/g ±2% monomethyl 
arsenic, 34 µg/g ±21% dimethyl arsenic, 7 µg/g ±16% unknown methyl arsenical, 5 
µg/g ±9% OSO3-arsenosugar, and about 17 µg/g of thio-arsenicals(237). Total arsenic 
and its species were determined in marine biota like clams, pearl oyster, cuttlefish 
and shrimps from seven offshore sites in the western Arabian Gulf. AsB, DMA, TMAO, 
AsC, arsenosugar-glycerol (As-Gly) and inorganic arsenic were speciated using HPLC-
ICP-MS. 58-81% of the total As was in the form of AsB and only 0.03-0.8% were found 
in the more toxic inorganic forms(238). Arsenic and mercury were determined and 
speciated in the muscles and livers of 26 fishes obtained from seven freshwater fish 
species caught in the River Elbe, Germany. The median concentrations of As in fish 
liver were 162 μg/kg and in fish muscles were 92 μg/kg. AsB  was dominant and 




Supplements derived from marine organisms like cod liver oil and capelin oil were 
also noted to contain arsenic in them. In addition, cases of arsenic intoxication were 
also reported in South Asian Countries after the consumption of a bird’s nest(216, 
219, 240-245). 
The use of arsenic compounds as pesticides and herbicides also contribute to human 
exposure to arsenic. Aryloarsenicals are widely used as food additives for animals. 
This includes 4-hydroxy-3-nitrophenylarsonic acid (Roxarsone, ROX) and para-
arsanilic acid (AsA) (4-aminophenylarsonic acid) both are commonly used in the 
poultry industry to prevent diseases and promote growth. Arsenic was also detected 
in measurable concentrations in dog food. Although only a small amount of arsenic 
is absorbed by animals and the rest is excreted unchanged, the use of animal litter 
as organic fertilisers contributes to increasing arsenic levels in fruit, vegetables(246, 
247) and rice as all are capable of accumulating it(218, 246-251). Rice is well known 
for accumulating AsIII and AsV and it is a main source of food in many countries(252-
254). Fruit juices including apple and grape juices were found to contain high levels 
of arsenic and in some cases more than WHO 10 μg/L arsenic levels stated for 
drinking water quality guideline and these juices are important beverages consumed 
worldwide(206). Freeze-dried apples themselves where found to contain 
quantifiable levels of AsIII, AsV, DMA and MMA with the first two species being 
predominant(55, 226, 242, 255-258). 
The use of arsenic containing compounds as wood preservative, and in 
manufacturing semiconductors as well as the other industrial uses like the 
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production of glass and alloys are also responsible for polluting the environment 
with arsenic(232, 241).   
1.7.1.3 HPLC-ICP-MS 
This is the most widely used technique for multielement speciation analysis. Coupling 
of liquid chromatography with ICP-MS is straightforward because the nebulizer can 
be connected to the column outlet via a transfer tubing and can accept the effluent 
from HPLC using different chromatographic separation techniques like ion exchange, 
ion-pairing, reversed-phase, size-exclusion, etc.(259, 260). Figure 1.17 represents a 
typical HPLC-ICP-MS instrument. 
 
Figure 1.17 Graphical illustration of a typical HPLC-ICP-MS 
 
However, the selected mobile phase composition which depends on the relative 
polarity, solubility and the molecular weight of separated species should also be 
tolerable by ICP.  In addition, its flow rate must be compatible with that of the 
nebuliser which might limit the technique(259).  
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1.8 Aims and objectives  
The aim of this work is to determine Class 1 and Class 2A EI in pharmaceutical 
products and since the new guidelines suggest analytical techniques for this purpose, 
but without providing standard analytical procedures and methods, this work 
objectives are:  
1. Development of microwave assisted acid digestion for efficient extraction of EI 
from pharmaceutical samples. 
2. Optimisation of ICP-OES method for the determination of EI in pharmaceutical 
products. 
3. Optimisation of ICP-MS method for the determination of EI in pharmaceutical 
products. 
4. Validation of the optimised ICP-OES and ICP-MS analytical techniques using a solid 
reference material unlike the majority of the available work relying solely on spiked 
addition technique to validate the analytical method. 
5. Development and validation of HPLC-ICP-MS method for the speciation of arsenic 
in antacids as there is not any published data about what arsenic forms are present 
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2. The Optimisation, Validation and Analysis of Analgesics, 
cold and cough remedies by ICP-OES in Compliance ICH-Q3D 
Guidelines  
 
2.1 Introduction  
Inductively coupled plasma optical emission spectroscopy and inductively coupled 
plasma mass spectrometry have both been suggested as potential analytical 
solutions for the assessment of EI in pharmaceutical products. The following two 
chapters will consider the application of both techniques to analyse analgesic tablets, 
cold and cough syrups, cold and flu powders and antacids. The work will attempt to 
produce optimised and validated methods and assess the applicability of the 
techniques. 
In this chapter, ICP-OES will be considered. Published work in the literature where 
instrumental techniques were applied to commercially available pharmaceutical 
products is limited(1, 13, 45, 46, 125, 127, 128, 261-265). However, ICP-OES was used 
in previous studies to measure EI in some antitussive products(47). In the mentioned 
study, the samples were prepared in two different ways. The first method was to 
directly introduce the syrups after proper dilution, while the second method was to 
digest 2-3 ml of the syrups in PTFE vessels placed into a steel pressurised bomb. The 
vessels were then heated on a hot plate up to 130°C, only calcium, magnesium and 
iron were quantified, while the rest of the elements were below the detection 
limits(47). Although interesting, the work only studies a limited number of elements 
and not those in the Class 1 and Class 2A impurities required under the regulations. 
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In another study, Pb and Cd were analysed in paediatric syrups manufactured in 
different countries including England, Ireland, France, India, Pakistan, Egypt and 
Nigeria using AAS. The samples were prepared using dry ashing method on a hot 
plate and then using a furnace at 500°C. After that reverse aqua regia was added to 
digest the samples that were again heated to dryness before the addition of 
deionised water and finally analysed using AAS. Cd were present in detectable limits 
in almost all the products while Pb was detected in twenty-five products out of the 
fifty that were tested(263). This work was carried out before the introduction of the 
new regulations where the limits have had been significantly lowered and 
accordingly AAS would now lack the sensitivity required as it has a lower dynamic 
range and short-term precision in comparison with ICP based instruments(266). 
Støving et al(45)  used an ICP-OES method for quantitation of As, Cd, Cu, Cr, Fe, Hg, 
Ir, Mn, Mo, Ni, Os, Pb, Pd, Pt, Rh, Ru, V and Zn in iron oxide coated tablets 
manufactured by H. Lundbeck , Denmark, according to USP guidelines. The work was 
completed in 2013 before the final version of the guidelines was released. Reverse 
aqua regia was used to digest the samples and spiked recoveries were between 85.3–
103.8% except for Os, which had a spiked recovery of 161.5% due to memory effect. 
Fe and Pt were quantified in concertation of 182.8 ± 18.1 µg/g and 2.8 ± 0.2 µg/g, 
respectively. However, the method does not include Co and was validated using the 
spike addition technique only. In addition, the precision and accuracy of the method 
regarding the quantification of Os is poor (RSD 13.7%) and needs further 
development, which was even noted by the researchers(45). 
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ICP-OES was also used to measure EI in tricyclic antidepressants, which are hard to 
decompose with acids. Solid sampling electrothermal vaporization (ETV) was used to 
introduce the samples(127). Ten samples of pharmaceuticals, including amitriptyline 
hydrochloride, carbamazepine, clozapine, cyclobenzaprine hydrochloride, 
imipramine hydrochloride, ketotifen fumarate, loratadine, nortriptyline 
hydrochloride, promethazine hydrochloride and tetracycline hydrochloride, were 
analysed using ETV-ICP-OES to measure As, Cd, Cr, Cu, Mn, Mo, Ni, Pb, Pd, Pt, Rh, Ru 
and V. It was found that all elements were below the limit of detection (LoD), except 
for Cr that was measured in a concentration of 5.7 ± 0.4 μg/g in cyclobenzaprine 
hydrochloride only(127). The elements determined in this study are from different 
classes, however, the more toxic elements such as Hg from Class 1 and Co from Class 
2A were not included. The method was validated by comparing the obtained results 
with those obtained using ICP-MS for samples prepared using MIC. Recoveries were 
in the range of 91 to 103%. Hg was not included because of its high volatility, so this 
method is not suitable for it due to low sensitivity and/or losses in the pyrolysis step 
as noted in the paper. In addition, the method does not achieve the limits established 
by USP for As, Pb, V, Mo, Pd and Pt(127). 
ICP-OES was also used in a market surveillance study to determine Fe, Cu and Zn in 
113 pharmaceutical samples; those include captopril, enalapril, benazepril, lisinopril, 
ramipril, quinapril, valsartan, losartan, olmesartan, candesartan, hydrochlorothiazide, 
carbamazepine, diclofenac, paracetamol, tilidine and naloxone(265). Fe was found in 
some samples in concentrations ranging from 6 to 7115 µg/g, Cu was found in 
concentrations lower than the quantification limits and Zn was quantified in two 
samples only (ramipril and candesartan) in a concentration less than 20 µg/g. Other 
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techniques were used to quantify the remaining elements; those are ICP-MS and 
atomic absorption spectrometry technologies (GFAAS, CVAAS, HGAAS). All the 
mentioned techniques were validated using spike addition technique(265).  
As mentioned before in the introduction, relying solely on spiked addition technique 
to validate the analytical method is insufficient, because usually an acid digestion 
method is employed in  pharmaceutical samples. As a result, there is some question 
as to the validity of the results since the digestion process is not fully tested in the 
procedure involved. Using a solid SRM is important to validate not only the analysis 
procedure, but also the efficiency of the samples preparation method. 
ICP-OES would present a convenient tool for use in the pharmaceutical industry, as 
it is commonly available as a routine quality assurance/quality control (QA/QC) tool. 
Hence, it was decided to investigate its application in the analysis of elemental 
impurities. 
This work focuses on the development of an ICP-OES method to analyse the Class 1 
elements As, Cd, Hg and Pb and Class 2A Co, Ni and V and then applying it to 
commercial analgesic tablets and cold and cough syrups. The method validation and 
current issues related to the availability of an appropriate standard will be discussed. 
2.2 Experimental 
2.2.1 Reagents and Materials 
Trace metal grade acids, nitric acid (67-69% HNO3) and hydrochloric acid (34-37% HCl) 
were used for all experiments (Fisher Scientific, UK). Elements standards for ICP-OES 
and ICP-MS 1000 µg/mL each (SCP Science, QMX UK) were used for calibration. Eight 
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standard solutions were prepared by dilution with 4% reverse aqua regia (3 HNO3 : 1 
HCl v/v) to get concentrations ranging from 30 to 300 ng/mL as well as a blank. 100 
ng/mL of Sc and Y were added as internal standards to the calibration and samples. 
Ultrapure water with a resistivity of 18 MΩ cm was obtained using TripleRed water 
purification system (TripleRed laboratory technology, UK). To filter the samples; 
0.45µm polytetrafluoroethylene (PTFE) membrane filter (Agilent Technologies, China, 
supplied by Crawford Scientific, UK) were used. 
Standard reference material; NIST 3280 Mulivitamin/Multielement tablets (National 
Institute of Standards and Technology, USA; supplied by Laboratory of the 
Government Chemist (LGC), UK) was used to validate the method. 
2.2.2 Samples 
Six samples of analgesic tablets and six cold and cough remedies were acquired from 
local retailers in the Liverpool area. Some of the cold and cough remedies contain API 
like paracetamol or herbal extracts in them, while others were just for soothing the 
throat. See Table 2.1 
Table 2.1 Analgesic tablets and cold and cough remedies product information 
Product  Ingredients 
Maximum daily dose 
for patients 12 years old 






Excipients: potato starch, pregelatinised maize 




API: paracetamol and caffeine 
Excipients: starch pregelatinised, maize starch, 
polyvinyl pyrolidone, potassium sorbate, talc, 
stearic acid, croscarmellose sodium, 





Product  Ingredients 
Maximum daily dose 
for patients 12 years old 




Excipients: maize starch, pregelatinised maize 
starch, magnesium stearate, povidone and 






API: paracetamol, aspirin and caffeine 
Excipients: maize starch, microcrystalline 
cellulose, hydrogenated vegetable oil, 
hydroxypropyl methylcellulose, polyethylene 




API: aspirin and caffeine 
Excipients: microcrystalline cellulose, maize 
starch, hydroxypropyl methylcellulose, 






Excipients: potato starch, talc, calcium 
carbonate, lactose, citric acid, sodium lauryl 
sulphate and sodium saccharin 
4.20 
Cold and cough remedies 
Tixylix 
Glycerol, honey, sucrose,  citric acid, benzoic 
acid, lemon oil, distilled lime oil, terpeneless 





Excipients: maltitol, sorbitol liquid, glycerol, 
dispersible cellulose, xanthan gum, polysorbate 
80, methyl parahydroxybenzoate, propyl 
parahydroxybenzoate, acesulfame potassium, 




Byronia dioica, honey, sorbitol, lemon juice, 
methylparaben and water 
19.01 
Calcough 
Glycerine, sucrose, citric acid monohydrate, 
sodium benzoate, anthocyanin, blackcurrant 
flavour, blackcurrant juice, glucose and purified 
water 
52.50 






Menthol, aniseed oil, capsicum tincture, ginger 
oleoresin, clove oil, peppermint oil, glycerine, 
glucose, sucrose, tragacanth, benzoic acid, 
caramel, benzoin tincture, tolu tincture, 




All products were processed and analysed within ten days of their purchase, which 
was before the expiry date. 
2.2.3 Instrumentation  
For samples preparation Mixer Mill MM200 (Retsch, Germany) with 10 mL zirconium 
oxide grinding jars with push-fit lid and zirconium oxide grinding balls was used to 
grind the tablets at 20 Hz for 2 minutes. Microwave assisted acid digestion SP-D 
Microwave (CEM, Discover software) was used with 35 mL Pyrex vessels. The 
digestion programme is provided in Table 2.2. 
Table 2.2 CEM-SP-D microwave programme used to digest the samples 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
Elemental analysis was performed using ICP-OES (Thermo iCAP 6500 Duo, Thermo 
UK) with standard nebuliser, spray chamber and fittings. The instrument is 
equipped with a CETAC ASX 520 series (Thermo UK) autosampler and data was 
collected using Thermo Scientific iTEVA Software. The optimised ICP-OES conditions 
used to analyse the samples are provided in Table 2.3. 
Table 2.3 Overview of ICP-OES, iCAP 6500 series optimised parameters  
RF Power 1300 W 
Nebuliser Gas Flow 0.7 L/min 
Pump Speed 60 rpm 
Auxiliary Gas Flow 2.0 L/min 
Coolant Gas Flow 20 L/min 
Selected wavelengths 
As (189.0 nm), Cd (214.4 nm), Hg (184.9 nm), Pb (220.3 nm), 




2.2.4 ICP-OES Optimisation 
Nebuliser gas flow, pump rate, auxiliary gas flow, coolant gas flow, and radio 
frequency (RF) power were optimised starting from the lowest possible value that 
generated a signal to the highest possible value. Signals were assessed by measuring 
a stock solution containing a known concentration (300 ng/mL) of the seven 
elements (As, Cd, Hg ,Pb, Co, Ni and V)  at different settings for each parameter within 
its operational range.  The data obtained was assessed by comparing the signals and 
signal to blank ratios to obtain a setting with the best sensitivity for the elements.  
The signal to blank ratio was calculated by dividing the average signal obtained using 
a multielement standard with a concentration of 300 ng/mL by the average signal 
obtained using a blank (2% reverse aqua regia). 
2.2.4.1 Optimisation of nebuliser gas flow rate 
The procedure described in Section 2.2.4 was followed using a nebuliser gas flow rate 
range of 0.3-1.2 L/min. 
2.2.4.2 Optimisation of pump rate 
The procedure described in Section 2.2.4 was followed using a pump rate range of 
30-120 rpm. 
2.2.4.3 Optimisation of auxiliary gas flow rate 
The procedure described in Section 2.2.4 was followed using an auxiliary gas flow 
rate range of 0.2-2.0 L/min. 
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2.2.4.4 Optimisation of coolant gas flow rate 
The procedure described in Section 2.2.4 was followed using a coolant gas flow rate 
range of 10-20 L/min. 
2.2.4.5 Optimisation of RF power 
The procedure described in Section 2.2.4 was followed using RF power range of 750-
1350 W. 
2.2.4.6 Wavelengths selection 
Twenty-five different wavelengths for the seven elements in total were tested to 
determine the optimal analytical wavelength for each element that gave the lowest 
limit of detection (LoD) and limit of quantification (LoQ) with minimum interferences. 
The tested wavelengths were as the following: As (189.0, 193.7 and 449.4 nm), Cd 
(214.4, 226.5 and 326.1 nm), Hg (184.9, 194.2 and 253.6 nm), Pb (182.2, 216.9, 220.3 
and 261.4 nm), Co (228.6, 230.7, 237.8 and 238.8 nm), Ni (216.5, 221.6, 231.6 and 
341.4) and V (292.4, 309.3, 310.2 and 311.0 nm). 
2.2.5 Analytical figures of merit and method validation  
Linearity, range, precision, accuracy and specificity of the developed analytical 
method were evaluated using ICH Q2B guidelines(267).  
2.2.5.1 Limits of detection and limits of quantification 
Limits of detection (LoD) and Limits of quantification (LoQ) were calculated as 
described by Miller and Miller(268). Ten blanks (2% reverse aqua regia) were 
measured in triplicate along with a series of standards (10 to 300 ng/ml) and then 
the LoDs and LoQs  were calculated using three times the standard deviation (3σ) and 
ten times the standard deviation (10σ) criteria respectively. 
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2.2.5.2 Linearity and range 
Linearity was studied in the range of 5 to 50,000 ng/ml for Cd and Hg, 5 to 100,000 
ng/mL for Pb, Co and Ni and in the range of 10 to 100,000 ng/ml for As and V. 
Eight concentration points were assayed in triplicate. 
2.2.5.3 Accuracy and precision 
The accuracy and precision were evaluated using NIST 3280 
multivitamin/multielement tablets. The samples were also spiked with 50 ng/mL with 
respect to As, Cd, Hg, Pb, Co, V and Ni to complete a recovery analysis. The 
experiment was performed in triplicate.  
The precision of the method was evaluated as the repeatability, i.e. relative standard 
deviation (RSD).  
2.2.6 Optimisation of microwave assisted acid digestion procedure 
Microwave assisted acid digestion method was developed using NIST 3280 tablets.  
The exact preparation procedure as stated in NIST 3280 certificate was not followed. 
Six NIST 3280 tablets instead of fifteen were ground and 0.5g were digested instead 
of 0.4g. The digestion medium was reverse aqua regia not nitric, perchloric, and 
hydrofluoric (HF) acids(93). The use of HF was avoided because of the safety 
issues(269, 270) and the lower number of tablets was used to avoid moisture gain by 
a large mass of powder. 
Hydrofluoric acid is an extremely corrosive inorganic acid that is usually added to 
the digestion medium in order to completely digest materials like silicone dioxide. 
Exposure to hydrofluoric acid causes skin and eye burns and irritation, cough and 
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swelling of throat if inhaled, and in severe exposure pulmonary oedema(269, 270). 
Systemic effects include hypokalemia, hypocalcemia, hypomagnesemia and cardiac 
arrhythmias. Additionally, death was reported due to adverse effect of hydrofluoric 
acid exposure(269). 
Eight ml of reverse aqua (6 mL HNO3 and 2 mL HCl) were added to 0.5 g of ground 
tablets and the vessels were allowed to stand in a fume hood for 20 min. Cylindrical 
(6x3 mm) PTFE covered stirring bars (VWR, Europe) were added to the vessels to 
ensure continuous mixing and heat distribution within the samples. Finally, the 
samples were then vortex mixed using a rota mixer (Hook and Tucker Zenyx, UK) and 
placed in the microwave.  
Following digestion, samples were filtered. 4% reverse aqua regia was used to rinse 
the digestion vessels and the used filters three times (approximately 4 to 6 mL were 
used each time) to ensure complete transfer of the extracted elements. Then the 
filtered samples were diluted with deionised water to a final volume of 25 mL (Stock-
1). 
A further ten-fold dilution was performed by transferring 1 mL form Stock-1 to a 10 
mL volumetric flask and completing the volume with deionised water after the 
addition of internal standards. Gold (Au) was also added to the final samples and the 
calibration standards in a concentration of 1 µg/mL to overcome the memory effect 
of Hg(271-273).  
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2.2.6.1 Optimisation of the of microwave assisted acid digestion procedure 
temperature 
Maximum temperatures of 140, 160, 180, 200 and 210°C were used during the 
digestion method development. 
3.2.6.2 Optimisation of the microwave assisted acid digestion procedure time 
Holding times of 5, 10, 15 and 20 min were also tried to determine the optimum time 
for digestion.  
2.2.6.3 Optimisation of different acid ratios  
In addition to using reverse aqua regia to digest NIST 3280, an acid ratio of 9 HNO3: 
1 HCl v/v (7.2 mL HNO3 and 0.8 mL HCl) was also tested to compare microwave 
extraction efficiency using different acid ratios.  
Reverse aqua regia is used for environmental samples when the use of more 
corrosive and toxic acids is to be avoided(274, 275). It was also used for 
pharmaceutical APIs(18).   The HNO3: 1 HCl v/v acid ratio was tested as well because 
it was also used before to digest samples prior to ICP-based analysis(276). It was also 
used sometimes in combination with other reagents like hydrogen peroxide(277). 
With each tested condition, three samples of NIST 3280 were digested and assayed 
in triplicate. 
2.2.6.4 Microwave assisted acid digestion procedure validation 
The developed digestion procedure was validated by calculating the percentage 
recoveries for the elements of interest; using the certified values of NIST 3280 and 
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spike recoveries.  Spiked samples were prepared using the exact procedure as stated 
in Section 2.2.6, but with the addition of a spike of 50 ng/mL of the elements.  
The optimum method was chosen based on obtaining accepted recoveries that is 
70%–150% according to USP <233> with repeatability expressed as the relative 
standard deviation (RSD) to be <20%(9). However, because a standard reference 
material was used, recoveries between 95-105% with RSD of <5% were regarded as 
acceptable. 
2.2.6.5 Tablets grinding and sample homogeneity 
The effect of different grinding techniques on the method’s precision and sample 
homogeneity was tested by grinding six tablets using a glass mortar and pestle and 
another six tablets using the mixer mill as described in Section 2.2.3.  
2.2.6.6 Selection of suitable internal standard(s) 
Scandium (Sc) and yttrium (Y) (100 ng/ml) were added to both samples and standards 
prior to analysis. The corrected results for the internal standard were obtained using 
Thermo iTEVA software and compared with those without the internal standards. 
2.2.7 Analysis of analgesic tablets, cold and cough remedies 
For the analysis of the analgesic tablets, cold and cough remedies the samples were 
analysed using the optimised and validated ICP-OES method describe in Table 2.3. 
Solid samples were prepared as described in Section 2.2.6, using only one dilution 
step.  For syrups, 0.5 g were directly weighed into the vessels after shaking the 




2.3 Results and discussion 
2.3.1 ICP-OES Optimisation 
A comparison of signals and signal to blank ratios was performed. This allowed the 
assessment of the maximum signal but by using signal/blank ratio, it was also 
possible to assess the maximum sensitivity.  
2.3.1.1 Optimisation of nebuliser gas flow rate 
The nebuliser gas flow rate affects the analyte atomisation level by controlling the 
sample’s droplet size and its transit time through the plasma. Higher rates decrease 
the residence time, so the analyte will have shorter time to acquire the energy 
needed for transition and vice versa(278). 
Figures 2.1-2.7 show the signal and signal/blank ratios for Class 1 and Class 2A 
elements at different λ across the tested nebuliser gas flow rate of 0.3-1.2 L/min. 
 
 
Figure 2.1 The signal and signal/blank ratios for arsenic (300 ng/mL) at three 





Figure 2.2 The signal and signal/blank ratios for cadmium (300 ng/mL) at three 
different wavelengths using different ICP-OES nebuliser gas flow rates 
 
 
Figure 2.3 The signal and signal/blank ratios for mercury (300 ng/mL) at three 
different wavelengths using different ICP-OES nebuliser gas flow rates 
 
 
Figure 2.4 The signal and signal/blank ratios for lead (300 ng/mL) at four different 





Figure 2.5 The signal and signal/blank ratios for cobalt (300 ng/mL) at four different 
wavelengths using different ICP-OES nebuliser gas flow rates 
 
 
Figure 2.6 The signal and signal/blank ratios for nickel (300 ng/mL) at four different 
wavelengths using different ICP-OES nebuliser gas flow rates 
 
 
Figure 2.7 The signal and signal/blank ratios for vanadium (300 ng/mL) at four 




From the previous Figure 2.1-2.7, it is clear that relying on the analyte signal only 
does not ensure best sensitivity. As sensitivity is indicated by the signal to blank ratio, 
it is important for the signal to be high but also the blank to be low to obtain the 
maximum ratio. In cases where a high signal is obtained if the corresponding blank is 
high the ratio will be low. Here by looking at Figures 2.1 to 2.7 the signal can be seen 
as well as the ratio. If the signal for one condition is high but the ratio is low the 
difference is caused by a high blank level.  The optimum point for each condition  was 
based on the signal/blank ratio to maximise sensitivity.  
At higher nebuliser flow rates bigger droplets are formed and when this is combined 
with lower residence time in the plasma leading to a drop in all elements signals 
(Figures 2.1-2.7). By observing the corresponding ratio plots, a maximum sensitivity 
is clearly seen at 0.7 L/min for all elements.  
For some elements, the difference in signals and signal/blank ratios is obvious, like 
for example As (Figure 2.1). Looking at the signal only gives an indication that the 
best nebuliser gas flow rate is 0.2 L/min unlike signal/blank were the highest ratio; 
that is the highest analyte signal with the lowest blank signal was achieved at a 
nebuliser flow rate of 0.7 L/min. Another example from Class 2A elements is Co 
(Figure 2.5), where the highest signal appears to be at 0.4 L/min, while the highest 
signal/blank ratio is at 0.7 L/min.  
The same goes for the rest of the elements where the nebuliser gas flow rate that 
gave the highest sensitivity was 0.7 L/min. An exception is V, as a higher signal/blank 
ratio was achieved at a nebuliser gas flow rate of 0.8 L/min. However, for the sake of 
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time efficiency and analysing all the elements at the same conditions, a small drop in 
sensitivity (approximately 13%) can be tolerated due to its high PDE of 100 µg/day. 
2.3.1.2 Optimisation of pump rate 
The pump rate affects the volume of the aerosol droplets and thus the efficiency of 
nebulisation. Proper nebulisation is important for optimum sensitivity and precision. 
High pump speed leads to high sample delivery rate, which may increase the 
formation of large droplets in the spray chamber(278).  
Figures 2.8-2.14 show the signal and signal/blank ratios for Class 1 and Class 2A 
elements at different λ across the tested pump speed range of 30-120 rpm. 
 
Figure 2.8 The signal and signal/blank ratios for arsenic (300 ng/mL) at three 
different wavelengths using different ICP-OES pump rates 
 
 
Figure 2.9 The signal and signal/blank ratios for cadmium (300 ng/mL) at three 




Figure 2.10 The signal and signal/blank ratios for mercury (300 ng/mL) at three 
different wavelengths using different ICP-OES pump rates 
 
 
Figure 2.11 The signal and signal/blank ratios for lead (300 ng/mL) at four different 
wavelengths using different ICP-OES pump rates 
 
 
Figure 2.12 The signal and signal/blank ratios for cobalt (300 ng/mL) at four 





Figure 2.13 The signal and signal/blank ratios for nickel (300 ng/mL) at four 
different wavelengths using different ICP-OES pump rates 
 
 
Figure 2.14 The signal and signal/blank ratios for vanadium (300 ng/mL) at four 
different wavelengths using different ICP-OES pump rates 
 
From the above figures 2.8-2.14, the pump rate in this case has minimal effect on the 
analytical sensitivity. Both the standard signal and the signal/blank ratio did not show 
significant change across the tested pump rate range, so it was maintained at 60 rpm. 
2.3.1.3 Optimisation of auxiliary gas flow rate 
Auxiliary gas flow rate can affect the plasma position with high flow rates moving the 
plasma forward in the horizontal position. This can affect the signal at the detector 
by altering the focus of the emission as it changes position. It has a more profound 
effect with organic samples rather than aqueous samples. It was found that changing 
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the auxiliary gas flow rate with organic samples could change the distribution of 
solvent and thus the plasma excitation conditions(279). This is because organics will 
be consumed resulting in the formation of carbon which can plate onto the torch. 
Auxiliary gas flows rates can be increase to move the plasma and minimise plating 
effects as carbon can cause conduction with the RF coil and reduce the applied power 
to the plasma. 
The effect of changing the auxiliary gas flow rate on Class 1 and Class 2A elements 
dissolved in 2% reverse aqua regia is shown in Figures 2.15 – 2.21. 
 
Figure 2.15 The signal and signal/blank ratios for arsenic (300 ng/mL) at three 
different wavelengths using different ICP-OES auxiliary gas flow rates 
 
 
Figure 2.16 The signal and signal/blank ratios for cadmium (300 ng/mL) at three 






Figure 2.17 The signal and signal/blank ratios for mercury (300 ng/mL) at three 
different wavelengths using different ICP-OES auxiliary gas flow rates 
 
 
Figure 2.18 The signal and signal/blank ratios for lead (300 ng/mL) at four different 
wavelengths using different ICP-OES auxiliary gas flow rates 
 
 
Figure 2.19 The signal and signal/blank ratios for cobalt (300 ng/mL) at four 





Figure 2.20 The signal and signal/blank ratios for nickel (300 ng/mL) at four 
different wavelengths using different ICP-OES auxiliary gas flow rates 
 
 
Figure 2.21 The signal and signal/blank ratios for vanadium (300 ng/mL) at four 
different wavelengths using different ICP-OES auxiliary gas flow rates 
 
From figures 2.15-2.21, the standard signal for all elements dropped at higher 
auxiliary gas flow rate; however, this was accompanied with similar drops in the blank 
signal causing the signal/blank ratios to increase with increasing the auxiliary gas flow 
rate. As a result, an auxiliary gas flow rate of 2 L/min was selected as the optimum 
because the highest signal/blank ratio for Pb, Co, Ni and V was achieved at that rate. 
The remaining elements signal/blank ratios seemed not to be significantly affected 
with changes in the auxiliary gas flow rate. This may be because no organic containing 
matrix was present. Once a pharmaceutical matrix is present, this may cause an issue 
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with carbon plating onto the torch. The figures clearly demonstrate however that if 
adjustment was needed it would have a minimal effect on the sensitivity. 
2.3.1.4 Optimisation of coolant gas flow rate 
The coolant gas helps maintaining a stable plasma discharge(280), but it has limited 
effect on the analytical sensitivity(281). This was supported from the signals and 
signal/blank ratios obtained for Class 1 and Class 2A elements at different coolant 
gas flow rates. See Figures 2.22-2.28. 
 
Figure 2.22 The signal and signal/blank ratios for arsenic (300 ng/mL) at three 
different wavelengths using different ICP-OES coolant gas flow rates 
 
 
Figure 2.23 The signal and signal/blank ratios for cadmium (300 ng/mL) at three 





Figure 2.24 The signal and signal/blank ratios for mercury (300 ng/mL) at three 
different wavelengths using different ICP-OES coolant gas flow rates 
 
 
Figure 2.25 The signal and signal/blank ratios for lead (300 ng/mL) at four different 
wavelengths using different ICP-OES coolant gas flow rates 
 
 
Figure 2.26 The signal and signal/blank ratios for cobalt (300 ng/mL) at four 






Figure 2.27 The signal and signal/blank ratios for nickel (300 ng/mL) at four 
different wavelengths using different ICP-OES coolant gas flow rates 
 
 
Figure 2.28 The signal and signal/blank ratios for vanadium (300 ng/mL) at four 
different wavelengths using different ICP-OES coolant gas flow rates 
 
Minimal changes were obtained in signals and signal/blank ratios for most elements 
at the tested wavelengths when changing the coolant gas flow rate. However, there 
was a small improvement (about 2%) in signal/blank ratio at a coolant gas flow rate 
of 20 L/min for As 189.0nm, Cd 214.4nm, Pb 220.3nm and Ni 221.6nm, so it selected 
as the optimum setting. 
2.3.1.5 Optimisation of RF power 
One of the most critical settings for achieving optimum conditions and highest 
sensitivity is the radio frequency power(278). 
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Figures 2.29-2.35 represent the obtained signals and signal blank ratios using 
different RF powers over a range of 750-1350 W. 
 
Figure 2.29 The signal and signal/blank ratios for arsenic (300 ng/mL) at three 
different wavelengths using different ICP-OES radio frequency powers 
 
 
Figure 2.30 The signal and signal/blank ratios for cadmium (300 ng/mL) at three 
different wavelengths using different ICP-OES radio frequency powers 
 
 
Figure 2.31 The signal and signal/blank ratios for mercury (300 ng/mL) at three 





Figure 2.32 The signal and signal/blank ratios for lead (300 ng/mL) at four different 
wavelengths using different ICP-OES radio frequency powers 
 
 
Figure 2.33 The signal and signal/blank ratios for cobalt (300 ng/mL) at four 
different wavelengths using different ICP-OES radio frequency powers 
 
 
Figure 2.34 The signal and signal/blank ratios for nickel (300 ng/mL) at four 





Figure 2.35 The signal and signal/blank ratios for vanadium (300 ng/mL) at four 
different wavelengths using different ICP-OES radio frequency powers 
 
From the illustrated results in the Figures 2.29-2.35, the standard signal increases 
with the increase of RF power. Higher plasma powers causes an increase in plasma 
temperature(133) and as emission intensity is directly proportional to temperature 
this can be seen in the linear graphs produced for the signal. The issue here is that 
not only does signal increase linearly but blank signal may also increase linearly which 
results in the signal/blank ratio plots shown in Figures 2.29-2.35. 
 The signal/ blank ratio shows the best sensitivity at 800 W. The ratio at this low RF 
power is high because the blank signal has dropped significantly more than the signal 
for the standard. This finding is consistent with the fact that the cool plasma is 
sometimes used to minimise interferences(145). However, the stability of the signal 
is an issue at these low powers due to the practical limits dictated by the plasma 
stability. As a result, there is a need to assess the LoD and LoQ at different RF powers. 
Five RF powers were used to calculated LoD and LoQ for Class 1 and Class 2A 
elements. Those are 750W, 900W, 1050W, 1150W and 1300W.  
LoD and LoQ is the lowest amount of analyte in a sample, which can be detected or 
quantitatively determined, respectively, with suitable precision and accuracy(267).  
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An example of how the calculations were performed is the following: 
Figure 2.36 represents the calibration line equation and R2 value for V 292.4nm at 
1300W.   
 
Figure 2.36 V 292.4nm Calibration line obtained using RF power of 1300W 
 
 
The average of the 10 blanks reading is 296.63 counts/second (Cts/S) with σ of 3.55 
From the obtained calibration linear line equation, the slope=4861.7 and the 
intercept= 294.99 








  ….. Equation 2.2 
 































(296.63 + (3x3.55)) − 294.99
4861.7
=  






           = 0.00253 µg/mL =2.53 ng/mL 
 
LoQ =
(296.63 + (10x3.55)) − 294.99
4861.7
=  






         = 0.00764  µg/mL = 7.64 ng/mL 
 
Table 2.4 demonstrates the calculated LoDs and LoQs (ng/mL) using different RF 
powers. 




750W 900W 1050W 1150W 1300W 
Element 
(λ-nm) 
LoD LoQ LoD LoQ LoD LoQ LoD LoQ LoD LoQ 
As189.0  10.62 32.25 4.89 14.72 5.01 14.89 4.09 11.95 1.85 5.86 
As193.7  11.31 33.93 7.52 22.23 2.59 7.89 4.28 13.04 2.48 7.28 
Cd214.4  2.87 8.75 0.67 2.07 0.71 2.14 0.99 3.01 0.29 0.87 
Cd226.5  1.90 5.80 0.79 2.36 0.81 2.43 1.01 3.03 1.05 3.09 
Hg184.9  14.18 42.31 3.62 11.22 3.16 9.54 2.62 8.13 0.69 2.23 
Hg194.2  9.32 27.97 4.85 14.41 3.51 11.57 2.32 7.09 1.47 4.43 
Pb182.2  9.80 30.38 5.89 18.25 4.50 13.49 4.10 12.29 1.76 5.56 
Pb216.9  7.91 23.65 4.53 13.59 6.53 19.46 6.14 18.73 1.54 4.88 
Pb220.3  9.05 27.26 3.08 9.50 3.35 10.00 3.51 10.29 1.52 4.73 
Co228.6  2.86 8.57 1.04 3.08 1.23 3.76 1.27 3.88 0.52 1.58 
Co230.7  4.53 13.53 1.52 4.55 1.49 4.45 1.60 4.79 1.10 3.65 
Co237.8  32.69 98.07 12.52 40.05 10.71 32.27 6.49 20.11 7.71 25.91 
Co238.8  9.49 28.47 3.78 11.52 3.18 9.71 3.65 10.96 3.77 11.18 
Ni216.5  4.56 13.91 2.48 7.43 2.08 6.23 1.97 6.01 4.25 12.61 
Ni221.6  2.84 8.49 1.07 3.21 0.85 2.58 1.12 3.36 0.97 3.20 
Ni231.6  2.35 7.06 1.39 4.16 1.34 4.12 1.28 3.98 0.59 1.74 
V292.4  4.89 14.72 2.59 7.85 1.46 4.45 2.05 6.30 2.53 7.64 
V309.3  2.65 7.95 2.07 6.41 1.27 4.12 1.45 4.41 4.05 13.18 
V310.2  6.86 21.28 4.48 13.67 3.32 10.12 3.02 9.20 3.34 9.99 
V311.0  3.31 10.11 2.51 7.53 2.52 7.57 3.45 10.69 4.66 15.09 
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From Table 2.4, RF power of 1300 W gave the lowest LoD and LoQ for Class 1 and 
Class 2A elements, so it was chosen as the optimum setting to perform the analysis 
using ICP-OES. 
2.3.1.6 Wavelengths selection 
It is worth mentioning that sensitivity was found to be poor for As 449.4 nm, Cd 326.1 
nm, Hg 253.6 nm, Ni 341.4 nm, and Pb 261.4 nm, so all these lines were excluded 
from any further work due to the unreliable results obtained using them. An example 
is Figure 2.37, which demonstrates clearly the poor correlation obtained for the 
calibration curve using As 449.4nm. 
 
Figure 2.37 Calibration curve with poor correlation coefficient when using As 
449.4nm due to the poor signal at this wavelength. 
 
Based on the optimisation results one wavelength was chosen for each element 
taking into consideration the possible interferences for each line by visual evaluation 
of the spectra for any potential overlapping peaks. For example, there is a spectral 
overlap between As 228.8 nm and Cd 228.8 nm. In addition, certain interferences 






























were found using Thermo iTEVA® software such as Mg with V 309.3 nm and Ca with 
V 310.2 nm (Figure 2.38).   
 
Figure 2.38 Wavelength interferences determined using iTEVA software 
 
The selected wavelengths were as follows: As (189.0 nm), Cd (214.4 nm), Hg (184.9 
nm), Pb (220.3 nm), Co (228.6 nm), Ni (231.6 nm) and V (292.4 nm). Other lines were 
optimised in case a later interference in a sample was observed to allow an 
alternative line to be adopted. 




2.3.2 Analytical figures of merit and method validation  
2.3.2.1 Limits of detection and limits of quantification 
LoD and LoQ were calculated for Class 1 and Class 2A elements at the selected 
wavelengths using the optimised ICP-OES conditions as described in Sections 2.3.1.1 
- 2.3.1.6 
The results are summarised in Table 2.5.  
Table 2.5 ICP-OES limits of detection and Limits of quantification for Class 1 and 














As189.0 41.59 2.78 4857.38 40.93 49.93 69.40 0.0019 0.0059 1.85 5.86 
Cd214.4 81.52 3.06 36540.67 79.81 90.69 112.10 0.0003 0.0009 0.30 0.88 
Hg184.9 42.34 1.85 8455.48 42.00 47.88 60.83 0.0007 0.0022 0.70 2.23 
Pb220.3 103.06 3.50 7634.47 101.93 113.55 138.04 0.0015 0.0047 1.52 4.73 
Co228.6 132.70 2.05 13535.48 131.83 138.85 153.21 0.0005 0.0016 0.52 1.58 
Ni231.6 137.99 7.51 45238.98 134.02 160.51 213.06 0.0006 0.0017 0.59 1.75 
V292.4 296.63 3.55 4861.70 294.99 307.28 332.14 0.0025 0.0076 2.53 7.64 
*Av. = Average 
 
2.3.2.1 Linearity and range 
According to ICH guidelines, the linearity of an analytical procedure is defined as ‘its 
ability (within a given range) to obtain test results that are directly proportional to 
the concentration (amount) of analyte in the sample’(267).  
Judging the linearity is often done by examining the correlation coefficient (R2) of the 
linear regression line for the obtained emission intensity (Cts/S) versus standard 
analyte concentrations. 
Eight concentration points were assayed in triplicate and showed good linearity in 
the tested range, with a correlation coefficient (R2) value of above 0.995. The linear 
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regression equation and its R2, for each of the calibration curves are summarised in 
Table 2.6. 
Table 2.6 Linearity data for Class 1 and Class 2A elements using ICP-OES 
Element Range (ng/ml)* Calibration equation R2 Value 
As 189.0 nm 10 - 100,000 y= 431.51x + 35.96 0.9975 
Cd 214.4 nm 5 - 50,000 y= 10599x + 127.1 0.9978 
Hg 184.9 nm 5 - 50,000 y= 921.39x + 49.06 0.9997 
Pb 220.3 nm 5 - 100,000 y= 871.84x + 59.67 0.9990 
Co 228.6 nm 5-100,000 y= 5403.8x + 118.7 0.9978 
Ni 231.6 nm 5-100,000 y= 3644x + 192.7 0.9979 
V  292.4 nm 10-100,000 y= 3502.9x + 92.84 0.9998 
* The lower concertation in the range was chosen by taking into consideration the results 
obtained from the LoQs calculation. 
 
2.3.2.2 Accuracy and precision 
According to ICH guidelines, accuracy is expressed as ‘the closeness of agreement 
between true value of analyte in samples and test result obtained by the method’, 
while precision is defined as ‘the closeness of agreement (degree of scatter) between 
a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions’(267).  
The precision is expressed as the relative standard deviation (RSD) of replicate 
measurement and is divided into three categories: repeatability (intra-day precision), 
intermediate precision (inter-day precision) and reproducibility (between 
laboratories precision)(267). 
The accuracy and precision were evaluated using NIST 3280, where % recoveries 
between 95-105% indicate the method’s accuracy and RSD less than 5% were 
targeted for acceptable precision. A microwave assisted acid digestion procedure 
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was developed for this purpose and the results will be discussed in the following 
sections.  
2.3.3 Optimisation of microwave assisted acid digestion procedure 
NIST 3280 samples were prepared for digestion as described in Section 2.2.6.  
The first challenge of using the only available solid standard reference material; NIST 
3280, was the low concentration of Class 1 elements (As, Cd Hg and Pd) that becomes 
below the optimised ICP-OES method’s LoQs (Table 2.7). The second challenge as 
mentioned before is the absence of Hg. As a result validating the ICP-OES method for 
Class 1 elements is impractical using NIST 3280. 
Table 2.7 The concentration of elements (ng/mL) in NIST 2380 after dilution 
Element ICP-OES-LoQs  NIST 3280(93)  After 50X Dilution  After 500X Dilution  
As 5.86 132 2.64 0.264 
Cd 0.87 80.15 1.603 0.1603 
Hg 2.23 N/A N/A N/A 
Pb 4.73* 272.7 5.454 0.5454 
Co 1.58 810 16.2 1.62 
Ni 1.74 8430 168.6 16.86 
V 7.64 8000 160 16 
*Although Pb LoQ is lower than the nominal concentration after 50X dilution, the variation 
and error in the sample preparation as well as the inherent variation of Pb concentration 
within NIST 3280 made the measurement of Pb using ICP-OES unreliable. 
 
In the initial development steps, reverse aqua regia was used as the digestion 
medium, since it contains more hydrochloric acid than the 9 HNO3 : 1HCl (v/v), which 
helps digesting organic matrices more efficiently.  
A blank (8 ml reverse aqua regia) subjected to the exact same procedure as NIST 3280, 
filtered and finally diluted, was analysed in triplicate using ICP-OES to check if it adds 
any elements to the samples and thus gives false high results. All elements 
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concentrations were below LoDs and thus there is no risk of contaminating the 
samples during preparation (See Table 2.8 ).  
Table 2.8 Obtained concentrations using the developed and optimised ICP-OES 
method for reverse aqua regia following microwave digestion, n=3 
Element Concentration (ng/ml) RSD 
As 189.0 nm <LoD (1.85) 37.78 
Cd 214.4 nm <LoD (0.30) 78.25 
Hg 184.9 nm <LoD (0.70) 35.93 
Pb 220.3 nm 0.59 68.15 
Co 228.6 nm 0.47 25.36 
Ni 231.6 nm <LoD (0.59) 31.84 
V  292.4 nm 0.54 51.20 
 
2.3.1.1 Optimisation of the of microwave assisted acid digestion procedure 
temperature  
2.3.1.1.1 One stage vs three stages of digestion method 
The first parameter to be optimised for the digestion procedure was the temperature. 
So, ramping for ten minutes followed by holding for twenty minutes at 160°C, 180°C, 
200°C and 210°C was performed. The obtained recoveries and RSDs were calculated 
and represented in Table 2.9. 
Table 2.9 One-stage microwave-assisted acid digestion procedure for NIST 3280, at 
different temperatures, using ICP-OES for analysis. n=3 
Element 160°C 180°C 200°C 210°C 
λ-nm %Recovery* RSD %Recovery RSD %Recovery RSD %Recovery RSD 
As189.0  <LoQ (5.86) - <LoQ (5.86) - <LoQ (5.86) - <LoQ (5.86) - 
Cd214.4  <LoQ (0.88) - <LoQ (0.88) - <LoQ (0.88) - <LoQ (0.88) - 
Hg184.9 N/A - N/A - N/A - N/A - 
Pb220.3  <LoQ (4.73) - <LoQ (4.73) - <LoQ (4.73) - <LoQ (4.73) - 
Co228.6 49.65 11.07 70.09 22.84 58.67 10.66 79.49 12.67 
Ni231.6  54.95 71.23 78.93 16.63 63.68 22.36 72.71 15.62 
V292.4 72.28 12.05 55.69 18.99 86.57 36.76 88.62 19.42 
* Concentration (ng/g) 
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Going beyond 210°C caused practical problems represented as occasional damaged 
caps (Figure 2.39) and thus sample loss (Figure 2.40) due to the rapid pressure build-
up and the continuous venting and release of hot vapour to reduce the pressure.  
 
Figure 2.39 Thermal degradation of caps when holding at 220°C for 20 minutes  
 
 
Figure 2.40 Sample loss due to caps damage during digestion procedure when 
holding at 220°C for 20 minutes 
 
In addition, increasing the temperature to 200°C and beyond using a one-stage 
digestion procedure caused charring of some of the powder at the vessel’s wall, 
which led to poor repeatability and inconsistent results. To overcome this problem a 
three-stages procedure was tried where the temperature is increased gradually to 
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allow the different samples components to digest at different stages and that was 
successful in preventing charring as well as in reducing the pressure build up. Figure 
2.41  shows the digested samples using one and three stages procedure. 
 
Figure 2.41 NIST 3280 digest using: A) One-stage procedure, B) Three-stages 
procedure 
 
To reduce caps deformation, custom venting at low temperatures where included in 
the three-stages digestion procedure to minimise the hot vapour contact with the 
caps. The results obtained were found to be acceptable while keeping the caps 
physically intact. Figure 2.42 shows the pressure build up and vent using one-stage 
and three-stages digestion procedure. 
 
Figure 2.42 The pressure profile for microwave digestion procedure of NIST 3280. 
A) One-stage digestion procedure at 210 °C with a hold for 20 minutes and B) Three-




2.3.1.2 Optimisation of the three-stages digestion procedure time 
From Table 2.9, 210°C gave recoveries of more than 70% for Class 2A elements, but 
with poor repeatability, so this temperature was used in the third stage of the 
digestion procedure. 120°C and 180°C were used for the first and second stages 
respectively. 
The effect of hold time on the percentage recoveries for the elements was studied 
by holding for 5, 10 and 15 minutes at the same temperature, which is 210°C. The 
obtained results showed satisfactory recoveries with good precision by holding for 5 
minutes only, so for the sake of time efficiency holding for 5 minutes was chosen to 
study the effect of different temperatures. Table 2.10 illustrates the obtained results. 
 
Table 2.10 Optimisation of digestion time using three-stages digestion procedure, 
n=3 
 
Method 1-Total time = 40 minutes 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 15 min 
Element   % Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 
Cd 214.4 nm <LoQ (0.88 ng/g) - 
Hg 184.9 nm N/A - 
Pb 220.3 nm <LoQ (4.73 ng/g) - 
Co 228.6 nm 99.96 1.45 
Ni 231.6 nm 104.03 1.58 





Table 2.10, continued 
Method 2-Total time = 35 minutes 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 10 min 
Element   % Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 
Cd 214.4 nm <LoQ (0.88 ng/g) - 
Hg 184.9 nm                                    N/A - 
Pb 220.3 nm <LoQ (4.73 ng/g) - 
Co 228.6 nm 98.4 5.74 
Ni 231.6 nm 103.92 4.83 
V 292.4 nm 103.18 4.72 
Method 3-Total time = 30 minutes 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
Element   % Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 
Cd 214.4 nm <LoQ (0.88 ng/g) - 
Hg 184.9 nm N/A - 
Pb 220.3 nm <LoQ (4.73 ng/g) - 
Co 228.6 nm 99.82 3.88 
Ni 231.6 nm 100.11 4.25 
V 292.4 nm 96.88 3.02 
 
At this point, a solid residue was still present in the mixture after digesting NIST 3280. 
This is due to the presence of ingredients like silicon dioxide that will not be fully 
digested using reverse aqua regia. The use of more corrosive and toxic acids like 
hydrofluoric acid is not necessary, because all the elements of interest are extracted 
and dissolved in the liquid phase, which is supported by the good recoveries and RSDs 
obtained (Table 2.10- Method 3). 
2.3.1.3 Testing the elements extraction efficiency of different acid ratios  
Nitric acid alone is commonly used to extract elements and digest samples(282-287), 
so the next step in the procedure development was to try a higher ratio of nitric acid 
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as the digestion medium. In this case, a ratio of  9 HNO3: 1 HCl. The obtained results 
are illustrated in Table 2.11. 
Table 2.11 Percentage recoveries for NIST 3280 using 9 HNO3: 1 HCl, n=3 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 102.03 1.58 
Cd 214.4 nm <LoQ (0.88 ng/g) - 99.52 2.17 
Hg 184.9 nm N/A - 98.17 3.82 
Pb 220.3 nm <LoQ (4.73 ng/g) - 97.64 2.25 
Co 228.6 nm 95.67 6.22 99.10 1.65 
Ni 231.6 nm 76.47 4.73 95.24 2.84 
V 292.4 nm 99.50 3.21 101.78 1.23 
Reverse aqua regia was more efficient in extracting Ni than the 9 HNO3 : 1 HCl (v/v) 
acid ratio, which is consistent with previous findings. Ni recoveries were about 70-
80% using SRM 1573 (certified tomato leaves), BCR 146 (certified sewage 
sludge)(288), SRM 1575 (certified pine needles), RM 8433 (certified corn bran) and  
RM 8436 (certified durum wheat flour)(284).   
Based on that, reverse aqua regia was the acid mixture used to digest pharmaceutical 
samples in this work. 
2.3.1.4 Microwave assisted acid digestion procedure validation 
2.3.1.4.1 Digestion efficiency assessment using spike addition vs. NIST 3280 
certified levels 
The reliability of the spike recoveries recommended for validation by USP <233>(96) 
was tested using the three-stages optimised method at different maximum 
temperatures (140, 160, 180 and 210°C). The % recoveries based on the certified 
elements levels were also calculated. 
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 As demonstrated in Table 2.12 spike recoveries were between 95-105% even at low 
temperatures where actually only a fraction of the elements was extracted which is 
reflected clearly in the recoveries calculated based on NIST 3280 certificate as they 
were in some cases below USP <233> accepted recovery of 70%. 
That suggest the need for validating any developed procedure using a solid reference 
material that represents the whole process rather than relying solely on spiked 
recoveries.  
Table 2.12 NIST 3280 percentage recoveries using different temperatures for the 
microwave assisted acid digestion methods, n=3 
Method 1 
Stage 1: Ramp Time= 5 min, Temperature= 50°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 110°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 140°C, Hold time= 5 min 
 NIST 3280 certified levels Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 99.30 1.18 
Cd 214.4 nm <LoQ (0.88 ng/g) - 98.73 4.77 
Hg 184.9 nm N/A - 97.59 4.68 
Pb 220.3 nm <LoQ (4.73 ng/g) - 100.27 3.94 
Co 228.6 nm 60.07 7.71 95.23 2.68 
Ni 231.6 nm 55.69 16.63 104.69 2.09 
V 292.4 nm 63.26 8.249 101.18 2.48 
Method 2 
Stage 1: Ramp Time= 5 min, Temperature= 70°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 130°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 160°C, Hold time= 5 min 
 NIST 3280 certified levels Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 102.19 1.05 
Cd 214.4 nm <LoQ (0.88 ng/g) - 97.69 2.33 
Hg 184.9 nm N/A - 100.80 2.54 
Pb 220.3 nm <LoQ (4.73 ng/g) - 95.43 4.95 
Co 228.6 nm 52.44 7.53 103.76 2.33 
Ni 231.6 nm 61.83 9.53 99.88 3.86 





Table 2.12, continued 
Method 3 
Stage 1: Ramp Time= 5 min, Temperature= 90°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 150°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
 NIST 3280 certified levels Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 98.18 1.41 
Cd 214.4 nm <LoQ (0.88 ng/g) - 99.81 4.15 
Hg 184.9 nm N/A - 102.44 2.17 
Pb 220.3 nm <LoQ (4.73 ng/g) - 96.81 4.95 
Co 228.6 nm 76.07 6.78 95.47 5.04 
Ni 231.6 nm 72.27 10.05 95.54 3.78 
V 292.4 nm 80.88 4.18 101.76 3.16 
Method 4 
Stage 1: Ramp Time= 5 min, Temperature= 110°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 170°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 200°C, Hold time= 5 min 
 NIST 3280 certified levels Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 95.85 5.01 
Cd 214.4 nm <LoQ (0.88 ng/g) - 103.19 2.44 
Hg 184.9 nm N/A - 102.42 3.53 
Pb 220.3 nm <LoQ (4.73 ng/g) - 96.68 2.64 
Co 228.6 nm 62.71 3.36 97.83 4.77 
Ni 231.6 nm 63.97 7.40 101.11 2.52 
V 292.4 nm 88.57 4.91 104.60 2.27 
Method 5 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
 NIST 3280 certified levels Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
As 189.0 nm <LoQ (5.86 ng/g) - 95.62 4.85 
Cd 214.4 nm <LoQ (0.88 ng/g) - 97.98 2.52 
Hg 184.9 nm N/A - 97.88 3.78 
Pb 220.3 nm <LoQ (4.73 ng/g) - 102.41 3.17 
Co 228.6 nm 99.82 3.88 103.49 2.75 
Ni 231.6 nm 100.11 4.25 97.76 3.70 





2.3.1.4.2 Validating the optimised digestion procedure for Class 1 elements  
For As, Cd, Hg and Pb the method was validated by comparing the results obtained 
for the analysis of an experimental formulation of certified tablets that are still under 
development with those obtained from ICP-MS using kinetic energy discrimination 
(KED). This gave results from an identical sample via two different analysis techniques. 
Those tablets were prepared in cooperation with the Coalition for Rational 
Implementation of the USP Elemental Impurities Requirements/Technical and 
Analytical Challenges (TAC) sub-committee, by spraying standard solutions of 
elements over pharmaceutical grade lactose. The next step was granulation of the 
lactose and other powdered excipients and then compressing it as tablets, each 
weighing approximately 0.25 g. Gold standard was also added in a similar way to 
retain Hg within the tablets(289).  
The results showed good agreement as illustrated in Table 2.13. 
Table 2.13 Validation for Class 1 elements using two different techniques (mean ± 
σ, n=3) 
Optimised ICP-OES method ICP-MS using (KED) 
As 189.0 nm=2.37±0.006 µg/g, RSD=1.70       75As = 2.45±0.06 µg/g, RSD=2.40 
Cd 214.4 nm =0.85±0.005 µg/g, RSD=0.60        111Cd =0.87±0.02 µg/g, RSD=2.21 
Hg 184.9 nm=3.47±0.019 µg/g, RSD=0.55        202Hg =3.80±0.08 µg/g, RSD=2.05 
Pb 220.3 nm=1.71±0.048 µg/g, RSD=2.78       208Pb =1.89±0.02 µg/g, RSD=1.13 
  
To make reference tablets that are more representative of real pharmaceutical 
samples and thus provide better reflection of the digestion procedure efficiency, test 
tablets formulated from excipient containing EI such as iron oxide and silicon dioxide 
were produced by TAC sub-committee. The excipients were added in amounts that 
would theoretically provide three different concentrations of Class 1 and Class 2A 
elements.   
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 Those tablets were digested in 10 mL reverse aqua regia instead of 8 mL because 
they contain considerably higher amounts of silicon dioxide that is hard to digest. 
Following preparation. The samples were analysed using the optimised ICP-OES 
method. 
Table 2.14 illustrate the obtained results. 
Table 2.14 Analysis results of three TAC formulas containing different levels of Class 
1 and Class 2A elements using ICP-OES, n=3 
Element 
Formula-1 (30% PDE) ICP-OES   
Theoretical(µg/g)* Concentration(µg/g) RSD %Recovery  
As 189.0 nm 6.65 3.83 2.74 57.59  
Cd 214.4 nm 1.58 1.36 3.09 86.08  
Hg 184.9 nm 6.48 3.92 2.34 60.49  
Pb 220.3 nm 2.27 2.28 2.44 100.44  
Co 228.6 nm 8.68 7.96 5.51 91.71  
Ni 231.6 nm 6.58 5.79 4.53 87.99  
V 292.4 nm 22.25 19.64 3.64 88.27  
      
Element 
Formula-2 (100% PDE) ICP-OES   
Theoretical(µg/g)*  Concentration(µg/g) RSD %Recovery  
As 189.0 nm 19.8 15.17 4.61 76.62  
Cd 214.4 nm 5.26 4.94 3.75 93.92  
Hg 184.9 nm 19.45 18.89 5.14 97.12  
Pb 220.3 nm 6.67 6.41 3.94 96.10  
Co 228.6 nm 22.08 19.61 5.01 88.81  
Ni 231.6 nm 10.55 10.24 2.24 97.06  
V 292.4 nm 22.7 18.28 3.31 80.53  
      
Element 
Formula-3 (300% PDE) ICP-OES   
Theoretical(µg/g)* Concentration(µg/g) RSD %Recovery  
As 189.0 nm 49.2 45.55 3.42 92.58  
Cd 214.4 nm 15.76 12.63 2.15 80.14  
Hg 184.9 nm 48.61 51.09 2.84 105.10  
Pb 220.3 nm 17.35 14.59 3.47 84.09  
Co 228.6 nm 50.12 37.67 2.76 75.16  
Ni 231.6 nm 16.75 13.43 3.94 80.18  
V 292.4 nm 0.9 <LoD (2.53x10-3)  - -  
*The theoretical concentrations were calculated based on available EI data for each 
excipient(31) and from the certified values in case of silicon dioxide, where an XRF reference 
material was used in the formulation  
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The calculated elements % recoveries for the three formulations were more than 
70% except for As and Hg in formula 1. This low recovery (about 60%) is due to more 
than one factor. Firstly, as the amount of excipients containing the elements was 
reduced, the homogenisation and distribution of the excipients in the formula 
becomes more challenging. With the fact that only three tablets were used for 
digestion, the homogenisation issue becomes more significant. Secondly and more 
importantly, the recoveries were based on EI concentrations taken from work by Li 
et al(31). However different batches of excipients were used from the original paper 
and hence because of varying concentrations the theoretical levels maybe inaccurate. 
With higher amounts of the excipients being used in formulas 2 and 3, the excipients 
distribution throughout the formulas improved and higher recoveries were obtained. 
2.3.1.5 Tablets grinding and sample homogeneity  
Another challenge arose during the development of the microwave assisted acid 
digestion procedure was the variation of the results which suggested a problem in 
the homogeneity of the samples.  
Before digesting the tablets, it was necessary to grind a suitable number of them to 
get a homogenized mixture to be used to get the 0.5g of the powder for digestion.   
Two techniques were used to grind the tablets and homogenise the powder, the first 
one was using glass mortar and pestle and the second one was using a mixer mill.  
A comparison of RSDs using the two grinding techniques are shown in Table 2.15. It 
was clear that using the mixer mill enhanced the homogeneity of the samples as the 
RSD dropped from 6-10 to less than 5% for all elements. The difference in 
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homogeneity was obvious by naked eye as flakes of the tablets’ coating material 
were seen in the powder’s mixture when the glass mortar and pestle were used to 
grind them. Figure 2.43 illustrates the difference in homogeneity represented by the 
powder appearance when both techniques were used for grinding the tablets. 
Table 2.15 Digestion repeatability when two different techniques were used to 
grind NIST 3280 tablets prior to digestion, n=3 
 
 Using Glass Mortar and pestle Using Mixer Mill MM200 
Element %Recovery RSD %Recovery RSD 
Co 228.6 nm 102.82 7.56 99.82 3.88 
Ni 231.6 nm 97.52 7.96 99.10 4.82 
V 292.4 nm 97.02 7.27 96.88 3.02 
 
 
Figure 2.43 NIST 3280 powder, ground using: A) Glass mortar and pestle, B) Mixer 
mill 
 
This suggests that for coated tablets such as NIST 3280 using an instrumental method 
for grinding might be necessary especially when the tablets are coated with materials 
that could include trace elements to get reproducible results. 
 Some coating materials such as ferric oxide (red, yellow and black) were found to 
contain 0.03-0.037 µg/g of Pb, 0.04-0.080 µg/g of As, 37.8-123.5 µg/g of Co, 57.7-
96.0 µg/g of Ni and 43.9-436 µg/g of V. Another example for a coating material is 
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titanium dioxide, which is used to coat NIST 3280. It was found to contain 0.08 µg/mL 
of As, 0.04 µg/g of Cd, 0.01 µg/g of Hg, 2.15 µg/f of Pb, 3.31 µg/g of Co, 12.90 µg/g 
of Ni, 5.30 µg/g of V(31). The inability of the grinding method to evenly distribute the 
elemental impurities from the coating would cause the variation seen in the mortar 
and pestle technique.  
2.3.1.6 Selection of suitable internal standard(s)  
Internal standardisation is effective in maintaining long-term stability, improving 
accuracy and precision for ICP-OES by reducing errors caused by uncontrolled 
variation in noise response and the different composition of samples matrices(290, 
291).  
Two internal standards were used to improve accuracy and precision of the 
optimised ICP-OES method, Sc 225.2 nm and Y 371 nm. The corrected results 
obtained using iTEVA software after analysing the reference tablets were compared 
with those obtained without internal standard correction for the same samples. The 
results illustrated in Table 2.16 shows that both Sc and Y were effective in improving 
the method’s precision, however, Sc was more efficient in improving the results 
accuracy as Y generated lower concentration in comparison with the certified levels. 
As a result, Sc 225.2nm was selected as the internal standard to be used for all the 






Table 2.16 Concentrations (µg/g) obtained with and without the use of Sc 225.2nm 
and Y 371nm as internal standards, n=3 
Element-nm With Sc 225.5  With Y 371  Without IS* Reference 
  TAC-Tablets   ICP-MS (KED) 
As 189.0  2.37±0.006  1.67 ±0.004  2.70 ±1.35   2.45±0.06  
Cd 214.4  0.85±0.005  0.72 ±0.05  0.78 ± 0.15  0.87±0.02  
Hg 184.9  3.47±0.019  3.28 ±0.02  3.66 ±1.95  3.80±0.08   
Pb 220.3  1.71±0.048  1.65 ± 0.042  2.57 ±1.82  1.89±0.02   
 NIST 3280-Tablets Certified levels  
Co 228.6  0.80 ±0.040  0.70 ±0.045  0.81 ±0.15  0.81 ±0.01  
Ni 231.6  8.45 ± 0.041  8.34 ±0.042  8.35 ±3.64  8.34 ±0.30  
V 292.4 7.69 ±0.027  7.58 ± 0.028  7.85 ±2.11  8.00 ±2.00  
*IS= internal standard 
 
2.3.4 Analysis of analgesic tablets, cold and cough remedies 
The concentration of elemental impurities in each product was calculated based on 
the maximum allowed dose as stated by the products’ manufacturers to generate 
numbers that are comparable to the ICH Q3D guidelines were the limits are set as 
PDEs as described before. The maximum daily doses for cough remedies formulated 
as syrups were determined by weighing the corresponding volumes using analytical 
balance.  
All product samples were spiked to calculate the spiked recoveries and NIST 3280 
samples were also digested with each product to make sure that the method is 
accurate each time it was used for product’s analysis. The percentage recoveries for 
quantifiable elements in the reference tablets were always between 95-105% as well 
as the spiked recoveries. 




Table 2.17 Elemental impurities (µg/day) in analgesic tablets analysed using ICP-














As 189.0 15 <LoD (1.85X10-3) 95.97 3.25 
Cd 214.4 5 0.45± 0.009 97.77 2.54 
Hg 184.9 30 <LoD (7.00X10-4) 101.91 4.32 
Pb 220.3 5 1.07± 0.001 100.03 3.62 
Co 228.6 50 1.07± 0.059 98.89 4.51 
Ni 231.6 200 50.71± 0.028 99.37 2.64 
V 292.2 100 <LoD (2.53X10-3) 101.04 3.41 
      
Hedex Extra 
As 189.0 15 <LoD (1.85X10-3) 97.79 2.94 
Cd 214.4 5 0.55±  0.089 99.03 1.19 
Hg 184.9 30 <LoD (7.00X10-4) 96.71 1.42 
Pb 220.3 5 4.14± 0.052 99.15 2.74 
Co 228.6 50 2.87± 1.10 104.77 3.51 
Ni 231.6 200 <LoD (5.90X10-4) 100.18 3.42 
V 292.2 100 <LoD (2.53X10-3) 98.24 2.14 
      
Anadin 
Extra 
As 189.0 15 <LoD (1.85X10-3) 95.20 3.21 
Cd 214.4 5 0.41±  0.009 101.96 2.61 
Hg 184.9 30 <LoD (7.00X10-4) 96.64 4.01 
Pb 220.3 5 3.51± 0.05 99.63 2.03 
Co 228.6 50 <LoD (5.20X10-4) 98.82 2.29 
Ni 231.6 200 <LoQ (1.75X10-3) 100.42 2.55 
V 292.2 100 <LoD (2.53X10-3) 100.61 3.26 




As 189.0 15 <LoD (1.85X10-3) 97.31 2.00 
Cd 214.4 5 0.62±  0.054 95.23 3.77 
Hg 184.9 30 <LoD (7.00X10-4) 97.75 4.51 
Pb 220.3 5 3.91± 0.087 96.41 3.32 
Co 228.6 50 <LoD (5.20X10-4) 98.45 2.61 
Ni 231.6 200 <LoQ (1.75X10-3) 103.96 3.21 
V 292.2 100 <LoD (2.53X10-3) 103.02 2.28 






Table 2.18  Elemental impurities (µg/day) in cold and cough remedies analysed 
using ICP-OES mode (mean ± σ, n=3) 
 
Products Elements 











As 189.0 15 <LoD (1.85X10-3) 100.73 4.01 
Cd 214.4 5 6.19± 0.023 97.86 3.17 
Hg 184.9 30 <LoD (7.00X10-4) 97.66 3.99 
Pb 220.3 5 22.68± 0.043 95.13 2.11 
Co 228.6 50 <LoQ (1.58X10-3) 100.53 2.59 
Ni 231.6 200 <LoQ (1.75X10-3) 98.46 2.65 
V 292.2 100 <LoD (2.53X10-3) 103.66 3.77 
   
   
Calpol 
SixPlus 
As 189.0 15 <LoD (1.85X10-3) 97.06 2.51 
Cd 214.4 5 <LoD (3.00X10-4) 102.01 1.38 
Hg 184.9 30 16.87± 0.031 96.13 1.61 
Pb 220.3 5 55.27± 0.028 98.73 2.81 
Co 228.6 50 11.44± 0.047 95.03 1.45 
Ni 231.6 200 <LoD (5.90X10-4) 97.06 1.66 
V 292.2 100 <LoD (2.53X10-3) 102.89 3.07 
   
   
Nelsons 
Sootha  
As 189.0 15 <LoD (1.85X10-3) 95.73 1.07 
Cd 226.5 5 2.22± 0.048 97.93 2.05 
Hg 184.9 30 <LoD (7.00X10-4) 95.133 4.41 
Pb 220.3 5 7.79±   0.05 97.46 2.15 
Co 228.6 50 <LoQ (1.58X10-3) 100.41 3.51 
Ni 231.6 200 <LoQ (1.75X10-3) 99.82 3.08 




   
Calcough 
As 189.0 15 <LoD (1.85X10-3) 100.79 2.98 
Cd 214.4 5 7.23± 0.04 97.13 2.59 
Hg 184.9 30 9.01± 0.027 97.68 1.71 
Pb 220.3 5 20.24± 0.05 95.66 3.52 
Co 228.6 50 6.02± 0.021 102.86 2.08 
Ni 231.6 200 <LoQ (1.75X10-3) 100.53 2.29 




   
Lemsip 
As 189.0 15 <LoD (1.85X10-3) 98.26 1.86 
Cd 214.4 5 9.69± 0.22 97.39 2.17 
Hg 184.9 30 <LoD (7.00X10-4) 102.32 2.17 
Pb 220.3 5 25.84± 0.10 98.53 3.89 
Co 228.6 50 9.13± 0.048 96.66 3.56 
Ni 231.6 200 <LoQ (1.75X10-3) 99.78 2.35 
V 292.2 100 <LoD (2.53X10-3) 96.93 3.14 














As 189.0 15 <LoD (1.85X10-3) 95.73 2.98 
Cd 214.4 5 9.21± 0.043 100.33 2.77 
Hg 184.9 30 <LoD (7.00X10-4) 96.26 3.07 
Pb 220.3 5 41.95± 0.26 104.67 2.96 
Co 228.6 50 42.10± 0.059 95.67 1.78 
Ni 231.6 200 <LoQ (1.75X10-3) 103.33 2.37 
V 292.2 100 <LoD (2.53X10-3) 99.61 3.86 
From the results, it is noted that four products exceed the regulations’ PDE for Cd 
and six products exceed the PDE for Pb. 
Hg, Co and Ni were also quantified in some products, but the concentrations present 
are within the PDEs stated in ICH Q3D guidelines 
The daily dosage of medications has an effect on the elemental impurity limits that 
can be tolerated. For example, Tixylix can be taken in three different daily dosages 
according to the patient’s age. As a result, three different EI concentrations of Cd and 
Pb will be introduced to the patients based on their age as illustrated in Table 2.19. 
Table 2.19 Daily exposure (µg/day) for Tixylix when given in different dosages 
based on patient’s age  
 Daily Exposure (µg/day) 
Medication maximum daily dosage  Cd 214.4 nm Pb 220.3 nm 
1-5 years: 12.05 g/day 1.54 5.67 
5-12 years: 24.1 g/day 3.09 11.34 
>12 years: 48.20 g/day 6.19 22.68 
 
From Table 2.19 , it is clear that the medication dosage plays a role in whether the 
pharmaceutical product exceeds the permitted limits or not.  Taking Cd as an 
example, if the product is to be given for children under twelve years old, the Cd 
concentration is less than 5 µg/day; it exceeds the limits once the product is given for 




The developed ICP-OES method and microwave assisted acid digestion for 
pharmaceutical products was successfully validated using NIST 3280 as well as from 
supporting results obtained using ICP-MS/KED. The method showed excellent 
recoveries between 95-105% with good repeatability expressed as RSD of less than 
5% for all elements. Those limits met the regulations requirements. The method is 
also specific as any spectra with major interferences were excluded and only those 
with minimal interferences were chosen for analysis. LoDs and LoQs were below the 
target limits, which supports the suitability of the ICP-OES for EI determination. 
The obtained results for commercial pharmaceutical products that were analysed 
emphasise the need for a validated method for elemental impurities analysis as many 
of them exceed the PDEs for both Cd and Pb. This needs high attention as the new 
regulation was applied to all pharmaceutical products in January 2018 and any 
products that fail the new requirement will be withdrawn from the market.  
This work also highlights the fact that even products with no API may also contain 
significant amount of trace elements, which emphasises the fact that one of the 
major sources for elemental impurities is the excipients used for the formulation of 
pharmaceutical products.   
From the previous results, ICP-OES can be successfully used for the determination of 
EI in pharmaceuticals. However, ICP-OES lacks the sensitivity required to analyse 
products with high daily intake, that is more than 1 L/day like in the case of large 
volume parenteral, because the limits will drop below the method’s LoQs.  
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An example is Pb (LoQ= 0.00473 µg/mL) that has a PDE of 5 µg/day, which means it 
will has a limit of 0.00455 µg/mL  for a product with daily dosage of 1,100 mL. 
Due to that, a method using ICP-MS that offers higher sensitivity than ICP-OES will be 
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3. The Optimisation, Validation and Analysis of analgesics, 
cough remedies, cold and flu products and antacids by ICP-MS 
in Compliance ICH-Q3D Guidelines  
 
3.1 Introduction  
ICP-MS was successfully used by Kauffman et al(262) to measure the concentration 
of Pb in forty-five pharmaceutical products including some analgesics and 
nonsteroidal anti-inflammatory drugs (NSAIDs). The highest Pb concentration among 
ten ibuprofen samples manufactured in India and England was 12 ng/g. It is 
important to control the concentration of Pb and keep it as low as possible due to its 
known toxicity that affects various physiological systems including the CNS which 
could have severe health effects especially on children(6, 7).  
In addition, a calcium-based product that is used as antacid was estimated to deliver 
a maximum daily mass of 2.7µg of Pb per day to consumers(262). However, this study 
focuses on Pb only and the rest of Class 1 and Class 2A elements were not included. 
In another study conducted using microwave induced combustion (MIC)-ICP-MS to 
assay over the counter enteric coated aspirins of different brands, traces of Class 1 
and Class 2 elements were found in different concentrations ranging from 0.002-0.88 
µg/g(46). For example, one aspirin brand was found to contain 0.71 µg/g of As, 0.014 
µg/g of Pb, 0.57 µg/g of Ni and 0.88 µg/g of V(46). However, the method was 
validated using spike addition technique only, which is as discussed in Chapter 2 may 
give false indication of the method’s accuracy especially when microwave-assisted 
techniques are used for sample preparation as in this case where MIC was used. In 
addition, Co from Class 2A was not included in the analysis. 
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As mentioned in Section 1.1.1, the instrument was also used to analyse active 
pharmaceutical ingredients including furazolidone, ethambutol, pyrazinamide and 
dicyclomine-HCl were traces of Ti, Cr, Mn, Cu, Cd and Pb were found in 
concentrations ranging from 0.1 to 38.2 ng/g(17). In this study, As and Hg form Class 
1 as well as Ni and V from Class 2A were not included in the analysis. Additionally, 
the samples were digested prior to analysis however; the method was validated using 
NIST 1643b, which is a water reference sample and the maximum temperature 
reached was 60-80°C, which was found to be inefficient as discussed in Section 
2.3.1.1. 
In addition, tablets containing captopril showed As contents of 0.1 µg/g. Another 
captopril API sample contained 0.3 µg/g of As. The method was validated using 
spiked addition technique(265).  
All the previously mentioned studies emphasise the need for a reliable validated 
method to analyse elemental impurities in pharmaceuticals and thus control their 
levels to be within the allowed PDEs, because it is clear that some API(18, 97, 265) 
and/or excipients(31) used in the production of pharmaceutical products may 
contain high levels of EI. 
However, just like with ICP-OES methods, most of the developed ICP-MS techniques 
for the analysis of pharmaceutical impurities were validated using spiked recoveries 
as suggested in USP<233> chapter(1, 18, 265, 292, 293). 
This chapter focuses on the development of an ICP-MS method to analyse the Class 
1 elements As, Cd, Hg and Pb and Class 2A Co, Ni and V and then applying it to 
commercial analgesic tablets, cold and cough syrups, cold and flu powders and 
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antacids. The optimised ICP-MS method was validated using NIST 3280 
Mulivitamin/Multielement tablets. 
3.2 Experimental 
3.2.1 Reagents and Materials 
For the reagents, materials and standard references - see Section 2.2.1. 
Eight standard solutions were prepared by dilution with 2% reverse aqua regia (3 
HNO3 : 1 HCl v/v) to get concentrations ranging from 5 to 200 ng/mL as well as a blank. 
10 ng/mL of 45Sc, 98Y,103Rh and 159Tb were added as internal standards to the 
calibration and samples in addition to 1 µg/mL of Au. 
Argon gas (purity > 99.995%) was supplied by AirProducts, UK and He gas (purity 
99.995%) was supplied by BOC, UK. 
3.2.2 Samples 
The twelve samples analysed using the validated ICP-OES method were reanalysed. 
In addition, six cold and flu powders provided in sachets and six antacid products 
were acquired from local retailers in the Liverpool area (Table 3.1).  
All products were processed and analysed within ten days of their purchase, before 







Table 3.1 Cold and flu powders and antacids product information 
Product  Ingredients 
Maximum daily dose for 
patients 12 years old 
and over  (g/day) 





Excipients: sucrose, sodium citrate, citric acid, 
tartaric acid, sodium cyclamate, ascorbic acid, 
starch, natural colour (E 100), spray dried 




API: paracetamol  
Excipients: sucrose, sodium citrate, citric acid, 
tartaric acid, sodium cyclamate, ascorbic acid, 
starch, natural colour (E 100), spray dried 






API: paracetamol and phenylephrine 
hydrochloride 
Excipients: ascorbic acid, sucrose, sodium 
citrate, citric acid, maize starch, sodium 
cyclamate, saccharin sodium, lemon, lemon, 
flavour, honey flav-o-lok, honey flavour and 




API: paracetamol and phenylephrine 
hydrochloride 
Excipients: Ascorbic acid, sucrose, sodium 
citrate, citric acid, sodium cyclamate, saccharin 
sodium, blackcurrant juice, blackcurrant 
polvaromas, blackcurrant flavour, natural 





API: paracetamol and phenylephrine 
hydrochloride 
Excipients: ascorbic acid, citric acid, sucrose, 
aspartame, sodium citrate, saccharin sodium, 




API: paracetamol and phenylephrine 
hydrochloride 
Excipients: ascorbic acid, citric acid, sucrose, 
aspartame, sodium citrate, saccharin sodium, 








Table 3.1, continued 
Product  Ingredients 
Maximum daily dose for 
patients 12 years old 




API: sodium alginate, sodium bicarbonate and 
calcium carbonate 
Excipients: carbomer, methyl (E 218) and propyl 
(E 216) parahydroxybenzoate, sachharin sodium, 







API: sodium alginate, sodium bicarbonate and 
calcium carbonate 
Excipients: xylitol, carmellose sodium, 
magnesium stearate, macrogol 20000, mannitol 
(E 421), copovidone, acesulfame-K, aspartame (E 





API: calcium bicarbonate, magnesium carbonate 
and alginic acid 
Excipients: sodium hydrogen carbonate, 
sucrose, glucose monohydrate, povidone, talc, 
magnesium stearate, dextrates, saccharin 
sodium, lemon cream flavour (contains lemon 
oil, lime oil, orange oil, l-menthol, vanillin, 
maltodextrin, gum Arabic, ascorbic acid, 
butylhydroxyanisol) and peppermint flavour 
(contains peppermint oil, maltodextrin, gum 




API: calcium bicarbonate and light magnesium 
carbonate and sodium bicarbonate 
Excipients: saccharine sodium maize starch, 





API: calcium bicarbonate and heavy magnesium 
carbonate  
Excipients: sucrose, glucose, spearmint flavour, 





API: calcium bicarbonate 
Excipients: sucrose, maize starch, calcium 





3.2.3 Instrumentation  
For sample preparation instrumentation - see Section 2.2.3.  
A Thermo XSeries quadrupole-based ICP-MS instrument (Thermo, UK), equipped 
with a collision reaction cell (CCT) incorporating kinetic energy discrimination was 
used for the analysis of Class 1 and Class 2A elements. The ICP-MS instrument is 
equipped with a CETAC ASX 520 series (Thermo, UK) autosampler and data was 
collected using Thermo Scientific PlasmaLab Software.  
Solutions were pumped to the nebuliser using a multi-channel peristaltic pump. The 
sample introduction unit consisted of a Meinhard concentric nebulizer and conical, 
impact bead spray chamber cooled to 1 °C in a Peltier cooling mould.  
The instrument was optimised based on signal and signal to blank ratios. The ICP-MS 
optimum conditions used throughout this experiment are listed in Table 3.2. 
Table 3.2  Overview of ICP-MS Thermo XSeries optimised parameters in CCT 
operation mode 
Minor 
Lens 2 -36.9 
Lens 3 -136.5 
Forward power (W) 1400 
Horizontal 90 
Vertical 370 
D2 (V) -100 
DA (V) -37.6 
Coolant gas flow (L/min) 14 
Auxiliary gas flow (L/min) 0.9 
Major 
Extraction (V) -130 
Lens 1 (V) -1.5 
Focus (V) 0 
D1 (V) -34.5 
Pole bias (V) -7 
Hexapole bias (V) -10 
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Table 3.2 continued  
  
Nebuliser gas flow (L/min) 0.98 
Sampling Depth (mm) 140 
Global 
Standard resolution 125 
High resolution 125 
Analougue detector 1900 
PC detector 3850 
Add. Gases 
He gas flow rate (mL/min) 3.5 
Others 
Pump speed (rpm) 30 
Sampling cone and type Nickel 
Skimmer cone and type Nickel, Xt 
 
3.2.4 ICP-MS Optimisation 
Five key parameters were selected for optimisation using signal and signal/blank 
ratio for both standard and CCT mode. The rest of the parameters were adjusted to 
pass the tune test were a solution containing 10 ng/mL of a mixture of elements (7Li, 
9Be, 48Ti, 59Co, 115In, 137Ba, 140Ce, 207Pb, 209Bi, 238U) covering a wide range of atomic 
masses is used to provide information about peak widths, sensitivity and oxide 
species. The tune test was performed each time the instrument is to be used on both 
standard and CCT modes and only after passing the test the analyses were completed. 
The test is considered successful if the conditions represented in Table 3.3 were met.  
Table 3.3 Passed tune test conditions, ICP-MS Thermo XSeries 
                                                Acquisition Parameters Ratio Results 
Standard Mode 7Li>1000 156Ce O/140Ce<0.03 
 115In>250000 115In/101Bkg>100000 
 238U>500000 238U/220Bkg>100000 
   
CCT Mode 59Co>10000 156Ce O/140Ce<0.02 
 78Ar2<20  
 115In>50000  




Nebuliser gas flow, pump rate, auxiliary gas flow, coolant gas flow, and radio 
frequency (RF) power were optimised starting from the lowest practically possible 
value to the highest possible one, using both standard and CCT mode. That was 
performed by measuring a stock solution containing a known concentration (30 
ng/mL) of the seven elements at different settings for each parameter within the 
mentioned range, followed by comparing the obtained signals and signal to blank 
ratios to get a setting with the best sensitivity for the elements.  
The signal to blank ratio was calculated by dividing the average signal obtained using 
a multielement standard with a concentration of 30 ng/mL by the average signal 
obtained using a blank (2% reverse aqua regia). 
3.2.4.1 Optimisation of nebuliser gas flow rate 
The procedure described in Section 3.2.4 was followed using a nebuliser gas flow rate 
range of 0.5-1.3 L/min. 
3.2.4.2 Optimisation of pump rate 
The procedure described in Section 3.2.4 was followed using a pump rate range of 
10-60 rpm. 
3.2.4.3 Optimisation of auxiliary gas rate 
The procedure described in Section 3.2.4 was followed using an auxiliary gas rate 
range of 0.5-1.5 L/min. 
3.2.4.4 Optimisation of coolant gas rate 
The procedure described in Section 3.2.4 was followed using a coolant gas rate range 
of 10-20 L/min. 
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3.2.4.5 Optimisation of RF power 
The procedure described in Section 3.2.4 was followed using RF power range of 800-
1500W. 
3.2.4.6 Optimisation of helium gas flow rate for operating CCT  
For CCT mode, the helium gas flow rate was also optimised (2.5-4.5 L/min) by 
analysing NIST 3280 samples and the best flow rate was decided based on the 
obtained elements recoveries with minimal interferences and good reproducibility.  
3.2.4.7 Selection of suitable internal standards and analytical atomic mass units  
Scandium (45Sc), yttrium (89Y), rhodium (103Rh), indium (115In) and terbium (159Tb) (10 
ng/ml), were added to both samples and standards prior to analysis. The corrected 
results for the internal standard was obtained using PlasmaLab software (Thermo 
UK). 
Eighteen different atomic masses for the seven elements in total were tested to 
determine the optimal analytical atomic mass unit (amu) for each element that gave 
the lowest LoD and LoQ with minimum interferences. The tested m/z are listed in 
Table 3.4. 
Table 3.4 Class 1 and Class 2A elements atomic masses optimised for elemental 
analysis using ICP-MS and their relative abundance 











Table 3.4, continued 












4.2.5 Analytical figures of merit and method validation  
3.2.5.1 Limits of detection and limits of quantification 
LoD and LoQ were calculated as described in Section 2.2.5.1, using 10 blanks and a 
series of standards ranging from 1 to 30 ng/ml according to the method of Miller and 
Miller(268) 
3.2.5.2 Linearity and range 
Linearity was obtained as described in Section 2.2.5.2 and studied in the range of 5-
1000 ng/mL ng/ml were eight concentration points were assayed in triplicate. 
3.2.5.3 Accuracy and Precision 
The accuracy and precision were evaluated using NIST 3280. The samples were also 
spiked with 10 ng/mL with respect to As, Cd. Hg, Pb, Co, V and Ni. The experiment 
was performed in triplicate.  
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3.2.6 Sample preparation and revalidation of the microwave assisted acid 
digestion procedure 
The procedure used was identical to that used in Section 2.2.6. However, for 
microwave assisted acid digestion, SP-D Microwave (CEM) with 80 mL quartz vessels 
were used instead of the 35 mL vessels and the program used is illustrated in Table 
3.5. 
Table 3.5 CEM-SPD microwave programme used to digest the samples 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
 
3.2.7 Analysis of pharmaceutical samples 
Pharmaceutical samples were prepared as described in Section 2.2.7. Following 
preparation, the samples were analysed using the optimised and validated ICP-MS-
CCT method. 
3.3 Results and discussion 
3.3.1 ICP-MS Optimisation 
A comparison of signals and signal to blank ratios was performed as described in 
Section 2.3.1 
3.3.1.1 Optimisation of nebuliser gas flow rate  
The standard signal increased with increasing the nebuliser gas flow rate until 
reaching the optimum value as more droplets with suitable size were produced. 
However, after the optimum setting big droplets with shorter plasma residence time 
started from leading to a decrease in sensitivity. 
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As illustrated in Figure 3.1, the optimum nebuliser gas flow rate for As using ICP-MS 
standard mode is 0.98 L/min. At this setting, the signal/blank ratio is the highest, 
which means that at a nebuliser gas flow rate of 0.98 L/min the standard signal is the 
highest, which is also consistent with the signal graph and the blank signal is the 
lowest. Using CCT gave the same optimum setting of 0.98 L/min. The signal/blank 
ratio increased significantly from approximately 7 to 700 when CCT mode was 
activated due to its capability of reducing polyatomic interference such as 40Ar35Cl+, 
59Co16O+, and 38Ar37Cl+(183). 
 
Figure 3.1 The signal and signal/blank ratios for arsenic (30 ng/mL) using ICP-MS 
standard and CCT modes at different nebuliser gas flow rates (L/min) 
 
For Cd (Figure 3.2), the optimum nebuliser gas flow rate using ICP-MS standard mode 
is also 0.98 L/min at both standard and CCT modes. However, the highest standard 
signal was obtained at a flow rate of 1 L/min. This can be explained as a higher drop 
in the blank signal occurred at a 0.98 L/min nebuliser gas flow rate giving a higher 
ratio and thus better sensitivity. This emphasises the need to optimise the instrument 





Figure 3.2 The signal and signal/blank ratios for cadmium (30 ng/mL) using ICP-MS 
standard and CCT modes at different nebuliser gas flow rates (L/min) 
 
On the other hand, Hg showed the highest sensitivity (signal/blank) at a nebuliser gas 
flow rate of 0.4 L/min on standard mode, and 0.7 L/min on CCT mode. The standard 





Figure 3.3 The signal and signal/blank ratios for mercury (30 ng/mL) using ICP-MS 
standard and CCT modes at different nebuliser gas flow rates (L/min) 
 
In the case of Pb (Figure 3.4), the highest signal/blank ratio and best sensitivity was 
obtained at a nebuliser gas flow rate of 0.98 L/min using both standard and CCT 
modes. The standard signal was the highest at a nebuliser gas flow rate between 0.9 
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and 1 L/min on both modes. The high standard signal and the low blank signal at the 
same settings made signal/blank ratio to be the highest at 0.98 L/min.  
 
Figure 3.4 The signal and signal/blank ratios for lead (30 ng/mL) using ICP-MS 
standard and CCT modes at different nebuliser gas flow rates (L/min) 
 
A behaviour similar to Pb was also observed for Co (Figure 3.5) 
 
Figure 3.5 The signal and signal/blank ratios for cobalt (30 ng/mL) using ICP-MS 
standard and CCT modes at different nebuliser gas flow rates (L/min) 
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Ni and V show similarity in having the highest standard signal accompanied with the 
highest signal/blank ratio at a nebuliser gas flow rate of 0.98 L/min at standard mode. 
For CCT  mode, the highest signal for both elements was obtained at 0.98L /min, but 
the highest signal/blank ratio was at 1.1 L/min (Figures 3.6 and 3.7). 
 
Figure 3.6 The signal and signal/blank ratios for nickel (30 ng/mL) using ICP-MS 




Figure 3.7 The signal and signal/blank ratios for vanadium (30 ng/mL) using ICP-MS 
standard and CCT modes at different nebuliser gas flow rates (L/min) 
 
The nebuliser gas flow rate was adjusted to 0.98 L/min for both standard and CCT 
modes, because this rate gave the best sensitivity for most elements. The reduction 
in Ni and V sensitivity was approximately 5% in comparison with what was obtained 
at a flow rate of 1.1 L/min. However for Hg, the reduction in sensitivity is more 
significant (approximately 10%), but for the time efficiency and multi-element 
analysis this drop in sensitivity can be tolerated, because its PDE (30 µg/day) is much 
higher than the allowed 5 µg/day for Cd and Pb. 
3.3.1.2 Optimisation of pump rate  
As mentioned is Section 2.3.1.2, high pump speed leads to the formation of large 
droplets in the spray chamber which reduces the analytical sensitivity. This was also 
observed with ICP-MS-CCT as the standard signal for all elements dropped 
significantly at a pump rate of 50 rpm and more.  
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For As and Cd, the highest signal/blank ratio at standard mode was the highest at a 
pump speed of 40 rpm. However, using CCT mode, the highest signal/blank ratio was 
obtained at pump speed of 30 rpm, because at this speed the standard signal also 
improved significantly leading to an increase in the signal/blank ratio and thus higher 
sensitivity. See Figures 3.8 and 3.9. 
 
Figure 3.8 The signal and signal/blank ratios for arsenic (30 ng/mL) using ICP-MS 




Figure 3.9 The signal and signal/blank ratios for cadmium (30 ng/mL) using ICP-MS 
standard and CCT modes at different pump rates (rpm) 
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Hg on the other hand showed a different behaviour towards changing the pump 
speed. Using ICP-MS-standard mode the highest standard signal and highest 
signal/blank ratio was obtained at a pump speed of 50 rpm (Figure 3.10). Using CCT, 
the standard signal increased gradually with increasing the pump rate until a speed 
of 50 rpm was reached. After that, the signal dropped significantly due to the 
formation of larger droplets. The signal/blank ratio was the highest using CCT at a 
pump rate of 20 rpm, which suggests that at this speed, the blank signal was the 
lowest and thus the best sensitivity for Hg was at a pump rate of 20 rpm. 
 
Figure 3.10 The signal and signal/blank ratios for mercury (30 ng/mL) using ICP-MS 




In the case of Pb (Figure 3.11), again, the standard signal using both modes increased 
with increasing the pump rate up to 50 rpm and then it dropped. However, the 
signal/blank ratio reached a maximum at a pump rate of 40 rpm on standard mode 
and 30 rpm on CCT mode then minimal changed occurred at higher rates. This can 
be explained as similar changes occurred to the blank causing the ratio to remain 
unchanged. 
 
Figure 3.11 The signal and signal/blank ratios for lead (30 ng/mL) using ICP-MS 




The standard signal for Co and Ni showed a behaviour similar to Pb on both modes. 
In case the of the signal/blank ratio, using standard mode, the highest ratio was 
obtained on a pump rate of 40 rpm and then with increasing the pump rate to 60 
rpm, both the signal and the signal/blank ratio dropped. Using CCT mode, the highest 
signal/blank ratio was obtained at a pump rate of 30 rpm. At higher pump rates, the 
signal/blank ratio decreased slightly for both elements (Figures 3.12 and 3.13).  
 
 
Figure 3.12 The signal and signal/blank ratios for cobalt (30 ng/mL) using ICP-MS 




Figure 3.13 The signal and signal/blank ratios for nickel (30 ng/mL) using ICP-MS 
standard and CCT modes at different pump rates (rpm) 
 
Finally, both the standard signal for V and the signal/blank using ICP-MS-standard 
mode increased with increasing the pump rate up to 40 rpm and then reached a 
plateau. Using CCT mode a behaviour similar to Ni was observed giving the highest 





Figure 3.14 The signal and signal/blank ratios for vanadium (30 ng/mL) using ICP-
MS standard and CCT modes at different pump rates (rpm) 
 
The pump rate was adjusted to 40 rpm using standard mode and 30 rpm using CCT 
mode. These pump speeds gave the best sensitivity for all element except for Hg. The 
loss in Hg sensitivity is accepted (approximately 20%) for the sake of faster multi-
element analysis and its relatively higher PDE (30 µg/day). 
3.3.1.3 Optimisation of auxiliary gas flow rate  
The auxiliary gas flow rate is used to change the position of the base of the plasma 
relative to the tube and the injector. Using ICP-MS-standard mode, the standard 
signal for all elements except As increased gradually with increasing the auxiliary gas 
flow rate. The signal/blank ratio reached a maximum at a flow rate of 0.9 L/min for 
111Cd, 112Cd, 207Pb and 208Pb, while the remaining elements at their tested m/z ratio 





Figure 3.15 The signal and signal/blank ratios for arsenic (30 ng/mL) using ICP-MS 
standard and CCT modes at different auxiliary gas flow rates (L/min) 
 
 
Figure 3.16 The signal and signal/blank ratios for cadmium (30 ng/mL) using ICP-




Figure 3.17 The signal and signal/blank ratios for cadmium (30 ng/mL) using ICP-




Figure 3.18 The signal and signal/blank ratios for lead (30 ng/mL) using ICP-MS 
standard and CCT modes at different auxiliary gas flow rates (L/min) 
 
 
Figure 3.19 The signal and signal/blank ratios for cobalt (30 ng/mL) using ICP-MS 




Figure 3.20 The signal and signal/blank ratios for nickel (30 ng/mL) using ICP-MS 




Figure 3.21 The signal and signal/blank ratios for vanadium (30 ng/mL) using ICP-
MS standard and CCT modes at different auxiliary gas flow rates (L/min) 
 
When using ICP-MS-CCT the standard signal for all elements, with exception of As, 
dropped when increasing the rate for more than 1.2-1.3 L/min, while the signal/blank 
ratio was improved at an auxiliary gas flow rate of 0.9 L/min. The sensitivity towards 
113Cd and 59Co was not significantly changed with changing the auxiliary gas flow 
rates (Figures 3.15-3.21).  
On the other hand, As sensitivity was improved with increasing the auxiliary gas flow 
rate using both standard and CCT modes (Figure 3.15). 
The auxiliary gas flow rate was adjusted to 0.9 L/min for both standard and CCT 
modes. 
3.3.1.4 Optimisation of coolant gas flow rate  
The coolant gas flow is one of the conditions that has minimum effect on the 
analytical sensitivity. The standard signal for As improved slightly with increasing the 
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coolant gas flow rate from 10 to 12 L/min and then reached a plateau, when 
operating the ICP-MS using standard mode. Using CCT mode, the standard signal 
started to drop gradually when the coolant gas flow rate was increased to 16 L/min 
and more. The signal/blank ratio remained almost constant over the tested range 
using standard mode, but dropped slightly when the rate was increased to 16 L/min 
using CCT mode due to the drop in the standard signal (Figure 3.22). 
 
Figure 3.22 The signal and signal/blank ratios for arsenic (30 ng/mL) using ICP-MS 
standard and CCT modes at different coolant gas flow rates (L/min) 
 
The standard signal for Cd dropped slightly with increasing the coolant gas flow rate 
using both modes, and the signal/blank ratio dropped severely at a coolant gas flow 
rate of 20 L/min when the instrument was operated on standard mode. Although the 
signal dropped at the same rate, this sharp decrease in the signal/blank ratio is due 
to the significant increase in the blank signal. The signal/blank ratio using CCT mode 
increased slightly when the coolant gas flow rate was increased up to 14 L/min, then 
it decreased.  113Cd is an exception as the signal/blank ratio remained almost 




Figure 3.23 The signal and signal/blank ratios for cadmium (30 ng/mL) using ICP-
MS standard and CCT modes at different coolant gas flow rates (L/min) 
 
The standard signal for Hg behaved similarly to Cd on both modes, however, the 
signal/blank ratio gradually increased with increasing the coolant gas flow rate on 
both modes. This is due to the significant drop in the blank signal at higher rates 





Figure 3.24 The signal and signal/blank ratios for mercury (30 ng/mL) using ICP-MS 
standard and CCT modes at different coolant gas flow rates (L/min) 
 
The standard signal and signal/blank ratio for Pb using ICP-MS-standard mode 
behaviour was similar to Cd (Figure 3.23). The standard signal gradually decreased 
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with increasing the coolant gas flow rate and the signal/blank ratio was minimum on 
a rate of 20 L/min due to the increase in the blank signal. Using CCT mode the 
standard signal behaved similarly, but the signal/blank ratio changed slightly and 
gave the highest ratio at 14 L/min (Figure 3.25).  
 
Figure 3.25 The signal and signal/blank ratios for lead (30 ng/mL) using ICP-MS 
standard and CCT modes at different coolant gas flow rates (L/min) 
 
Class 2A elements; Co and Ni were affected similarly to Class 1 elements. The best 
signal/blank ratio and highest sensitivity was achieved at a coolant gas flow rate of 
14 L/min. On the other hand, V sensitivity was not significantly affected with 




Figure 3.26 The signal and signal/blank ratios for cobalt (30 ng/mL) using ICP-MS 
standard and CCT modes at different coolant gas flow rates (L/min) 
 
 
Figure 3.27 The signal and signal/blank ratios for nickel (30 ng/mL) using ICP-MS 




Figure 3.28 The signal and signal/blank ratios for vanadium (30 ng/mL) using ICP-
MS standard and CCT modes at different coolant gas flow rates (L/min) 
 
From the coolant gas flow rate optimisation results, the rate was adjusted to 14 L/min 
for both standard and CCT modes.  
3.3.1.5 Optimisation of RF power  
With ICP-MS-CCT, the plasma was extinguished at an RF power of 800 W. As a result, 
the signal/blank ratio for all elements using CCT mode were calculated over RF power 
range between 900 to 1500 W. 
The highest signal/blank ratio for both Class 1 and Class 2A elements was obtained 
at an RF power of 900 W using both modes except for Hg, where the highest 
signal/blank ratio using standard mode was at 800 W. 
Figures 3.29-3.35 represent the obtained signals and signal/blank ratios using 




Figure 3.29 The signal and signal/blank ratios for arsenic (30 ng/mL) using ICP-MS 
standard and CCT modes at different RF powers (W) 
 
 
Figure 3.30 The signal and signal/blank ratios for cadmium (30 ng/mL) using ICP-




Figure 3.31 The signal and signal/blank ratios for mercury (30 ng/mL) using ICP-MS 




Figure 3.32 The signal and signal/blank ratios for lead (30 ng/mL) using ICP-MS 
standard and CCT modes at different RF powers (W) 
 
 
Figure 3.33 The signal and signal/blank ratios for cobalt (30 ng/mL) using ICP-MS 




Figure 3.34 The signal and signal/blank ratios for nickel (30 ng/mL) using ICP-MS 




Figure 3.35 The signal and signal/blank ratios for vanadium (30 ng/mL) using ICP-
MS standard and CCT modes at different RF powers (W) 
 
 
Due to plasma stability issues at low RF powers, similar to those encountered in ICP-
OES, the LoD and LoQ were assessed at different RF powers like in the case of ICP-
OES (Section 2.3.1.5). The selected powers were 900 W, 1000 W, 1100 W, 1200 W, 
1300 W, 1400 W and 1500 W. 






Table 3.6 Class 1 and Class 2A LoDs and LoQs (ng/mL) calculated using ICP-MS-
standard mode at different RF powers 
Standard Mode 900 W 1100 W 1300 W 1400 W 1500 W 
75As 
LoD 0.567 0.811 0.762 0.702 1.588 
LoQ 1.712 2.441 2.212 2.110 2.769 
111Cd 
LoD 0.187 0.152 0.045 0.037 0.026 
LoQ 0.586 0.443 0.098 0.091 0.075 
112Cd 
LoD 0.151 0.014 0.028 0.027 0.023 
LoQ 0.453 0.416 0.086 0.083 0.069 
113Cd 
LoD 0.153 0.013 0.033 0.032 0.028 
LoQ 0.461 0.401 0.099 0.096 0.084 
198Hg 
LoD 0.917 0.763 0.619 0.583 0.562 
LoQ 2.759 2.289 1.877 1.795 1.724 
201Hg 
LoD 0.594 0.557 0.625 0.612 0.581 
LoQ 1.788 1.677 1.883 1.841 1.747 
202Hg 
LoD 0.615 0.688 0.643 0.599 0.604 
LoQ 1.873 1.991 1.865 1.832 1.753 
204Hg 
LoD 0.145 0.661 0.321 0.303 0.562 
LoQ 0.437 1.996 0.966 0.915 1.693 
206Pb 
LoD 0.349 0.136 0.061 0.066 0.100 
LoQ 1.051 0.409 0.184 0.199 0.301 
207Pb 
LoD 0.347 0.135 0.061 0.065 0.078 
LoQ 1.043 0.407 0.183 0.197 0.231 
208Pb 
LoD 0.316 0.132 0.059 0.065 0.083 
LoQ 0.927 0.409 0.185 0.198 0.248 
59Co 
LoD 0.264 0.242 0.136 0.108 0.096 
LoQ 0.804 0.722 0.417 0.332 0.296 
58Ni 
LoD 0.891 0.525 0.261 0.198 0.204 
LoQ 2.673 1.602 0.789 0.595 0.612 
60Ni 
LoD 0.237 0.206 0.147 0.136 0.129 
LoQ 0.712 0.627 0.445 0.415 0.397 
61Ni 
LoD 0.211 0.187 0.135 0.191 0.201 
LoQ 0.622 0.581 0.394 0.591 0.623 
62Ni 
LoD 0.271 0.315 0.153 0.145 0.196 
LoQ 0.828 0.955 0.461 0.437 0.588 
50V 
LoD 1.368 2.097 1.019 0.657 0.727 
LoQ 4.284 0.699 0.348 0.245 0.243 
51V 
LoD 20.879 4.786 6.865 6.331 7.691 







Table 3.7 Class 1 and Class 2A LoDs and LoQs (ng/mL) calculated using ICP-MS-CCT 
mode at different RF powers  
CCT Mode 900 W 1100 W 1300 W 1400 W 1500 W 
75As 
LoD 0.209 0.030 0.064 0.048 0.060 
LoQ 0.622 0.095 0.191 0.149 0.181 
111Cd 
LoD 0.060 0.023 0.013 0.012 0.013 
LoQ 0.189 0.069 0.031 0.037 0.038 
112Cd 
LoD 0.067 0.028 0.013 0.007 0.008 
LoQ 0.199 0.063 0.041 0.022 0.023 
113Cd 
LoD 0.063 0.021 0.011 0.013 0.014 
LoQ 0.191 0.062 0.032 0.039 0.041 
198Hg 
LoD 0.497 0.587 0.479 0.574 0.719 
LoQ 1.796 0.761 1.435 1.723 2.165 
201Hg 
LoD 0.512 0.496 0.480 0.567 0.972 
LoQ 1.241 1.487 1.441 1.705 2.021 
202Hg 
LoD 0.431 0.481 0.482 0.585 0.961 
LoQ 1.234 1.484 1.432 1.701 2.043 
204Hg 
LoD 0.166 0.118 0.113 0.341 0.375 
LoQ 0.501 0.364 0.343 1.028 1.129 
206Pb 
LoD 0.113 0.024 0.017 0.015 0.021 
LoQ 0.339 0.073 0.052 0.045 0.062 
207Pb 
LoD 0.111 0.0233 0.017 0.014 0.021 
LoQ 0.336 0.0710 0.050 0.043 0.061 
208Pb 
LoD 0.110 0.027 0.017 0.014 0.021 
LoQ 0.327 0.069 0.049 0.041 0.059 
59Co 
LoD 0.460 0.211 0.301 0.091 0.116 
LoQ 1.378 0.641 0.918 0.299 0.354 
58Ni 
LoD 0.327 0.171 0.151 0.077 0.095 
LoQ 0.981 0.515 0.481 0.232 0.287 
60Ni 
LoD 0.074 0.123 0.134 0.089 0.107 
LoQ 0.226 0.374 0.408 0.268 0.314 
61Ni 
LoD 0.079 0.125 0.156 0.078 0.098 
LoQ 0.235 0.369 0.461 0.212 0.291 
62Ni 
LoD 0.109 0.074 0.169 0.130 0.140 
LoQ 0.331 0.222 0.609 0.391 0.421 
50V 
LoD 1.195 0.139 0.128 0.007 0.010 
LoQ 3.625 0.417 0.040 0.201 0.032 
51V 
LoD 6.980 0.589 0.741 0.159 0.191 
LoQ 20.859 1.791 2.223 0.485 0.581 
RF of 1400 W was chosen as the optimum power for the simultaneous determination 
of the Class 1 and Class 2A elements, although Hg with CCT gave lower LoD and LoQ 
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at lower powers, but for the sake of time efficiency, it was determined to analyse Hg 
with the rest of the elements at 1400 W. 
3.3.1.6 Optimisation of helium gas flow rate for operating CCT  
From the previously demonstrated optimisation results, CCT mode improved the 
analytical sensitivity for most elements, which is consistent with previous findings 
that CCT reduces interferences (185, 187, 189). For example, 75As LoQ was reduced 
from 2.110 to 0.149 ng/mL and 51V LoQ dropped from 19.065 to 0.485 ng/mL when 
CCT mode was activated (Tables 3.4 and 3.5). This is expected as CCT has the ability 
to reduce polyatomic interferences as described in Section 1.6.4.1. As a result, all the 
samples were analysed using ICP-MS-CCT. He(g) flow rate was optimised to get a 
suitable flow rate that will eliminate interferences without significantly reducing 
Class 1 and Class 2A elements sensitivity. Only helium was tested as a possible cell 
gas. 
To optimise the He(g) flow rate with samples containing different components, NIST 
3280 Multivitamin/Multielement tablets were digested and analysed in triplicates 
using CCT mode with different He(g) flow rates. This is in order to have a background 
noise similar to what can possibly be obtained with real samples. Percentage 
recoveries and RSDs were taken into consideration when determining the optimum 






Table 3.8 NIST 3280 Multivitamin/Multielement tablets elemental recoveries 
(mean and RSD, (n=3)) using different helium gas flow rates with ICP-MS-CCT. 
  He(g) Flow Rate 
 2.5 L/min 3.0 L/min 3.5 L/min 4.0 L/min 4.5 L/min 
 %Rec* RSD %Rec RSD %Rec RSD %Rec RSD %Rec RSD 
As 41.67 22.37 44.08 20.01 104.1 4.52 105.2 17.92 95.21 15.6 
Cd 68.65 1.16 86.36 0.63 95.63 2.44 104.8 6.08 105.1 23 
Hg N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Pb 101.5 1.58 102.8 2.55 97.84 2.7 97.97 5.11 97.04 2.97 
Co 97.63 22.13 105.1 23.54 99.23 0.5 102.0 2.62 102.4 7.15 
Ni 50.96 8.28 60.89 7.42 99.76 3.65 96.40 2.02 95.28 6.61 
V 97.93 9.22 98.06 9.56 100.3 8.7 96.33 2.75 102.3 3.35 
*%Recovery 
 
Higher rates gave recoveries for the elements of interest in the range of 95-105%, 
but to minimise He(g) consumption, 3.5 L/min was set as the optimum flow rate. 
3.3.1.7 Selection of suitable internal standards and analytical atomic mass units 
 
The atomic masses chosen for analysis as well as the internal standards used were 
selected based on the recovery results obtained using NIST 3280 
multivitamin/multielement tablets. As discussed in Section 1.4, NIST 3280 tablets are 
composed of a formulation containing vitamin and carotenoid gelatine beadlets, a 
mineral pre-mix, and a binder, all compressed into tablets and film coated. The 
tablets contain minerals like Ca, Na, Mo, Fe and Sn that can cause significant 
interferences with the Class 1 and Class 2A elements.  
Table 3.9 show the % recoveries and RSDs obtained using the optimised ICP-MS-CCT 





Table 3.9 NIST 3280 elements’ isotopes recoveries and RSDs using different 
internal standards 
 
45Sc 89Y 103Rh 115In 159Tb 
Element %Rec RSD %Rec RSD %Rec RSD %Rec RSD %Rec RSD 
75As 95.62 1.40 81.81 5.88 95.27 2.43 100.5 3.41 94.75 3.64 
111Cd 95.62 5.19 85.91 5.19 95.11 2.58 105.9 0.46 97.23 1.68 
112Cd 233.3 10.6 138.4 7.85 208.1 4.19 508.7 3.83 391.73 17.41 
113Cd 66.05 5.83 60.99 8.36 68.78 4.88 77.55 10.37 72.73 13.60 
206Pb 83.66 7.83 88.82 9.31 89.06 3.62 87.88 4.27 88.27 2.72 
207Pb 87.51 8.01 87.34 9.74 81.44 4.28 79.28 4.89 87.06 1.71 
208Pb 94.92 6.22 89.12 5.37 95.63 3.04 90.11 4.50 98.88 1.09 
59Co 95.60 6.71 89.05 5.53 95.53 1.00 100.5 1.01 95.44 5.04 
58Ni 743.0 11.5 447.9 9.34 811.0 13.6 940.6 4.33 645.68 13.40 
60Ni 98.28 1.11 82.93 8.32 95.99 2.06 88.07 4.08 95.49 12.70 
61Ni 98.99 4.58 77.78 9.87 187.0 14.8 161.6 2.91 122.78 14.10 
62Ni 70.09 1.30 53.77 8.97 67.74 12.1 88.12 4.79 63.024 13.30 
50V 1202 10.1 289.5 10.71 2244 9.00 2681.2 3.56 1826.9 21.60 
51V 95.47 0.27 86.19 2.18 100.40 2.82 105.14 3.56 94.88 0.87 
The following atomic masses were selected for samples analysis: As (75 amu), Cd (111 
amu), Pb (208 amu), Co (59 amu), Ni (60 amu) and V (51 amu). The isotopes with the 
highest abundance were used, except for Cd and Ni. 114Cd is the most abundant 
isotopes followed by 112Cd. However, both suffer from interferences that lead to false 
high concentrations. For example, 114Sn, 97Mo16O1H and 98Mo16O interferes with 
114Cd, while 112Sn, 40Ca16O2, 95Mo16O1H and 96Mo16O+ interferes with 112Cd. In the case 
of Ni, 58Ni suffers from interferences with 23Na35Cl+, 40Ca18O+, 40Ca17O1H+, 42Ca16O+, 
29Si2+ and 23Na35Cl+(183, 184). 
Although CCT can efficiently eliminate most of the polyatomic interferences, 




Regarding the internal standard, when 89Y was used as an internal standard to 
compensate for matrix effect it gave lower concentrations than the certified values. 
Corrections using 45Sc gave RSD> 5% with 208Pb and 59Co. On the other hand, 115In 
produced recoveries <95% for 208Pb and 60Ni. In case of using 159Tb, the 208Pb RDS was 
more than 10%. As a result, 103Rh  was selected as the internal standard to correct for 
the method’s accuracy and improve the precision for Class 1 and Class 2A elements. 
Because Hg is not included in NIST 3280, TAC-formulas that were described in Section 
2.3.1.4.2 were used to test the method efficiency in analysing Hg. Table 3.10 
represents the obtained results. 
Table 3.10 Concentrations of Hg in TAC-formulas and RSDs using different internal 
standards, n=3 
 
Formula-1 (30 %PDE) , Hg Concentration(µg/g): Theoretical=6.48, ICP-OES=3.92,RSD=5.14% 
Element 
45Sc 89Y 103Rh 115In 159Tb 
 (µg/g) RSD  (µg/g) RSD  (µg/g) RSD  (µg/g) RSD  (µg/g) RSD 
198Hg 4.01 10.86 1.81 9.48 3.04 8.94 4.58 5.59 3.39 6.09 
201Hg 4.02 10.94 1.82 9.67 3.99 8.86 4.58 5.84 3.39 6.18 
202Hg 4.02 10.81 1.83 9.61 3.83 8.51 4.58 5.89 3.39 6.25 
204Hg 3.81 11.82 1.65 10.29 2.69 8.91 4.33 6.84 3.16 6.99 
  
  
Formula-2 (100 %PDE), Hg Concentration(µg/g): Theoretical=19.45,ICP-OES=18.89, RSD=5.34% 
Element 
45Sc 89Y 103Rh 115In 159Tb 
 (µg/g) RSD  (µg/g) RSD  (µg/g) RSD  (µg/g) RSD  (µg/g) RSD 
198Hg 19.11 5.72 15.15 5.75 18.87 5.14 19.53 5.31 18.62 5.03 
201Hg 19.14 5.29 15.21 5.31 18.85 5.4 19.52 5.32 18.69 5.63 
202Hg 19.13 5.62 15.25 5.32 18.97 5.16 19.53 5.55 18.69 5.88 






Table 3.10, continued 
Formula-3 (300 %PDE),  Hg Concentration(µg/g): Theoretical=48.61,ICP-OES=51.09,RSD=7.84% 
Element 
45Sc 89Y 103Rh 115In 159Tb 
 (µg/g) RSD  (µg/g) RSD  (µg/g) RSD  (µg/g) RSD  (µg/g) RSD 
198Hg 53.16 9.31 45.31 9.23 49.98 8.87 52.49 8.74 49.75 8.66 
201Hg 53.09 9.09 45.50 9.05 49.93 8.69 52.85 8.94 49.87 8.47 
202Hg 53.07 9.06 45.51 9.03 50.15 8.42 52.86 8.55 49.88 8.57 
204Hg 45.99 10.15 32.03 10.13 40.92 9.01 46.52 9.99 38.03 8.97 
Comparing the results obtained using ICP-MS-CCT with those obtained using ICP-OES, 
it is noticed that the choice of internal standard is important. Correction using 45Sc, 
115In gave higher results in comparison with the concentration obtained using ICP-
OES, while 89Y gave lower results. 103Rh was also selected to correct for Hg and the 
atomic mass selected is 202 m/z. 
3.3.2 Method validation and analytical figures of merit 
3.3.2.1 Limits of detection and limits of quantification  
LoD and LoQ were calculated for Class 1 and Class 2A elements at the selected m/z 
using the optimised ICP-MS conditions as described in Section 2.3.1.5. 
The results are summarised in Table 3.11 
Table 3.11  ICP-MS limits of detection and Limits of quantification for Class 1 and 
Class 2A elements 
 Blanks 
σ Slope Intercept Av.+3σ Av.+10σ 
LoD LoQ 
Element Av.* ng/mL ng/mL 
75As 28.00 5.67 390.98 26.17 45.03 84.77 0.048 0.149 
111Cd 35.80 5.57 1585.50 33.05 52.52 91.54 0.012 0.037 
202Hg 1212.53 883.42 5537.84 652.11 3862.76 10046.72 0.585 1.701 
208Pb 164.56 56.59 14477.39 137.28 334.39 730.56 0.014 0.041 
59Co 84.85 73.62 2483.40 78.64 305.70 821.03 0.091 0.299 
60Ni 47.75 107.48 4645.89 6.49 370.18 1122.52 0.078 0.240 
51V 7476.31 898.55 19355.67 7081.94 10171.97 16461.84 0.159 0.485 
*Av. = Average 
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3.3.2.2 Linearity and Range 
Eight concentration points were assayed in triplicate and showed good linearity in 
the tested range, with a correlation coefficient (R2) value of above 0.995. The linear 
regression equation and its R2, for each of the calibration curves are summarised in 
Table 3.12. 
Table 3.12 Linearity data for Class 1 and Class 2A elements using ICP-MS-CCT 
Element Range (ng/ml) Calibration equation R2 Value 
75As 1-1000 y = 185.73x + 26.169 0.9999 
111Cd 1-1000 y= 810.76x + 12.742 0.9998 
202Hg 1-1000 y= 1975.1x + 625.11 0.9999 
208Pb 1-1000 y= 14477x+ 137.28 0.9998 
59Co 1-1000 y= 2483.4x + 78.639 0.9999 
60Ni 1-1000 y= 540.57x + 6.4974 0.9998 
51V 1-1000 y= 1269.8x + 708.19 0.9997 
 
 
3.3.2.3 Accuracy and precision 
The accuracy and precision were evaluated using NIST 3280, where % recoveries 
between 95-105% indicate the method’s accuracy and RSD less than 5% indicate the 
method’s precision.  The microwave assisted acid digestion procedure was 
revalidated as another instrument with larger vessels were used. In addition, the ICP-
MS-CCT method sensitivity allows the quantification of Class 1 elements using NIST 
3280 except for Hg, which was validated using TAC-formulas. The results are 






Table 3.13 Accuracy and repeatability results of the optimised ICP-MS-CCT method 
obtained using NIST 3280 expressed as % recoveries and RSDs respectively, n=3 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
75As  100.86 3.40 97.34 0.47 
111Cd 104.59 0.46 104.73 0.09 
202Hg N/A N/A 97.94 1.23 
208Pb  102.54 2.90 98.21 0.15 
59Co  100.52 1.01 95.20 0.23 
60Ni 97.06 3.75 101.13 0.32 
51V  97.29 4.57 96.10 0.82 
 
Table 3.14 Analysis results of three TAC formulas containing different levels of 
Class 1 and Class 2A, n=3 
Element 
Formula-1 (30%PED) ICP-OES ICP-MS-CCT 
Theoretical(µg/g)   (µg/g) RSD  (µg/g) RSD 
As  6.65 3.83 2.74 3.31 0.99 
Cd 1.58 1.36 3.09 1.34 5.81 
Hg  6.48 3.92 5.34 3.83 8.51 
Pb  2.27 2.28 5.44 2.16 2.85 
Co  8.68 7.96 5.51 8.92 3.58 
Ni  6.58 5.79 4.53 5.52 2.31 
V  22.25 19.64 3.64 20.49 3.22 
    
  
Element 
Formula-2 (100%PED) ICP-OES ICP-MS-CCT 
Theoretical(µg/g)   (µg/g) RSD  (µg/g) RSD 
As  19.8 15.17 4.61 16.61 7.4 
Cd 5.26 4.94 3.75 4.78 0.38 
Hg  19.45 18.89 5.14 18.96 5.16 
Pb  6.67 6.41 3.94 5.95 3.72 
Co  22.08 19.61 5.01 19.35 0.92 
Ni  10.55 10.24 6.24 10.45 2.59 
V  22.7 18.28 3.31 17.22 8.91 
    
  
Element 
Formula-3 (300%PED) ICP-OES ICP-MS-CCT 
Theoretical(µg/g)   (µg/g) RSD  (µg/g) RSD 
As  49.2 45.55 3.42 42.64 5.25 
Cd 15.76 12.63 2.15 12.11 6.99 
Hg  48.61 51.09 7.84 50.14 8.42 
Pb  17.35 14.59 3.47 13.09 5.72 
Co  50.12 37.67 7.76 37.18 6.36 
Ni  16.75 13.43 5.94 12.59 6.69 




3.3.3 Revalidation of the microwave assisted acid digestion procedure 
The first step was to measure a blank of 8 ml reverse aqua regia subjected to the 
exact same procedure as NIST 3280. The elements concentrations were below LoDs 
as illustrated in Table 3.15, which was similar to the findings using ICP-OES. 
 
Table 3.15 Obtained concentrations using the developed and optimised ICP-MS-
CCT method for reverse aqua regia following microwave digestion, n=3 
Element Concentration (ng/mL) %RSD 
75As <LoD (4.80X10-5) 1.89 
111Cd <LoD (1.20X10-5) 0.99 
202Hg  <LoD (5.85X10-5) 2.50 
208Pb 0.001 2.30 
59Co 0.001 0.42 
60Ni 0.004 1.00 
51V <LoD (1.59X10-5) 6.08 
 
The next step was to compare the efficiency of the acid ratio 9 HNO3: 1 HCl in 
extracting Class 1 elements with that of reverse aqua regia, since with ICP-MS all the 
elements of interest are in concentrations higher than LoQs even after dilution prior 
to analysis, except for Hg which is not part of NIST 3280 formulation. From the results 
represented in Table 3.16, reverse aqua regia was more efficient in extracting Ni and 







Table 3.16 Percentage recoveries for NIST 3280 using 9 HNO3: 1 HCl and reverse 
aqua regia for digestion, n=3 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
 9 HNO3: 1 HCl Reverse aqua regia 
Element   % Recovery RSD % Recovery RSD 
75As  93.61 6.03 100.86 3.40 
111Cd 99.02 5.79 104.59 0.46 
202Hg N/A N/A N/A N/A 
208Pb  101.14 8.27 102.54 2.90 
59Co  99.83 5.46 100.52 1.01 
60Ni 75.51 1.53 97.06 3.75 
51V  100.53 0.98 97.29 4.57 
 
The final step to test the effect of temperature on extraction efficiency of As, Cd and 
Pd from NIST 3280 tablets. Spiked samples were also analysed, and the recoveries 
obtained were compared with those calculated based on the certified elements 
concentrations in NIST 3280. As illustrated in Table 3.17 the results confirm the 
conclusions reached using ICP-OES which are depending on spike recoveries solely to 
measure the accuracy of the digestion-analysis methods is insufficient and a solid 
reference material is required for proper evaluation and validation of the methods. 
Furthermore, reaching a maximum temperature of 210°C was found to be necessary 
to ensure adequate extraction of Classes 1 and 2A elements consistently. Lower 
temperature, i.e. 200°C gave good extraction results, but occasionally, the extraction 
for some elements may fall below 95% or gave RSD >5%, so 210°C was selected as 





Table 3.17 NIST 3280 percentage recoveries using different temperatures for the 
microwave assisted acid digestion methods, n=3 
Method 1 
Stage 1: Ramp Time= 5 min, Temperature= 50°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 110°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 140°C, Hold time= 5 min 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
75As  10.57 89.76 99.51 0.72 
111Cd 50.54 11.82 98.69 0.87 
202Hg N/A N/A 100.83 2.45 
208Pb  89.26 2.35 100.32 1.55 
59Co  51.80 7.07 100.20 0.47 
60Ni 60.53 26.59 95.45 1.44 
51V  64.66 6.18 103.72 0.40 
Method 2 
Stage 1: Ramp Time= 5 min, Temperature= 70°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 130°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 160°C, Hold time= 5 min 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
75As  84.26 5.96 99.04 3.22 
111Cd 93.45 5.88 104.70 2.10 
202Hg N/A N/A 99.12 15.79 
208Pb  96.63 1.74 100.08 3.25 
59Co  68.60 1.06 100.23 2.45 
60Ni 65.13 1.16 96.67 9.72 
51V  62.93 1.08 95.36 3.05 
Method 3 
Stage 1: Ramp Time= 5 min, Temperature= 90°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 150°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
75As  102.59 32.89 103.64 0.64 
111Cd 95.97 9.44 98.02 0.58 
202Hg N/A N/A 97.21 3.19 
208Pb  97.82 3.21 99.47 0.79 
59Co  60.31 3.27 95.06 0.86 
60Ni 58.98 3.75 99.67 1.25 





Table 3.17, continued 
Method 4 
Stage 1: Ramp Time= 5 min, Temperature= 110°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 170°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 200°C, Hold time= 5 min 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
75As  98.43 4.94 95.00 0.16 
111Cd 99.78 0.81 98.97 0.56 
202Hg N/A N/A 104.94 1.89 
208Pb  97.27 4.13 99.22 0.91 
59Co  96.25 7.65 99.58 0.45 
60Ni 95.48 6.13 98.96 1.42 
51V  104.99 1.65 97.22 0.93 
Method 5 
Stage 1: Ramp Time= 5 min, Temperature= 120°C, Hold time= 5 min 
Stage 2: Ramp Time= 5 min, Temperature= 180°C, Hold time= 5 min 
Stage 3: Ramp Time= 5 min, Temperature= 210°C, Hold time= 5 min 
 NIST 3280 certificate Spike addition 
Element   % Recovery RSD Spiked Recovery RSD 
75As  100.86 3.40 97.34 0.47 
111Cd 104.59 0.46 104.73 0.09 
202Hg N/A N/A 97.94 1.23 
208Pb  102.54 2.90 98.21 0.15 
59Co  100.52 1.01 95.20 0.23 
60Ni 97.06 3.75 101.13 0.32 
51V  97.29 4.57 96.10 0.82 
 
 
3.4 Analysis of pharmaceutical samples 
The twelve products analysed with ICP-OES were reanalysed using ICP-MS and the 







Table 3.18 Elemental impurities (µg/day) in analgesic tablets analysed using ICP-
MS-CCT mode (mean ± σ, n=3) 
Products* Elements 









75As 15 <LoD (4.80X10-5) 99.25 4.57 
111Cd 5 0.48 ±0.075 95.42 3.05 
202Hg 30 <LoD (5.85X10-4) 96.74 2.87 
208Pb 5 1.91 ±0.002 98.88 4.09 
59Co 50 0.98 ±0.048 96.78 2.15 
60Ni 200 51.01 ±0.12 98.63 3.57 
51V 100 <LoD (1.59X10-4) 99.57 3.57 
      
Hedex Extra 
75As 15 <LoD (4.80X10-5) 95.98 4.15 
111Cd 5 0.56 ±0.086 102.56 3.64 
202Hg 30 <LoD (5.85X10-4) 97.84 5.01 
208Pb 5 3.87 ±0.023 100.56 2.98 
59Co 50 2.65 ±0.910 103.48 5.14 
60Ni 200 10.54 ±0.59 101.59 3.58 
51V 100 <LoD (1.59X10-4) 98.65 3.45 
      
 Anadin 
Extra 
75As 15 <LoD (4.80X10-5) 97.84 4.25 
111Cd 5 0.39  ±0.008 98.88 4.68 
202Hg 30 <LoD (5.85X10-4) 96.57 3.57 
208Pb 5 3.44  ±0.047 95.89 1.98 
59Co 50 1.87 ±0.013 100.94 2.58 
60Ni 200 <LoD (7.80X10-5) 99.99 2.76 
51V 100 <LoD (1.59X10-4) 100.59 1.59 




75As 15 <LoD (4.80X10-5) 102.65 2.35 
111Cd 5 0.68  ±0.006 100.25 1.65 
202Hg 30 <LoD (5.85X10-4) 95.78 4.05 
208Pb 5 4.17  ±0.041 103.54 2.08 
59Co 50 <LoD (9.10X10-5) 98.57 3.64 
60Ni 200 <LoD (7.80X10-5) 98.51 3.05 
51V 100 <LoD (1.59X10-4) 97.99 2.35 





Table 3.19 Elemental impurities (µg/day) in cold and cough remedies analysed 
using ICP-MS-CCT mode (mean ± σ, n=3) 
Products Elements 








75As 15 <LoD (4.80X10-5) 95.25 5.03 
111Cd 5 5.96 ±0.022 95.33 4.07 
202Hg 30 <LoD (5.85X10-4) 97.73 3.07 
208Pb 5 20.93 ±0.035 95.89 4.09 
59Co 50 13.13 ±0.048 96.44 1.15 
60Ni 200 10.01 ±0.10 96.31 2.45 
51V 100 <LoD (1.59X10-4) 98.26 4.10 
      
Calpol 
SixPlus 
75As 15 <LoD (4.80X10-5) 96.86 5.06 
111Cd 5 <LoD (1.20X10-5) 101.4 4.51 
202Hg 30 18.10 ±0.057 98.57 3.21 
208Pb 5 50.97 ±0.033 100.41 3.98 
59Co 50 14.45 ±0.048 103.48 5.14 
60Ni 200 <LoD (7.80X10-5) 102.48 4.41 
51V 100 <LoD (1.59X10-4) 97.93 2.89 
      
Nelsons 
Sootha  
75As 15 <LoD (4.80X10-5) 99.53 3.27 
111Cd 5 1.45 ±0.050 103.85 4.79 
202Hg 30 <LoD (5.85X10-4) 101.54 4.27 
208Pb 5 10.33 ±0.067 99.13 4.98 
59Co 50 3.58 ±0.052 105.06 1.85 
60Ni 200 2.73 ±0.083 101.56 1.22 
51V 100 <LoD (1.59X10-4) 103.26 4.17 
 
 
    
Calcough 
75As 15 <LoD (4.80X10-5) 99.61 3.55 
111Cd 5 7.57 ± 0.051 96.73 2.95 
202Hg 30 8.20 ±0.028 95.53 5.06 
208Pb 5 19.02 ±0.055 96.87 4.61 
59Co 50 4.63 ±0.048 97.89 4.18 
60Ni 200 15.69 ±0.12 95.53 3.57 
51V 100 <LoD (1.59X10-4) 99.26 1.19 
 
 





75As 15 <LoD (4.80X10-5) 96.16 4.43 
111Cd 5 8.49 ±0.25 96.86 2.17 
202Hg 30 <LoD (5.85X10-4) 95.48 5.31 














59Co 50 10.87 ± 0.13 99.73 3.29 
60Ni 200 13.67 ±0.18 95.93 3.33 
51V 100 <LoD (1.59X10-4) 96.26 2.68 




75As 15 <LoD (4.80X10-5) 97.23 4.84 
111Cd 5 10.14 ± 0.079 95.86 2.62 
202Hg 30 <LoD (5.85X10-4) 95.81 1.59 
208Pb 5 35.89 ±0.022 98.46 5.8 
59Co 50 42.29 ±0.068 96.65 4.48 
60Ni 200 21.86 ±0.015 95.48 5.19 
51V 100 <LoD (1.59X10-4) 95.33 2.85 
 
The results obtained from analysis cold and flu powders as well as antacids are 
illustrated in Table 3.20 and Table 3.21. 
Table 3.20 Elemental impurities (µg/day) in cold and flu powders analysed using 
ICP-MS-CCT mode (mean ± σ, n=3) 
Products Elements 









vitamin C  
75As  15 <LoD (4.80X10-5) 95.40 0.15 
111Cd 5 <LoD (1.20X10-5) 95.81 0.43 
202Hg 30 <LoD (5.85X10-4) 96.14 1.79 
208Pb  5 0.43 ±0.012 102.11 2.04 
59Co  50 0.54 ±0.023 100.85 0.42 
60Ni 200 <LoD (7.80X10-5) 99.38 0.12 
51V  100 <LoD (1.59X10-4) 103.29 1.16 
 
 
    
Boots-with 
vitamin C 
75As  15 <LoD (4.80X10-5) 96.59 0.66 
111Cd 5 <LoD (1.20X10-5) 97.66 0.47 
202Hg 30 <LoD (5.85X10-4) 96.26 1.01 
208Pb  5 0.50 ±0.030 104.81 0.46 
59Co  50 <LoD (9.10X10-5) 96.95 0.27 
60Ni 200 5.83 ±0.078 98.57 0.48 
51V  100 <LoD (1.59X10-4) 100.41 0.36 
 
 














75As  15 <LoD (4.80X10-5) 98.16 1.89 
111Cd 5 <LoD (1.20X10-5) 100.5 1.88 
202Hg 30 5.30 ±0.069 97.15 2.49 
208Pb  5 <LoD (1.40X10-5) 99.63 1.69 
59Co  50 <LoD (9.10X10-5) 105.19 0.8 
60Ni 200 <LoD (7.80X10-5) 101.64 1.36 
51V  100 <LoD (1.59X10-4) 100.33 1.28 
 
 
    
Beechams 
Blackcurrant 
75As  15 <LoD (4.80X10-5) 96.47 0.86 
111Cd 5 <LoD (1.20X10-5) 102.45 0.87 
202Hg 30 4.29 ±0.108 95.69 0.73 
208Pb 5 <LoD (1.40X10-5) 103.92 1.18 
59Co 50 <LoD (9.10X10-5) 104.42 1.11 
60Ni 200 0.81 ±0.098 95.63 1.04 







75As 15 <LoD (4.80X10-5) 95.12 0.58 
111Cd 5 <LoD (1.20X10-5) 95.00 0.42 
202Hg 30 5.12 ±0.10 101.79 1.18 
208Pb 5 2.77 ±0.028 102.44 0.93 
59Co 50 0.63 ±0.013 97.22 0.35 
60Ni 200 <LoD (7.80X10-5) 97.69 0.36 
51V 100 14.6 ±0.41 98.21 1.03 
  
 
   
Lemsip 
Max-Lemon 
75As 15 <LoD (4.80X10-5) 103.23 0.78 
111Cd 5 <LoD (1.20X10-5) 103.45 1.04 
202Hg 30 5.04 ±0.87 103.98 2.98 
208Pb 5 3.17 ±0.042 100.15 3.45 
59Co 50 <LoD (9.10X10-5) 101.22 0.67 
60Ni 200 <LoD (7.80X10-5) 104.23 0.73 







Table 3.21 Elemental impurities (µg/day) in antacids analysed using ICP-MS-CCT 
mode (mean ± σ, n=3) 
Products Elements 









75As 15 <LoD (4.80X10-5) 96.86 2.15 
111Cd 5 <LoD (1.20X10-5) 97.59 3.53 
202Hg 30 <LoQ (1.70X10-3) 95.48 4.09 
208Pb 5 7.98 ±0.22 96.58 2.75 
59Co 50 1.95 ±0.06 99.81 1.69 
60Ni 200 6.71 ±0.14 100.58 1.89 
51V 100 <LoD (1.59X10-4) 97.62 2.84 






75As 15 0.82 ±0.011 97.15 3.51 
111Cd 5 0.75 ±0.036 98.69 1.58 
202Hg 30 <LoQ (1.70X10-3) 100.59 3.51 
208Pb 5 0.48 ±0.021 101.98 3.06 
59Co 50 0.83 ±0.070 96.54 3.51 
60Ni 200 7.96 ±0.210 98.75 2.94 
51V 100 <LoD (1.59X10-4) 100.2 4.15 
      
Rennie 
Extra 
75As 15 0.79 ±0.025 100.26 2.84 
111Cd 5 3.40 ±0.130 97.59 3.13 
202Hg 30 <LoQ (1.70X10-3) 99.84 4.15 
208Pb 5 1.73 ±0.081 100.98 2.06 
59Co 50 0.99 ±0.041 97.85 2.48 
60Ni 200 19.58 ±0.26 97.53 2.90 
51V 100 <LoD (1.59X10-4) 96.54 2.15 
      
 Superdrug 
75As 15 8.53 ±0.091 99.56 3.56 
111Cd 5 1.75 ±0.180 102.35 2.45 
202Hg 30 <LoD (5.85 X10-4) 98.56 3.56 
208Pb 5 7.83 ± 0.56 96.53 1.59 
59Co 50 3.65 ± 0.24 103.58 4.98 
60Ni 200 12.68 ±0.78 95.83 3.45 
51V 100 15.03 ±1.66 98.48 2.48 
      
Rennie 
75As 15 0.62 ±0.05 100.98 1.48 
111Cd 5 1.88 ± 0.45 96.48 3.87 
202Hg 30 <LoD (5.85 X10-4) 97.86 1.59 
208Pb 5 0.74 ±0.03 98.64 2.48 
59Co 50 1.86 ±0.21 102.65 3.48 
60Ni 200 25.43 ±0.39 96.56 1.45 
51V 100 2.69 ±0.15 98.63 1.89 











75As 15 2.70 ± 0.11 97.53 2.15 
111Cd 5 0.73 ±0.09 98.87 1.85 
202Hg 30 <LoQ (1.70X10-3) 103.45 3.68 
208Pb 5 5.75 ±0.56 99.99 2.35 
59Co 50 1.82 ±0.24 96.84 3.08 
60Ni 200 38.08 ±0.96 97.12 2.56 
51V 100 8.788 ±0.19 102.34 2.05 
 
The final findings regarding the analysed pharmaceutical samples are that the 
analgesic tablets include Cd, Pd, Co and Ni, but all in acceptable concentrations below 
the PDEs. However, four out of the six cold and cough remedies will provide a daily 
concentration of Cd exceeding the regulations PDE of 5 µg/day and all of them 
provide Pd in concentrations more than the allowed 5 µg/day. They also contain Hg, 
Co and Ni within the allowed PDEs. On the contrary, the cold and flu powders have 
Hg, Pb, Co, Ni and V in them but in concentrations that do not exceed the PDEs. 
Regarding the antacids, all Class 1 and Class 2A elements were quantified and three 
products contain Pd in concentrations that will provide levels higher than the allowed 
PDE of 5 µg/day if the maximum daily dose is consumed. 
Furthermore, even for the elements that were quantified in levels not exceeding 
their PDEs, in some products their concentrations in the maximum daily dose will 
provide about half the allowed PDE or more, like for example, Co in Superdrug 





The developed ICP-MS method was successfully validated with NIST 3280. Excellent 
recoveries between 95-105% with good repeatability expressed as RSD of less than 
5% for all elements were obtained with minimal interferences. Those limits met the 
regulations requirements.  
The calculated LoDs and LoQs were below the targeted limits, which also support the 
method suitability for EI determination.   
The results obtained from the analysed pharmaceutical products show the need for 
validated methods to meet the new guidelines requirements and produce 
pharmaceutical products with minimum hazardous elements for human 
consumption. This is needed to avoid the toxic effects of elements like Pb for example, 
which was found in nine of the tested products in concentrations exceeding the 
allowed PDE of 5 µg/day and the exposure to it may cause gastrointestinal problems, 













Speciation of Arsenic in Antacids 









To assess the ‘risk factor’ that is discussed within the regulation, speciation is 
suggested in cases where individual species may present an increased risk(10). A 
literature review of the area shows no published work on pharmaceutical products 
and speciation of metals as impurities, except for the speciation of arsenic in one 
injectable medication used for the treatment of visceral leishmaniasis(202).  
The following work seeks to assess the species present in antacids since it is already 
known that As is present as demonstrated by the data provided in Section 3.4 and no 
information is available on the species present. These products are known to use 
sodium alginate to form a protective barrier for the stomach. The alginate maybe be 
seaweed derived, which is well known to contain As(206, 216, 296). As these papers 
clearly indicate the presence of the most toxic form AsIII, it is essential to assess the 
species present in  antacids to assess the risk and to see if the As is present in the 
most toxic form or not. 
Several coupled separation and detection techniques have been used for arsenic 
speciation in numerous samples. ICP is one the most effective sources for elemental 
analysis and it is easy to couple with chromatographic techniques such HPLC. 
HPLC/ICP-OES is used in some studies for speciation. However, due to the higher 
sensitivity and wider linear dynamic range of ICP-MS; HPLC/ICP-MS is more 
commonly used and becomes favoured for this purpose due to the fact that the level 
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of elements in samples, whether they were environmental, pharmaceutical or 
medical is usually low(221, 297). 
Other detection techniques(298) were also used for arsenic speciation, including 
coupled amperometric and ultraviolet detection(224), hydride generation atomic 
absorption spectrometry and hydride generation atomic fluorescence 
spectrometry(217, 232, 299). 
The chemical nature of arsenic compounds introduces another challenge to arsenic 
speciation analysis, because the compounds differ in functional groups, molecular 
sizes and pKa values. For example, in neutral solutions arsenic will primarily exist as 
oxyanionic acid. The pKa’s og the different species will be as follows: AsIII [H3AsO3] 
pKa’s= 9.3, 12.1 and 13.4, AsV [H3AsO4] pKa’s=2.3, 6.9 and 11.5, MMA pKa’s=3.6 and 
8.2, DMA pKa’s= 6.2, AsB pKa=2.2 as zwitter ion, AsC pKa=unknown as cation and the 
other arsenosugars as anions(299-301). 
Accordingly, many chromatographic systems can be used to separate the species 
such as different types of ion chromatography methods and that include anion 
exchange, cation exchange, ion exclusion and ion pair chromatography(215). Reverse 
phase chromatography(302) was also used as well as combination of two or more 
techniques to achieve complete separation of the various compound(221, 241, 300).  
Numerous samples were analysed for arsenic species throughout the years whether 
to comply with regulatory guidelines or to help assessing toxicity. Common 
environmental samples include air, water, soil and sediments(206, 220, 301, 303-
305).  Food related samples are also popular such as food supplements(306, 307), 
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juice(257, 308), rice(223, 226, 228, 256, 302), leafy vegetables(246, 247), 
poultry(255), seaweed, algae(33, 240, 309) and fish(219, 241). In addition to 
biologicals(4) like human hair, nails(225) and urine(53, 310).  
In this work, a method to speciate four arsenic compounds; AsIII, AsV, MMA and DMA 
in pharmaceutical antacid products using ion-pair reversed phase HPLC with ICP-MS 
for detection was developed and validated as pharmaceutical samples of this type do 
not appear in the published literature.  
The analysed antacids can be classified to two major groups; the first is the antacids 
containing alginic acid or its derivatives. Alginic acid is refined from brown algae and 
it has cosmetic uses as well as pharmaceutical uses. Pharmaceutical grade alginate 
can be used in the manufacturing of gels, membranes, microspheres, dressings for 
wound healing and for controlling drug release. It is also used to create a foam barrier 
for coating the stomach and reducing oesophageal irritation in antacids(311, 312). 
The second group is antacids not containing alginates or any of its derivatives. 
The antacids were grouped like that because algae and their derivatives are known 
to contain different arsenic species. In 1999, a study that measured the content of 
mineral arsenic in ten edible algae from different sources; France, Spain, Japan, 
Iceland, Australia, China and Hong Kong using bi-dimensional size-exclusion anion 
exchange HPLC with dual ICP-MS and electrospray MS/MS detection was published. 
The levels ranged from 1.9 to 62 µg/g(240). Another study conducted in 2009(33) 
showed that the seagrass Posidonia oceanica from the Mediterranean coast contains 
quantifiable concentrations of AsV, MMA, DMA, AsB and arsenoglycerol sugar. The 
species with the highest concentration was AsV = 0.366±0.008 µg/g. In the same study, 
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the brown algae Durvillaea antarctica and Lessonia nigrescens from the Chilean coast 
were also analysed. AsIII, AsV, DMA and other arsenosugars were quantified in 
Durvillaea antarctica with AsIII being the inorganic species with the highest 
concentration that is 0.304± 0.090 µg/g. For Lessonia nigrescens, the species with the 
highest concentration was AsIII= 105±8 µg/g. The only other species that was 
quantified was AsV. In this mentioned study anion and cation exchange HPLC-ICPMS 
were used for analysis(33). 
In this work, arsenic was speciated in antacids using ion-pair reversed-phase 
chromatography, a technique where an ion-pairing agent is used  to help retain ionic 
analytes and separate them. 
4.2 Experimental 
4.2.1 Reagents and Materials 
 
See Sections 2.2.1 and 3.2.1. 
Standard solutions of the following chemicals were prepared in water: sodium meta 
arsenite (AsIII) (Sigma-Aldrich, USA), sodium arsenate (AsV) dibasic heptahydrate 
(Sigma-Aldrich, India), monosodium acid methane arsonate (MMA) sesquihydrate 
(Supelco, USA) and cacodylic acid (DMA) (Sigma-Aldrich, Israel). Aqueous stock 
solutions of the arsenic species were prepared at a concentration of 1 mg/L as As and 
stored in the dark at 4°C. Multispecies calibration standard solutions in water and 0.3 
M phosphoric acid were freshly prepared from the stock solutions to get 
concentrations ranging from 1 to 50 ng/mL in addition to a blank. 
Two mobile phases were tested based on previous studies(53, 217, 223, 302, 313) 
that performed As species separation using reversed phase chromatography. The 
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first mobile phase (mobile phase-1) consisted of 10mM sodium 1-butanesulfonate 
(Sigma-Aldrich, Switzerland), 4mM malonic acid (Sigma-Aldrich, Japan), 4mM 
tetramethyl ammonium hydroxide pentahydrate (Sigma-Aldrich, USA), 5mM 
potassium dihydrogen orthophosphate (KH2PO4)  (Fisher scientific, UK) and 0.05% 
acetonitrile (HPLC grade, Sigma-Aldrich, Israel). The second mobile phase (mobile 
phase-2) consisted of 10mM tetrabutylammonium (TBA) phosphate monobasic 
(Sigma-Aldrich, USA), 1mM malonic acid, 20mM potassium dihydrogen 
orthophosphate and 2% methanol (HPLC grade, Sigma-Aldrich, UK). The pH was 
adjusted using HCl and potassium hydroxide (Sigma-Aldrich, USA). The mobile phase 
was filtered through a 0.45 µm nylon membrane filter (Whatman, USA) and degassed 
before use. 
4.2.2 Samples 
Three antacid products that contain alginate derivatives and three antacids without 
alginates were acquired from local retailers in the Liverpool area. For more details, 
see Section 3.2.2. 
4.2.3 Instrumentation  
See Sections 2.2.3 and 3.2.3. 
For liquid chromatographic separation a Thermo 4000 series HPLC pump, consisted 
of an injector fitted with a 100µl PEEK injection loop and equipped with a Spectra 
autosampler (Thermo Fisher Scientific, USA) were used. The exit of the HPLC column 
was directly connected to the nebulizer of the ICP-MS with polyetheretherketone 
(PEEK) tubing (HPLC-ICP-MS). For reversed phase chromatography, a Phenomenex 
Kinetex C18 column (100X4.60 mm, 5 µm particles) was tested and a Phenomenex 
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Gemini C18 column (250X4.60 mm, 4 µm particles) was used for optimum separation. 
Data was collected using Thermo-Plasma Lab Software. 
The pH of the mobile phase was measured using pH 211 microprocessor pH meter 
(Hanna Instruments, UK). A benchtop centrifuge (Hettich, Germany) was used for the 
extracted samples prepared for arsenic speciation to separate the liquid from the 
solid residue. 
4.2.4 HPLC analytical figures of merit and validation 
The HPLC developed method was validated according to ICH Q2B guidelines(267).  
4.2.4.1 Linearity and range 
Linearity was studied in the range of 1 to 50 ng/mL using six standards with 
concentrations covering the specified range assayed in triplicate. The correlation 
coefficient (R2), y-intercept and slope of the regression line were calculated. 
4.2.4.2 Accuracy 
Accuracy was assessed using nine determinations over three concentration levels (1, 
10 and 50 ng/mL) covering the specified range and was assayed in triplicate. The 
percent recoveries of the four species were calculated for the three concentrations. 
The samples were mass balanced using the ICP-MS data. 
4.2.4.3 Precision 
Repeatability was assessed using the same procedure for the determination of the 
accuracy described in Section 4.2.4.2. For intermediate precision, the procedure was 
repeated for three consecutive days. The standard deviation and relative standard 
deviation were calculated for each type of the investigated precision. 
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4.2.5.4 Limits of detection (LoDs) and limits of quantification (LoQs) 
With HPLC-ICP-MS, the signals generated are transient thus needed to be read using 
chromatography software incorporated into the transient signal components of the 
ICP-MS X Series. In each case, the peak area was used as the signal. Limits of detection 
(LoD) and Limits of quantification (LoQ) were calculated as described in Miller and 
Miller(268). 
4.2.5 Sample preparation 
4.2.4.1 Sample preparation for total determination of arsenic content 
See Sections 2.2.4 and 3.2.4.  
4.2.4.2 Optimisation of sample preparation for arsenic speciation 
Arsenic was extracted using different temperatures and media describe in previous 
studies(216, 256, 306, 307). Ground solid samples (0.5g) were accurately weighed 
and extracted with 10 mL of the extraction medium. Water(223) and 0.3 M 
H3PO4(306) were used as extraction medium.  The tested methods include using SPD-
80 microwave-assisted extraction procedure at a maximum temperature of 80°C 
(216, 256) and 95°C(306) for 30 minutes. Another method was to increase the 
temperature gradually starting from 55°C for 10 minutes, 75°C for 10 minutes and 
finally 95°C for 30 minutes(307), one hour and two hours. The samples were then 
centrifuged at 3600 rpm for 20 min, then the supernatant was filtered using 0.45µm 




Arsenic was extracted from three samples from each product. In addition, three 
spiked samples (with 10 ng/mL of each species) were also prepared and the assay of 
all samples was performed in triplicate.  
4.3 Results and discussion 
A mixture of AsIII, AsV, MMA and DMA with a concentration of 1 ng/mL was used to 
test the separation efficiency of the two selected mobile phases adjusted at different 
pH values using two different reversed phase columns.  The columns were 
conditioned as the following:  
Sequential elution of: 1) 100% methanol for 2 hrs, 2) 50% methanol for 2hrs, 3) 10% 
methanol for 2 hrs and finally, 4) the mobile phase for 3 hrs at a flow rate of 0.75 
mL/min(302).  
4.3.1 Testing the separation efficiency of mobile phase-1  
Mobile phase-1 that consisted of 10mM sodium 1-butanesulfonate, 4mM malonic 
acid 4mM tetramethyl ammonium hydroxide pentahydrate 5mM KH2PO4 and 0.05% 
acetonitrile was tested as it had been reported that it could separate the four 
selected arsenic species in about 5 minutes isocraticly(223, 254, 302). Gradient 
elution can cause baseline drift and thus extra time is required to reach equilibrium 
causing delay and increasing the total time needed for the analysis. In addition, this 
suggested method does not require a combination of two or more chromatographic 
techniques(223, 302) such as those that use of both anionic and cationic exchange 
chromatography for the same samples(33, 237). However, using similar mobile phase 
with two different columns was found to be inefficient in separating the four species, 




Figure 4.1 Obtained chromatogram for a mixture of AsV, AsIII, MMA and DMA 
using mobile phase-1 pH =2.7 with Kinetex C18 column 
 
 
Figure 4.2 Obtained chromatogram for a mixture of AsV, AsIII, MMA and DMA using 
mobile phase-1 at pH =2.7 with Gemini C18 column 
 
Table 4.1 summarises the tested chromatographic conditions using mobile phase-1 
Table 4.1 Tested chromatographic conditions using mobile phase-1 
Mobile phase 
10 mmol/L sodium 1-butanesulfonate, 4 mmol/L malonic 
acid, 4 mmol/L tetramethylammonium hydroxide, 5 
mmol/L KH2PO4 and 0.05% acetonitrile 
pH 2, 2.7*, 3, 4 and 4.5 
Flow rate 0.75 ml/min 
Columns 
1. Phenomenex Kinetex C18 column (100X4.60 mm, 5 µm 
particles) 
2. Phenomenex Gemini C18 column (250X4.60 mm, 4 µm 
particles) 
Column temperature Ambient 
Injection volume 20 µL 




4.3.1.2 Optimisation of mobile phase-1 
4.3.1.2.1 Effect of pH  
The degree of arsenic species ionisation at different pH depends on their pKa. 
Table 4.2 illustrates the structure and pKa of AsIII, AsV, MMA and DMA. 
Table 4.2 The structure and pKa of AsIII, AsV, MMA and DMA 
 
Abb.* Name Structure pKa 
AsIII Arsenite (arsenous acid) 
 
9.3, 12.1, 13.4 
AsV Arsenate (arsenic acid) 
 
2.3, 6.9, 11.5 
MMA Monomethylarsonic acid 
 
3.6, 8.2 





AsIII has a pKa value greater than 9, so at pH < 7 it will be present predominantly in 
the undissociated form as H3AsO3°. AsV will be mainly present as H2AsO4− at pH 
between 3 and 7, and as HAsO32- at pH >7(314). 
In case of the methylated species, MMA will be present in both dissociated 
(CH3AsO(OH)O−)and undissociated ,(CH3AsO(OH)2)  forms at pH between 3 and 4 at 
higher pH the degree of ionisation of MMA will increase. DMA will be present in both 
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dissociated ((CH3)2As(O)O−) and undissociated (CH3)2As(O)OH)  forms at pH between 
6 and 7(314). Figure 4.3 show the ionisation process of AsIII, AsV, MMA and DMA at 
different pH values. 
 
Figure 4.3 Ionisation of 1. AsIII, 2. AsV, 3. MMA and 4. DMA at different pH 
 
The degree of the species ionisation affects its interaction with the ion-pairing agent 
in the mobile phase and thus its retention time. The ionic end of ion-pairing agent 
interacts with the ionised arsenic species and its hydrophobic component interacts 
with the reversed-phase column. 
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In mobile phase-1, more than one ion pairing agent were added. Firstly, sodium 1-
butanesulfonate was added to form ion pairs with cationic analytes, because in the 
study from which this mobile phase was adopted(302), tetramethylarsonium and 
arsenocholine were included. Figure 4.4 is a general illustration of the interaction 
between the positively charged arsenic species and 1-butanesulfonate. 
 
Figure 4.4 A general illustration of the interaction between the positively charged 
arsenic species and butanesulfonate as an ion pairing agent used with reversed 
phase chromatography 
 
Secondly, tetramethylammonium hydroxide was added as ion-pairing agent to 
interact with anionic analytes. Figure 4.5 is a general illustration of the interaction 




Figure 4.5 A general illustration of the interaction between the negatively charged 
arsenic species and tetramethylammonium as an ion pairing agent used with 
reversed phase chromatography 
 
Higher ionisation of the analyte facilitates its interaction with the ion-pairing agent 
and thus its interaction with the stationary phase, which becomes governed by the 
hydrophobic interaction between the ion-pairing agent hydrophobic component and 
the relatively non-polar stationary phase.  
pH 2.7 was recommended in the referenced paper(302) and to investigate the effect 
of pH on the separation of the four selected arsenic species, pH values of 2, 2.7, 3, 4 
and 4.5 were tested.  
Higher pH was reported to shorten the retention time of MMA and DMA with this 
mobile phase(302), so the effect of pH was investigated in values not exceeding 5. 
Phenomenex Kinetex C18 column was assessed first with mobile phase-1 at different 
pH values in an attempted to separate the four arsenic species in the shortest 




Figure 4.6 Chromatograms obtained using mobile phase-1 with Kinetex C18 
column at pH A)2, B)2.7, C)3, D)4 and E)4.5 respectively 
199 
 
To know the order of the species elution, a standard for each species was injected 
separately as well as a mixture of the four species. The result is illustrated in Figure 
4.7. 
Figure 4.7 Order of elusion of  AsV, AsIII, MMA and DMA using mobile phase-1 at 
pH=3 with with Kinetex C18 column 
 
AsV was the first species to elute followed by AsIII, MMA and finally DMA. The elution 
order is similar to that obtained by Narukawa’s et al(302). AsIII and MMA peaks 
overlapped as illustrated in Figure 4.7. It was stated in the referenced work that  AsIII 
and MMA were very close to each other and overlaped after the analysis of multiple 
samples especially those containing high concentrations of sugars or proteins(302). 
From the obtained chromatograms (Figure 4.6), using mobile phase-1 with 
Phenomenex Kinetex C18 column did not separate the four arsenic species. This might 
be due to the need of more theoretical plates to achieve better separation, so 
Phenomenex Gemini C18 column was used with the same mobile phase adjusted at 
different pH values to evaluate the separation efficiency of the method. Figure 4.8 
represents the obtained chromatograms using mobile phase-1 adjusted to different 




Figure 4.8 Chromatograms obtained using mobile phase-1 with Gemini C18 column 
at pH A)2, B)2.7, C)3, D)4 and E)4.5 respectively 
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Even with the Phenomenex Gemini C18 column, the arsenic species did not 
completely separate, as AsIII and MMA peaks overlapped. In addition, changing the 
mobile phases’ pH changed the retention times of AsV MMA and DMA with both 
columns, but without improving the separation. This can be explained due the 
reduced hydrophobic characters of the tested cationic ion pairing agent; 
tetramethylammonium hydroxide leading to the co-elution of AsIII and MMA. Similar 
observations regarding the ion-pairing agent hydrophobic characteristics were noted 
by Afton et al(250). Afton et al(250) investigated tetraethyl ammonium perchlorate 
as an ion-pairing agent for the separation of Se and As in a method applied to river 
water, plant extract and urine matrices. 
As a result, TBA which is an ion-pairing agent with more hydrophobic characteristics 
was used. Mobile phase-2 was adopted from the work of  Do et al(53) and Hakala 
and Pyy(313). 
4.3.2 Testing the separation efficiency of mobile phase-2 
Mobile phase-2 consisted of 10mM TBA, 1mM malonic acid, 20mM potassium 
dihydrogen orthophosphate and 2% methanol. Although malonic acid was not 
included in the studies from which this mobile phase was adopted(53, 313), it was 
kept in the mixture because it was reported to act as a buffering agent that can 
improve arsenic species separation(203, 254, 302). The pH reported to be suitable 
for this mobile phase containing TBA was ranging between 6 and 7(53, 313), so this 
mobile phase was tried at pH=6. 
Phenomenex Kinetex C18 column and Phenomenex Gemini C18 column were tested 




Figure 4.9 Chromatograms obtained using mobile phase-2 at pH=6 with A) 
Phenomenex Kinetex C18 column and B) Phenomenex Gemini C18 column  
 
From Figure 4.9 mobile phase-2 was able to separate the four arsenic species of 




   …..Equation 4.1 (315) 
Where Rs is the resolution, tr is the peak retention time (tr1 < tr2) and W0.5 is the full 
width at half the peak’s maximum height. It is calculated for each two adjacent peaks. 
A resolution ≥ 1.5 is considered acceptable(315). 
Table 4.3 illustrates the resolution of the four arsenic species using Phenomenex 




Table 4.3 The resolution of the four arsenic species using mobile phase-2 with 
Phenomenex Kinetex C18 column and Phenomenex Gemini C18 column 
 Phenomenex Kinetex C18 Phenomenex Gemini C18 
AsIII - DMA 1.45 2.43 
DMA - MMA 1.49 1.49 
MMA - AsV 1.82 2.79 
As illustrated in Figure 4.9 and Table 4.3, the resolution enhanced using Phenomenex 
Gemini C18 column and so it was used for the rest of experiments. However, the 
resolution for DMA and MMA is almost 1.5, so further experiments were carried out 
to improve the method’s separation efficiency.  
Table 4.4 summarises the tested chromatographic conditions using mobile phase-2. 
Table 4.4 Tested chromatographic conditions using mobile phase-2 
Mobile phase 
10 mmol/L TBA, 1 mmol/L malonic acid, 20 mmol/L KH2PO4 
and 2% methanol 
pH 3, 4, 5, 6 and 7 
Flow rate 1 ml/min 
Columns 
(1) Phenomenex Kinetex C18 column (100X4.60 mm, 5 µm 
particles)  
(2) Phenomenex Gemini C18 column (250X4.60 mm, 4 µm 
particles) 
Column temperature Ambient 
Injection volume 20 µL 
 
4.3.2.2 Optimisation of mobile phase-2 
4.3.2.2.1 Effect of pH 
The effect of different pH values was investigated, because as mentioned before in 
Section 4.3.1.2.1, different pH can change the ionisation state of the species 
according to its pKa value and thus its ability to form ion-pair with TBA. Figure 4.10 is 
a general illustration of the interaction between the negatively charged arsenic 




Figure 4.10 a general illustration of the interaction between the negatively charged 
arsenic species and TBA 
 
To investigate the effect of mobile phase-2 pH on the separation of the four selected 
arsenic species, pH values of 3, 4, 5, 6 and 7 tested using Phenomenex Gemini C18 






Figure 4.11 Chromatograms using mobile phase-2 with Phenomenex Gemini C18 




From the obtained chromatograms, the pH plays an important role in the species 
separation (see Figure 4.3). At pH<4, AsIII and DMA will be present dominantly in their 
unionised form and thus cannot ion-pair with TBA, so both will co-elute early. AsV 
and partially MMA will become ionised forming an ion-pair with TBA. The resulting 
neutral complexes will elute according to their hydrophobic interaction with the C18 
column. At pH=6, AsIII still cannot form an ion-pair with TBA, because it will remain 
unionised, but the rest of the species will be ionised and will form an ion-pair with 
TBA. However, at pH=7 MMA and DMA will have similar interaction with the column 
and thus their peaks overlapped, because at this pH both species will almost 
completely be ionised thus form an ion-pair with TBA to the same extent and due to 
their structural similarity their hydrophobic interaction with the C18 stationary phase 
is very similar. Do et al(53) used the same mobile phase at pH 7 to speciate As in urine 
samples, but in this work, this pH gave poor resolution. The difference in the samples’ 
pH may have accounted for the resolution change. It can also be noticed in the 
referenced work that MMA and DMA peaks are close to each other(53). 
From the obtained pH optimisation results, pH 6 was chosen as the optimum value, 
and this pH is consistent with a previous work that used a similar mobile phase to 
separate As species in urine(313).  In that study the mobile phase lacked an organic 
component like methanol or acetonitrile and the early-eluting AsIII and DMA peaks 
were close to each other(313). Mobile phases containing TBA as ion-pairing agents 
and used with reversed phase chromatography were applied to urine samples and 




4.3.2.2.2 Composition of mobile phase-2 
The effect of the concentration of the ion-pairing agent itself was studied by 
comparing the obtained chromatograms when different concentrations of TBA were 
used in the mobile phase. 
TBA concentrations ranging from 0 to 20 mmol/L were investigated. The results are 
illustrated in Figure 4.12. 
 
Figure 4.12 Chromatogram obtained using Phenomenex Gemini C18 column + 
mobile phase-2 containg A) 0 mmol/L TBA, B) 5 mmol/L TBA, C) 10 mmol/L TBA and 
D) 20 mmol/L TBA 
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Removing TBA completely caused DMA and MMA peaks to merge and AsV to elute 
early. Because ion-pairs with hydrophobic tails are not formed to be retained by the 
stationary phase. AsIII was not affected as expected.  
Reducing the concentration of TBA from 10 mmol/L to 5 mmol/L separated the four 
species but decreased the resolution between MMA and AsV. On the other hand, 
increasing TBA concentration to 20 mmol/L made DMA and MMA peaks to overlap. 
As a result, TBA concentration of 10 mmol/L was maintained with the rest of the 
experiments. 
The effect of each of the components on the separation efficiency was tested by 
removing one component each time and studying the produced chromatogram. The 
first component removed was the buffering agent KH2PO4 and that led to delayed 
elution of the four peaks to more than 10 minutes as seen in Figure 4.13. 
 
Figure 4.13 Chromatogram obtained using Phenomenex Gemini C18 column 
column + mobile phase-2 at pH=6. A) 10 mmol/L TBA, 1 mmol/L malonic acid, 20 
mmol/L KH2PO4 and 2% methanol, B)10 mmol/L TBA, 1 mmol/L malonic acid and 
2% methanol  
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KH2PO4 concentration modifies the ionic force of the mobile phase. MMA and AsV 
elution was delayed with removing KH2PO4, while AsIII and DMA peaks retention 
times were not changed (Figure 4.13). AsIII is present mainly as unionised species at 
pH=6, so its retention time is not affected and it is eluting first because it lacks the 
ability to form ion-pair with TBA.  Because the run time increased with the removal 
of the buffering agent, it was kept in further experiments.  
The next component removed was malonic acid. The obtained chromatogram is 
represented in Figure 4.14. 
 
Figure 4.14 Chromatograms obtained using Phenomenex Gemini C18 column + 
mobile phase-2 at pH=6. A) 10 mmol/L TBA, 1 mmol/L malonic acid, 20 mmol/L 




Malonic acid changes the ionic force of the eluent. Removing it from the mobile 
phase improved the resolution particularly for DMA-MMA. See Table 4.5. 
Table 4.5 The resolution of the four arsenic species using Phenomenex Gemini C18 
column and mobile phase-2 with and without malonic acid at pH=6 
 
 With malonic acid Without malonic acid 
AsIII - DMA 2.43 6.40 
DMA - MMA 1.49 11.31 
MMA - AsV 2.77 14.69 
 
Although the total run time increased from 7 minutes to 10 minutes when malonic 
acid was removed from the mobile phase, the significant improvement in the 
resolution of DMA and MMA peaks lead to the removal of malonic acid from the 
mobile phase used with the rest of the experiments. The improvement in peaks 
resolution can be explained due the fact that malonic acid has a pKa of 2.83 and 
5.69, so at pH=6 it will be ionised as illustrated in Figure 4.15. 
 
Figure 4.15 Ionisation of malonic acid at different pH 
 
Malonate ions can compete with the negatively charged arsenic species for TBA 
leading to a decrease in their formation of ion pairs and thus decrease their 
partitioning with the stationary phase causing a reduction in their retention time. 
Finally, a mobile phase that consists only of 10 mmol/L TBA and 2% methanol was 
tried and it was noticed that AsV was severely affected where its elution was 





Figure 4.16 Chromatogram obtained using Phenomenex Gemini C18 column + 
mobile phase-2 at pH=6. A) 10 mmol/L TBA, 20 mmol/L KH2PO4 and 2% methanol, 
B) 10 mmol/L TBA and 2% methanol  
 
These observed changes can be explained as a result of changing the mobile phase’s 
ionic force which has an influence mainly on AsV in addition to the methylated species. 
Similar effects on the species ion-pair reversed phase separation were observed 
when changing the ionic strength by increasing or decreasing the concentration of 
TBA itself and/or the addition of disodium phosphate Na2HPO4 and H3PO4(53). 
2% Methanol was added in all cases to enhance the elution power especially towards 
AsV. Previous study (53) showed that without an organic solvent AsV will need more 
than 25 minutes to elute which is not practical for routine analysis(53). A methanol 
concentration of more than 2% cannot be used in order not to hinder the detection 
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ability of ICP-MS by affecting the plasma stability. It would require the addition of 
oxygen ashing to remove the excess solvent. AsIII was least affected by all the mobile 
phase changes as a result of it being unionised at pH<10 and thus not interacting at 
all with TBA. 
From the discussed experiments the mobile phase that was used for this work 
consisted of 10 mmol/L TBA, 20 mmol/L KH2PO4 and 2% methanol at pH= 6. The 
retention times for AsIII is 3.19 min., MMA is 4.19 min., DMA is 6.15 min., and AsV is 
8.91 min., accordingly, the total run time less than 10 minutes which is reasonable, 
see Figure 4.17.  
Figure 4.17 Illustration of As-species elution order; obtained by injecting a standard 




4.3.3 HPLC method validation 
4.3.2.1 Linearity and range 
Linearity in the range of 1 to 50 ng/mL for all four species gave R2 value of more than 
0.995. The results are summarised in Table 4.6. 




Linear regression line equation: Y= bX + a 
where b is the slope and a is the intercept 
R2 
AsIII 1.015-50.758 y= 892119x + 3883.5 0.9998 
DMA 1.026-51.291 y= 858110x + 1828.8 0.9996 
MMA 0.912-45.579 y= 863210x + 47742 0.9997 
AsV 1.000-50.013 y= 869141x + 45364 0.9984 
 
 
4.3.2.2 Accuracy and precision 
Calibration and test standards were freshly prepared and analysed on three 
consecutive days. The four species’ recoveries were always between 95-102% and 
the RSDs were always less than 5%. Detailed results are presented in Table 4.7. 
 
Table 4.7 Accuracy and Precision results, n=3 
 
                      Day 1                       Day 2                          Day 3 
AsIII, Theoretical Concentration= 1.02 ng/mL 
 Conc.* % Rec.**  Conc. % Rec.  Conc. % Rec. 
1 0.99 99.38 1 0.99 99.38 1 0.97 96.51 
2 0.98 97.75 2 0.97 97.02 2 0.99 98.61 
3 0.96 96.01 3 0.97 96.73 3 0.97 96.54 
σ 0.02  σ 0.01  σ 0.02  





Table 4.7, continued 
                      Day 1                       Day 2                          Day 3 
AsIII, Theoretical Concentration= 10.2 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 9.61 95.17 1 9.99 98.99 1 10.28 101.79 
2 10.09 99.88 2 9.94 98.47 2 9.96 98.67 
3 9.99 98.91 3 9.71 96.21 3 9.81 97.18 
σ 0.25  σ 0.15  σ 0.24  
RSD 2.54  RSD 1.50  RSD 2.37  
AsIII, Theoretical Concentration= 50.76 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 49.18 96.90 1 49.68 97.90 1 51.64 101.76 
2 48.27 95.10 2 49.01 96.58 2 50.61 99.72 
3 49.91 98.34 3 51.00 100.49 3 49.97 98.47 
σ 0.83  σ 1.01  σ 0.84  
RSD 1.68   RSD 2.02   RSD 1.66   
DMA, Theoretical Concentration= 1.03 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 1.01 101.07 1 0.98 97.53 1 0.95 95.23 
2 0.95 95.09 2 0.97 97.27 2 0.98 97.93 
3 0.95 95.36 3 0.99 99.38 3 0.99 98.72 
σ 0.25  σ 0.01  σ 0.02  
RSD 2.53  RSD 1.17  RSD 1.88  
DMA, Theoretical Concentration= 10.26 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 10.30 100.99 1 9.61 94.25 1 10.14 99.45 
2 9.78 95.92 2 9.88 96.91 2 10.06 98.59 
3 10.15 99.46 3 10.16 99.66 3 9.89 96.97 
σ 0.034  σ 0.8  σ 0.13  




Table 4.7, continued 
                      Day 1                       Day 2                          Day 3 
DMA, Theoretical Concentration= 51.29 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 52.69 102.73 1 49.67 96.85 1 51.73 100.86 
2 50.26 97.99 2 48.87 95.27 2 49.80 97.11 
3 49.53 96.57 3 50.27 98.00 3 50.17 97.81 
σ 1.66  σ 0.70  σ 1.02  
RSD 3.26   RSD 1.42   RSD 2.03   
MMA, Theoretical Concentration= 0.91 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 0.85 95.34 1 0.91 101.08 1 0.89 99.86 
2 0.87 97.68 2 0.86 95.26 2 0.85 95.28 
3 0.86 95.44 3 0.88 98.61 3 0.86 95.53 
σ 0.01  σ 0.03  σ 0.02  
RSD 1.37  RSD 2.97  RSD 2.65  
MMA, Theoretical Concentration= 9.12 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 8.91 97.93 1 9.19 101.03 1 9.24 101.61 
2 9.05 99.45 2 9.41 103.41 2 9.11 100.06 
3 9.36 102.88 3 9.06 99.59 3 9.04 99.33 
σ 0.23  σ 0.18  σ 0.11  
RSD 2.53  RSD 1.90  RSD 1.16  
MMA, Theoretical Concentration= 45.56 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 44.93 98.58 1 44.45 97.51 1 46.00 100.92 
2 44.78 98.25 2 43.66 95.80 2 44.80 98.30 
3 43.49 95.42 3 45.61 100.06 3 44.912 98.53 
σ 0.79  σ 0.98  σ 0.66  




Table 4.7, continued 
                      Day 1                       Day 2                          Day 3 
AsV, Theoretical Concentration= 1.00 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 0.96 96.77 1 0.95 95.16 1 0.95 95.77 
2 0.94 94.33 2 0.97 97.21 2 0.96 95.95 
3 0.99 99.32 3 0.96 96.01 3 0.99 99.78 
σ 0.03  σ 0.010  σ 0.02  
RSD 2.58  RSD 1.07  RSD 2.33  
AsV, Theoretical Concentration= 10.00 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 10.25 97.93 1 10.20 101.99 1 10.39 103.90 
2 10.08 99.45 2 9.82 98.21 2 9.98 99.81 
3 10.35 102.88 3 9.82 98.19 3 10.21 102.15 
σ 0.14  σ 0.22  σ 0.21  
RSD 2.53  RSD 2.20  RSD 2.01  
AsV, Theoretical Concentration= 50.01 ng/mL 
 Conc. % Rec.  Conc. % Rec.  Conc. % Rec. 
1 50.80 101.37 1 48.30 96.37 1 49.08 97.93 
2 49.52 98.80 2 50.09 99.95 2 50.00 99.76 
3 50.46 100.67 3 49.22 98.21 3 48.28 96.32 
σ 0.67  σ 0.89  σ 0.86  
RSD 1.32   RSD 1.82   RSD 1.75   
*Concentration, **% Recovery  
4.3.2.3 Limits of detection (LoDs) and limits of quantification (LoQs) 
The calculated limit of detection and limit of quantification were as follows: AsIII 
(0.0954- 0.279 ng/mL), DMA (0.118- 0.339 ng/mL), MMA (0.122- 0.353 ng/mL) and 
AsV (0.118- 0.362 ng/mL) respectively. 
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4.3.4 Samples preparation and analysis 
4.3.4.1 Determination of total arsenic concentration in six antacid products 
Before working on optimising the extraction procedure, total arsenic level in six 
commercially available antacid products was analysed by digesting 0.5g of the 
samples in 8 mL of reverse aqua regia followed by filtering and diluting the samples 
before analysing them using ICP-MS-CCT mode as described in Section 3.2.7. The 
results are summarised in Table 4.8. 





Daily Exposure in 
maximum dose (ng/day) 
1. Gaviscon suspension <LoD (0.048) N/A 
2. Gaviscon chewable tablets 38.25 ±0.54 819.53 ±11.59 
3. Rennie Extra 27.99 ±0.90 786.92 ±25.42 
4. Superdrug 452.17 ±4.85 8527.45 ±91.49 
5. Rennie 47.28 ±3.85 615.11 ±50.10 
6. Bisodol 372.43 ±15.18 2702.07 ±110.16 
*Antacids 1-3 contain alginates, while antacids 4-5 do not contain any 
As explained in experimental section 4.2.4.2, more than one temperature and 
extraction medium were used. Although in some research diluted acids such as nitric 
acid, hydrochloric acid, sulfuric acid and formic acid(223, 302, 307) were used as 
extraction media. Other studies(302, 306) suggested the use of diluted phosphoric 
acid instead, because it gives good extraction recoveries and sharp peaks when HPLC 
is used for separation(302, 306). For this reason 0.3 M phosphoric acid was chosen 
in this work in addition to water(216, 256, 316), which is widely used in previous 
published work. The concentration of phosphoric acid used (0.3 M) was based on the 
work of Wolle et al(306). Different concentration ranging from 0.1–0.5 M were tried 
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by Wolle et al(306) and 0.3 M was found to be the optimum concentration. 0.3 M 
phosphoric acid was also used for arsenic speciation in plants by Bohari et al(204). 
The use of organic solvents such as methanol, acetonitrile, acetone and 
chloroform(244, 248, 258, 317, 318) as extraction medium for sample preparation 
was avoided due to the need of complete evaporation of the organic phase before 
analysing using ICP-MS as the detector. This evaporation phase is used to avoid 
plasma temperature suppression effects. 
4.3.4.2 Investigating the arsenic microwave assisted extraction efficiency of water 
and 0.3 M phosphoric acid. 
All the samples were freshly prepared and analysed within the same day. 
Water was used to extract arsenic from the antacids using microwave assisted 
extraction at 80°C for 30 minutes, but the extracted levels for all species were below 
the LoDs. The obtained chromatogram is illustrated in Figure 4.18. 
 
Figure 4.18 Obtained chromatogram for Gaviscon chewable tablets using 
microwave assissted extraction with water for 30 minutes at 80°C 
 
In an attempt to enhance the extraction, the temperature was increased to 95°C, but 





Figure 4.19 Obtained chromatogram for Gaviscon chewable tablets using 
microwave assissted extraction with water for 30 minutes at 95°C  
 
 The next step was using 0.3M phosphoric acid instead of water with the microwave 
for 30 minutes at 95°C as well. The extraction improved but still the concentrations 
are at borderline with the LoQs, see Figure 4.20. 
 
Figure 4.20 Obtained chromatogram for Gaviscon chewable tablets using 
microwave assissted extraction with H3PO4 for 30 minutes at 95°C 
 
 
4.3.4.3 Optimisation of the microwave assisted extraction procedure using 0.3 M 
H3PO4 
To improve arsenic extraction from antacids, gradual increase of temperature was 
attempted starting from 55 °C for 10 minutes, 75°C for 10 minutes and finally 95°C 
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for 30 minutes as suggested by Jackson et al(307). This method lead to significant 
improvement in the extraction efficiency as the levels of the extracted arsenic was 
about 75% of the total. The method was applied to antacids containing alginates and 
because the total As concentration for Gaviscon suspension was below LoD, arsenic 
was extracted from Gaviscon chewable tablets and Rennie Extra only. The results are 
displayed in Table 4.9. 
Table 4.9 Concentration of arsenic species ± σ (ng/g) using microwave assisted 
extraction with 0.3M H3PO4 at 55°C for 10 minutes, 75°C for 10 minutes and 95°C 
for 30 minutes, n=3  
         Gaviscon chewable tablets Rennie Extra 
  Concentration Spiked Recovery Concentration Spiked Recovery 
AsIII 16.24 ±0.66 101.5% 12.40 ±0.61 95.4% 
DMA 8.29 ±0.33 95.6% 8.72 ±0.34 96.4% 
MMA <LoD (0.048) 97.7% <LoD (0.048) 102.9% 
AsV 7.18 ±0.33 100.7% <LoQ (0.149) 103.6% 
Total As 38.25 ±0.54  27.99 ±0.90  
%Extracted 83.10%  75.47%  
 
The final attempt to optimise the extraction procedure was to increase the hold time 
at 95°C for one hour instead of 30 minutes. This increased the recoveries to more 
than 95% for both the products without affecting the species stability and thus was 
considered the optimum procedure. The results are displayed in Table 4.10. 
Table 4.10 Concentration of arsenic species ± σ (ng/g) in antacids containing 
alginate using microwave assisted extraction with 0.3 M H3PO4 at 55°C for 10 
minutes, 75°C for 10 minutes and 95°C for 60 minutes, n=3 





AsIII 17.61 ±0.64 99.6 12.91 ±0.27 96.5 
DMA 11.62 ±0.32 104.2 9.74 ±0.14 95.2 
MMA <LoD (0.048) 97.7 <LoD (0.048) 95.0 
AsV 8.51 ±0.29 99.6 4.62 ±0.08 102.9 
Total Extracted 37.74 27.26 
Total As 38.25 ±0.54 27.99 ±0.90 




To make sure that H3PO4, microwave temperature and extraction time were not 
affecting the species stability, spiked samples that had undergone the whole 
procedure were analysed and spiked recoveries were calculated giving 95% or higher 
which suggests that the species were stable using these extraction conditions. The 
results are displayed in Table 4.11. 
Table 4.11 % Recovery of spiked samples prepared in water and H3PO4 subjected to 
the microwave extraction procedure; 55°C for 10 minutes, 75°C for 10 minutes and 
95°C for 60 minutes, n=3 
  Spiked As species in water Spiked  As species H3PO4 
 % Recovery RSD % Recovery RSD 
AsIII 101.80 1.32 100.90 1.30 
DMA 99.00 1.66 100.70 1.52 
MMA 101.17 2.12 102.63 2.37 
AsV 95.40 1.29 99.87 1.99 
 
Increasing the hold time at 95°C to greater than 60 minutes resulted in all the AsIII 
being converted to AsV even when the medium was water, which suggest that the 
microwave power itself in the presence of weak acids can alter the species if the 
samples are exposed to microwaves for a time exceeding 80 minutes. The same 
procedure of exposing a standard in water and another one in H3PO4 for microwaves 
using the optimised extraction method was performed. The results clearly 
demonstrates that 0.3 M H3PO4 will not oxidise AsIII to AsV. Figure 4.21 demonstrates 
the interconversion of AsIII to AsV when using the microwave for more than 80 




Figure 4.21 The interconversion of AsIII to AsV after exposing a standard in water 
and H3PO4 to microwaves for more than 80 minutes 
 
4.4.4. Speciation of arsenic in antacids 
The optimised microwave assisted extraction procedure using 0.3 M H3PO4 at 55°C 
for 10 minutes, 75°C for 10 minutes and 95°C for 60 minutes, was used to extract As 
from 5 antacid products that had a quatifiable level of total arsenic as displayed in 
Table 4.8 
The results for Gaviscon chewable tablets and Rennie Extra antacids containg 
alginate were displayed in Table 4.10. 
Gaviscon suspension has similar ingredients to Gaviscon chewable tablets, but it is 
formulated as a suspension and thus contains large quantity of water. In an attempt 
to concentrate the arsenic in it, the liquid formula was dried in an oven at 80°C, and 
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three samples containing 0.5g of the dried mass were analysed to measure the total 
arsenic content and another three samples were used to extract the arsenic species. 
The results are displayed in Table 4.12. 
Table 4.12 Arsenic content in the dried mass obtained from Gaviscon suspension 
 Total Concentration (ng/g) RSD Spiked Recovery 
75As 59.49 4.35 96.54 
Extracted species Concentration (ng/g) RSD Spiked Recovery 
AsIII 22.87 4.761 98.06 
DMA 17.41 3.884 98.59 
MMA <LoD (0.048) - 97.71 
AsV 15.89 3.789 103.68 
Total Extracted 56.18    
%Extracted 94.44%       
 
The speciation results for antacid products that do not contain alginates are 
displayed in Table 4.13. 
Table 4.13 Concentration of arsenic species ± σ (ng/g) in antacids without alginates 
using microwave assisted extraction with 0.3 M H3PO4 at 55°C for 10 minutes, 75°C 
for 10 minutes and 95°C for 1 hours, n=3 








AsIII 265.50±4.73 95.9 24.98±0.82 99.9 207.81±6.24 96.3 
DMA <LoD (0.048) 98.5 <LoD (0.048) 95.4 <LoD (0.048) 102.7 
MMA <LoD (0.048) 104.7 <LoD (0.048) 100.9 <LoD (0.048) 104.5 
AsV 172.50±5.81 102.7 20.40±0.69 103.3 164.21±6.22 103.3 
Total 
Extracted 438.00  45.38  372.02  
Total As 452.17±4.85  47.28±3.85  372.43±15.18  




An example of the obtained chromatograms for a product containing alginate and 




Figure 4.22 Obtained chromatograms for Rennie Extra with alginate & Rennie 
without alginate using microwave assissted extraction with 0.3 M H3PO4 at 55°C 
for 10 minutes, 75°C for 10 minutes and 95°C for 60 minutes 
 
From the speciation results, it was found that all the products contain AsIII and AsV, 
and the products that contain alginate derivatives also contain DMA (product 1, 2 
and 3). Alginate is usually obtained from brown algae, including species of Durvillaea, 
Laminaria, Lessonia, Ascophyllum, Ecklonia, Macrocystis and Sargassum. However, 
Sargassum is only used when nothing else is available of the other species(312, 319, 
320). Previous studies where some of these species were analysed found them to 
contain AsIII, AsV and DMA(33, 321, 322). For example, Durvillaea antarrctica was 
found to contain 0.304 mg/Kg of AsIII, 0.114 mg/Kg of AsV and 0.103 mg/Kg of DMA. 
In addition, Lessonia nigrescens was found to contain 105 mg/Kg of AsIII and 18.5 
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mg/Kg of AsV(33). Laminaria species were found to contain inorganic As species in 
concentrations ranging from 0.12 to 8.32 mg/Kg(323) and Sargassum was found to 
contain 62.3% of its total arsenic content in the form of AsV(324). 
In addition, these antacid products contain weak bases to neutralise excess stomach 
acid such as calcium carbonate, magnesium carbonate and sodium bicarbonate. 
When some pharmaceutical excipients(31) were analysed for trace metals, arsenic 
was found in the following: sodium alginate in a concentration of 420 ng/g, calcium 
carbonate in a concentration of 10 ng/g and magnesium carbonate in a concentration 
of 130 ng/g.  Sodium bicarbonate was not included in that study and no information 
was available regarding the presence or absence of arsenic as EI in it(31). These 
excipients, other than sodium alginate are also contributing to the arsenic 
concentration found in the analysed antacids as it is clear that products 4, 5 and 6 
were also found to have arsenic in them in the form of AsIII and AsV although they do 
not have alginate derivatives within their ingredients.  
It also noted that the dosage form of the pharmaceutical product contributes to the 
total amount of EI that patients can be exposed to on daily basis when consuming 
the product. An example is Gaviscon. The suspension formula contains considerable 
amount of water that diluted other solid ingredients, which led to the reduction of 
total arsenic concentration.   
Since AsIII is the most toxic species, its percentage was calculated with regards to the 





Table 4.14 Percentage of AsIII in the analysed antacid products 
Antacid* % of AsIII 
Gaviscon chewable tablets 46.03 




* Gaviscon suspension was excluded because As required a pre-concentration step in order 
to increase its concentration above the LoQ 
 
4.4 Conclusion 
Arsenic speciation in pharmaceutical products has not been published in the 
literature previously. This optimised HPLC-ICP-MS method proved to be capable of 
analysing and speciating arsenic in antacids. Although in the selected antacids, the 
levels do not exceed the maximum allowed daily dose (15 µg/mL) according to ICH-
Q3D guidelines, the fact that the species with the highest concentration is AsIII raises 
questions regarding how much these products can be considered safe for human 
consumption. This should also alert manufacturers and regulators to control the 
quality and safety of their products. Keeping in mind that many people suffering from 
indigestion or gastrointestinal acid reflux can take these products on an almost daily 
bases for a considerable period although it is not recommended(325). This will 






















5.1 General Conclusion 
With the new guidelines recently coming into effect, the need for new methods to 
determine elemental impurities in pharmaceuticals was highly emphasised in this 
work. Twenty-four commercially available pharmaceutical products were analysed 
using optimised and validated ICP-OES and ICP-MS equipped with collision reaction 
cell methods for the simultaneous analysis of arsenic, cadmium, mercury, lead, 
cobalt, nickel and vanadium. With four products found to contain cadmium in 
concentration exceeding the allowed PDE of 5 µg/day and nine products exceed the 
lead PDE of 5 µg/day, the need for new regulations is urgently required to ensure the 
safety of pharmaceutical products to consumers.  
It was found that not just some products exceed the allowed PDE, but also in some 
cases, the level of the elements present is 30% or more of the regulation’s PDE, like 
cobalt in Superdrug bronchial Balsam and lead in Lemsip cold and flu powders. 
According to the guidelines, this requires establishment of controls to ensure that 
the elemental impurities level does not exceed the PDE in the pharmaceutical 
products in which elements are in levels exceeding 30% of their PDEs. 
This work also highlights the fact that even products without active pharmaceutical 
ingredients may contain significant amount of elemental impurities, which 
emphasises the reality that one of the major sources for pharmaceutical impurities 
is the excipients used for the formulation of pharmaceutical products.   
The developed ICP-OES, ICP-MS and microwave assisted acid digestion for 
pharmaceutical products methods were successfully validated using the only 
commercially available standard reference material NIST 3280 
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Multivitamin/Multielement tablets as well as from supporting results obtained using 
TAC tablets that are still under development.  
The methods showed excellent recoveries between 95-105% with good repeatability 
expressed as RSD of less than 5% for all elements. Those limits met the regulations 
requirements. In addition, these methods are specific, as for ICP-OES any spectra 
with major interferences were excluded and only those with minimal interferences 
were chosen for analysis. In case of using ICP-MS, collision reaction cell with helium 
gas was used to minimise polyatomic interferences and any isotopes suffering from 
major interferences were excluded from analysis. LoDs and LoQs were below the 
target limits, which supports the suitability of the ICP-OES and ICP-MS for elemental 
impurities determination. 
Additionally, the need of a suitable solid reference material was brought to attention 
for proper validation of the analytical methods required of analysing pharmaceuticals 
for the purpose of determining elemental impurities, because relying on methods 
like spiked recoveries only may give a false indication about the efficiency and validity 
of the chosen analytical method. 
Regarding arsenic speciation, the optimised reversed phase HPLC-ICP-MS method 
was successful in analysing four arsenic species, AsIII, AsV, MMA and DMA and also 
questions the safety of pharmaceutical products that contain high level of toxic 





5.2 Future work 
The optimised digestion method proved to be efficient in extracting Class 1 and Class 
2A elements, but changes of the acid ratio, acid volume used, hold time duration 
and/or temperature may be required for elements from different classes particularly 
2B which have not been investigated extensively but maybe present due to 
intentional addition. A solid reference material that include these elements in 
representative concentration will be needed to ensure the digestion method 
efficiency. 
Regarding speciation, very limited work on pharmaceutical products has been 
published in this area. However, it is essential; to know what species are present from 
elements like arsenic, which was speciated in this work, mercury and chromium for 
example, where CrVI is known to be toxic and carcinogenic unlike CrIII(326, 327). This 
will provide better understanding of the toxicity of trace metals present in 
pharmaceutical products. 
Speciation analysis requires considerable work to optimise a method that is able to 
differentiate species of the same element with similar properties. The extraction 
method also needs considerable amount of optimisation and may differ according to 
the nature of the samples to be analysed. The need of suitable reference materials 
containing various species of elements is also required for proper optimisation and 
validation of the developed speciation methods. Speciation analysis for 
pharmaceutical products is expected to gain greater interest in the upcoming years 
with the new regulation implemented and with the increasing attention to the safety 
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